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Abstract 
The hallmark of all undifferentiated stem cells is their nearly unlimited self-renewal 
capacity and their potential to differentiate into a diverse range of specialised cell 
types. These unique properties of stem cells make them invaluable research tools 
and can potentially serve as a source of cells for regenerative therapies. Pluripotent 
stem cells such as human embryonic stem cells (hESCs) and induced pluripotent 
stem cells (iPS cells) are capable of producing almost any cell type in the human 
body, whereas multipotent adult stem cells exhibit limited self-renewal and a 
differentiation capacity that is restricted to the cell types of a particular lineage or a 
closely related family of cells. Since the discovery of stem cells, diverse culture 
conditions have been evaluated for different types of stem cells. In current standard 
in vitro cell culture techniques, xenogeneic reagents are used in the establishment, 
cultivation, and differentiation procedures. For the clinical applications of stem 
cells, however, xenogeneic reagents pose the risk of a severe immune response, and 
the transmission of viral or bacterial infections, prions, and unidentified zoonoses.  
 
In this study, we assessed the applicability of an automated cell culturing, imaging, 
and analysis system to evaluate undifferentiated growth dynamics of hESCs 
maintained in different culture media. The molecular mechanisms regulating self-
renewal and pluripotency of hESCs under hypoxic conditions were also elucidated. 
Furthermore, defined and xeno-free culture conditions for the expansion of stem 
cells were evaluated, developed, and optimised to meet the regulatory standards set 
by the directives of the European Union for the clinical application of stem cells. 
The applicability of a defined xeno-free medium for the derivation and maintenance 
of hESCs as well as for the expansion of iPS cells and adipose stem cells (ASCs) 
was evaluated.  
 
The results indicated that the automated cell culturing, imaging, and analysis system 
enables reliable analysis of the undifferentiated growth dynamics of hESCs in 
different culture conditions, and revealed more information than does conventional 
microscopic observation. Exposure to hypoxic conditions prevented spontaneous 
differentiation, supported self-renewal, and significantly increased the hESC 
proliferation. Fundamental differences in genes that are central to hypoxia 
signalling, calcium and PKC pathway, and the retinoic acid pathway were detected 
in different culture conditions under hypoxia. A key transcription factor for self-
renewal, Oct-4, was significantly upregulated under hypoxic conditions, indicating a 
possible mechanism for hypoxia-induced self-renewal and prevention of 
spontaneous differentiation.  
 
The results of these studies suggest that although a population of hESCs was able to 
adapt to human serum-containing culture conditions, several of the xeno-free culture 
media evaluated were unable to maintain hESC self-renewal. Here we developed a 
xeno-free medium formulation, RegES, that allowed for the derivation of 
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pluripotent hESC lines. Furthermore, hESCs, iPS cells, and ASCs can be propagated 
in the RegES medium for a prolonged period of time with a reasonable proliferation 
rate while maintaining their characteristics and differentiation potential.  
 
Clinical stem cell therapy trials are ongoing, which calls for a strong focus on the 
safety and quality of in vitro expanded stem cell transplants. By replacing 
xenogeneic products with a defined xeno-free medium, the safety and quality of the 
cells with therapeutic potential may be enhanced significantly. The use of 
completely defined conditions will allow for a better understanding of stem cell 
regulation and differentiation as well as provide more reproducible and reliable 
results. Culture conditions may have significant impact on the cell characteristics, 
thus proper characterization of cells with specific analyzing methods is necessary. 
Future studies should focus on validating the xeno-free culture conditions to 
demonstrate the ability for long-term culture, maintenance of key features of self-
renewal, differentiation potency, and genetic stability, as well as derivation, 
reprogramming, or isolation of new stem cell lines as a full proof-of-principle, and 
to provide for scale-up to a manufacturing level. Additional pre-clinical safety and 
efficacy studies are needed before the promise of the xeno-free products can be fully 
realised. The results of the present study indicate that the xeno-free RegES medium 
is applicable for further optimization of xeno-free establishment, culture, and 
differentiation of various stem cell types and can ultimately serve as a platform for 
the production of clinical-grade multi- and pluripotent stem cells and their 
derivatives for safer clinical cell-based therapy.  
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Tiivistelmä 
Erilaistumattomien kantasolujen erityispiirteitä ovat lähes rajaton jakautumiskyky 
sekä kyky erilaistua moniksi erilaistuneiksi solutyypeiksi. Näiden erityispiirteiden 
ansiosta kantasoluja voidaan hyödyntää sekä tutkimuksessa että regeneratiivisessa 
lääketieteessä. Pluripotentit kantasolut, kuten ihmisen alkion kantasolut ja 
indusoidut pluripotentit kantasolut, pystyvät erilaistumaan ainakin teoriassa miksi 
tahansa aikuisen yksilön solutyypiksi kun taas monikykyisillä aikuisen kantasoluilla 
on rajallinen jakaantumis- ja erilaistumiskyky, jolloin ne voivat muodostaa erilaisia 
solutyyppejä tietyn solulinjan sisällä. Aikojen kuluessa kantasoluja on viljelty 
monissa erilaisissa olosuhteissa. Tällä hetkellä yleisesti käytössä olevissa 
kantasolujen johtamis-, viljely-, ja erilaistamistekniikoissa käytetään eläinperäisiä 
ainesosia. Kliinisessä käytössä eläinperäiset ainesosat voivat aiheuttaa vakavan 
immunivasteen, viruksien ja bakteerien aiheuttamia infektioita, prionitauteja sekä 
toistaiseksi tunnistamattomia eläintauteja.  
 
Tässä työssä tutkittiin automatisoidun viljely-, kuvantamis- ja analyysimenetelmän 
soveltuvuutta erilaisissa viljelyolosuhteissa kasvatettujen erilaistumattomien 
ihmisen alkion kantasolujen kasvudynamiikan evaluoimiseksi. Lisäksi työssä 
tutkittiin alhaisen happipitoisuuden vaikutuksia ihmisen alkion kantasolujen 
uusiutumis- ja erilaistumiskykyyn sekä niihin vaikuttavia molekyylitason 
mekanismeja. Edelleen koostumukseltaan tunnettuja ja eläinperäisiä ainesosia 
sisältämättömiä kantasolujen viljelyolosuhteita evaluoitiin, kehitettiin ja optimoitiin 
täyttämään Euroopan Unionin direktiivien asettamat viranomaisvaatimukset 
kantasolujen kliinisistä sovelluksista. Työssä evaluoitiin koostumukseltaan 
tunnetun, eläinperäisiä ainesosia sisältämättömän viljelyliuoksen soveltuvuutta 
ihmisen alkion kantasolujen perustamisessa ja viljelyssä sekä indusoitujen 
kantasolujen ja aikuisen kantasolujen viljelyssä.  
 
Tämän työn tulokset osoittavat, että automatisoitu viljely-, kuvantamis- ja 
analysointimenetelmä mahdollisti erilaisissa viljelyolosuhteissa kasvatettujen 
erilaistumattomien ihmisen alkion kantasolujen kasvudynamiikan analysoinnin 
luotettavasti, tuottaen enemmän informaatiota kuin perinteinen mikroskooppinen 
tarkastelu. Alhainen happipitoisuus esti ihmisen alkion kantasolujen spontaania 
erilaistumista, tuki uusiutumiskykyä ja lisäsi merkittävästi jakaantumista. Alhaisessa 
happipitoisuudessa olennaisia eroja esiintyi alhaisen happipitoisuuden, kalsium ja 
PKC ja retinolihapon signaalireiteille keskeisten geenien ilmentymisessä erilaisissa 
viljelyolosuhteissa. Yhtä uusiutumiskyvylle merkittävää transkriptiotekijää Oct-
4:sta ilmentyi merkittävästi enemmän alhaisessa happipitoisuudessa, osoittaen 
mahdollisen mekanismin alhaisen happipitoisuuden indusoimalle uusiutumiskyvyn 
lisääntymiselle ja spontaanin erilaistumisen estämiselle. 
 
Tämän työn tulokset osoittavat, että useat eläinperäisiä ainesosia sisältävät 
viljelyliuokset eivät pystyneet ylläpitämään ihmisen alkion kantasolujen 
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erilaistumatonta kasvua. Osa ihmisen alkion kantasoluista kuitenkin kykeni 
adaptoitumaan ihmisen seerumia sisältävään viljelyolosuhteeseen. Tässä työssä 
kehitetty koostumukseltaan tunnettu ja eläinperäisiä ainesosia sisältämätön 
viljelyliuos RegES mahdollisti ihmisen alkion kantasolulinjojen perustamisen. 
Lisäksi RegES viljelyliuos mahdollisti ihmisen alkion, indusoitujen ja aikuisen 
kantasolujen pitkäaikaisen viljelyn, kantasolujen tehokkaan jakautumisnopeuden 
sekä ylläpiti kantasolujen erityispiirteitä ja erilaistumiskykyä.  
 
Parhaillaan kantasoluja hyödyntäviä kliinisiä soluterapiakokeita on jo käynnissä, 
mikä edellyttää keskittymistä erityisesti laboratorio-olosuhteissa lisättyjen 
solusiirteiden turvallisuuteen ja laatuun. Käyttämällä koostumukseltaan tunnettuja 
eläinperäisiä ainesosia sisältämättömiä tuotteita voidaan solutuotteiden turvallisuutta 
ja laatua parantaa merkittävästi. Koostumukseltaan tunnettujen olosuhteiden käyttö 
mahdollistaa kantasolujen säätelyn ja erilaistumisen syvempää ymmärtämistä sekä 
lisää tulosten toistettavuutta ja luotettavuutta. Viljelyolosuhteilla voi olla 
huomattavia vaikutuksia solujen erityispiirteisiin, jonka vuoksi solujen 
asianmukainen karakterisointi tarkoin määritellyillä analyysimenetelmillä on 
ensiarvoisen tärkeää. Tulevaisuudessa pitäisi keskittyä eläinperäisiä ainesosia 
sisältämättömien viljelyolosuhteiden validoimiseen ja osoittaa, että ne 
mahdollistavat solujen pitkäaikaisen viljelyn, ylläpitävät uusiutumiskyvyn 
erityispiirteitä, erilaistumiskykyä ja geneettistä stabiiliutta, mahdollistavat uusien 
kantasolulinjojen perustamisen, uudelleenohjelmoinnin ja eristämisen, sekä 
tuotannon lisäyksen. Täydentäviä prekliinisiä turvallisuus- ja tehokkuustutkimuksia 
tarvitaan vielä ennen kuin eläinperäisiä ainesosia sisältämättömien tuotteiden kaikki 
hyödyntämismahdollisuudet voidaan toteuttaa. Tämä työ osoittaa, että eläinperäisiä 
ainesosia sisältämätön viljelyliuos RegES soveltuu erilaisten kantasolujen 
perustamisen, viljelyn ja erilaistamisen jatkokehitykseen ja voi tulevaisuudessa 
toimia perustana kliinisten monikykyisten ja pluripotenttien kantasolujen sekä 
näiden johdannaisten turvallisessa tuotannossa kliinisiä soluterapiahoitoja varten.  
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1. Introduction 
The goal of regenerative medicine is to use cell-based therapy, biomaterials alone, 
or a combination of cells and biomaterials to replace and repair cells, tissues, or 
organs that are damaged due to disease or injury (Atala, 2006; Zuk, 2008). 
Therapeutic application of stem cells and their further differentiated progenitors is a 
promising and rapidly emerging area of regenerative medicine in which stem cell-
based treatments could be applied to treat numerous genetic and degenerative 
disorders. The general strategy for stem cell therapies is the expansion of 
undifferentiated stem cells, followed by differentiation to a specific cell type and 
delivery to the patient, where the cells functionally integrate into the damaged tissue 
and restore its normal function (Carpenter et al., 2009). Genetically modified stem 
cells could even be used to reverse inherited genetic defects that are responsible for 
diverse pathological disorders in humans and as vehicles to specifically deliver the 
therapeutic molecules in damaged tissues or organs (Strulovici et al., 2007; 
Choumerianou et al., 2008). Furthermore, in vivo stimulation of endogenous adult 
stem cells using specific growth factors leads to the development of novel stem cell-
based therapeutic approaches for regenerative medicine (Xu et al., 2008). Besides 
showing enormous potential for transplantation therapies, intense research on stem 
cells during the last few decades has revealed that these cells are invaluable tools for 
studying the early events of development, stem cell biology in general, as well as 
basic disease mechanisms, and can be used as an ideal biological platform for drug 
discovery and testing.  
 
Stem cells are characterised as undifferentiated cells capable of self-renewal and 
differentiation into a diverse range of specialised cell types. According to their 
origin, human stem cells are classified as adult, fetal, embryonic (ESCs), and 
induced pluripotent stem cells (iPS cells). Adult and fetal stem cells reside in adult 
and fetal tissues and ESCs can be isolated from the inner cells mass (ICM) of 
blastocysts, whereas iPS cells are artificially derived from a somatic cell, by 
inducing the "forced" expression of certain genes. The developing organs and 
tissues in a fetus contain stem cells that are needed for growth and maturation while 
the primary roles of adult stem cells in the human body are to repopulate the tissues 
by generating new mature cell types and regenerating damaged tissue in response to 
injury or disease. The ESCs and iPS cells exhibit nearly unlimited self-renewal 
capacity and are able to differentiate into a wide range of cell types, whereas tissue-
specific adult stem cells have limited self-renewal and differentiation capacity 
giving rise to only specific cell types (Choumerianou et al., 2008; Hipp and Atala, 
2008).  
 
The major advantage of iPS and adult stem cells is that they can be used in patient-
specific autologous therapies, thus avoiding immune rejection complications, 
whereas the use of ESCs may result in adverse immune reactions (Mimeault and 
Batra, 2006; Moore and Lemischka, 2006; Mimeault et al., 2007; Grinnemo et al., 
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2008). Adult stem cells and iPS cells, however, are likely produced only after 
initiation of the disease or damage in a patient, precluding their use in the acute 
phase of the injury. Diseases that might benefit from stem cell-based therapies 
include age-related functional defects, diabetes, heart disease, bone or connective 
tissue disorders, haematological and immune system disorders, cerebrovascular 
disease, liver and renal failure, spinal cord injuries, Alzheimer’s diseases and 
Parkinson’s disease, as well as many aggressive and recurrent cancers 
(Choumerianou et al., 2008; Hipp and Atala, 2008; Mountford, 2008).   
 
Although cell therapies using adult stem cells for several disorders have been in use 
for many decades since 1968, beginning with the first successful bone marrow 
transplant (Gatti et al., 1968; Bach and Boitard 1986), stem cell therapy has many 
hurdles to overcome before it will become a viable and widely used clinical option. 
To fully achieve the promise of regenerative medicine, it is necessary to understand 
the biology and properties of stem cells, to achieve efficient in vitro expansion and 
differentiation of stem cells to completely functional cell types, and to overcome the 
post-transplantation challenges that limit their use, such as tumor risk, genetic 
instability, and immune rejection. 
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2. Review of literature 
2.1 Stem cells 
2.1.1 Classification and sources of stem cells 
The common hallmark of all the undifferentiated stem cells is their nearly unlimited 
self-renewal capacity and differentiation potential that confer their primordial and 
vital role during the developmental process and throughout the lifespan in adult 
mammals. These unique properties make stem cells invaluable tools for studying 
stem cell biology and various diseases and show promise in providing a new source 
of cells for transplantation therapies and in vitro models for pharmaceutical testing.  
 
In mammalian development, the fertilised egg, the zygote, has the ability to generate 
an entire organism comprising more than 200 different cell types. During 
development, stem cells divide and produce more specialised cells. The zygote, with 
its ability to produce all of the differentiated cell types, including the extra 
embryonic tissues, is totipotent. Cell differentiation subsequently results in the 
formation of a blastocyst composed of outer cells and inner cells, known as the 
ICM, which remains undifferentiated. The outer cells form trophoblast cells that 
later develop into the embryonic membranes and placenta. The cells of the ICM are 
no longer totipotent, but retain the ability to develop into all cell types of the embryo 
proper, i.e., they remain pluripotent (Wobus and Boheler, 2005). During 
embryogenesis, the pluripotent stem cells of the ICM generate the primitive 
ectoderm that eventually gives rise to the three primary germ layers: ectoderm, 
mesoderm, and endoderm. The cells of each primary germ layer are committed to 
generating cells from multiple, but still a limited number, of lineages, i.e., they are 
multipotent. The ectoderm gives rise to the nervous system and the epidermis. The 
mesoderm gives rise to the connective tissue, muscles, bones, blood, and most of the 
internal organs, whereas the endoderm forms the gastrointestinal tract (Wobus and 
Boheler, 2005; Choumerianou et al., 2008). Throughout the life of an organism, 
multipotent stem and progenitor cells are present in various tissues and organs, 
regenerating and repairing the tissue in response to injury or disease.  
 
Human stem cells are classified according to their origin and their differentiation 
potential (Figure 1). Depending on their origin, stem cells are capable of producing 
any cell type of the human body, excluding extra embryonic tissues, and are referred 
to as pluripotent (ESCs and iPS cells), or they produce some specific cell types of a 
particular lineage or closely related family, and are referred to as multipotent (fetal 
and adult stem cells) (Choumerianou et al., 2008).  
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Figure 1. Stem cell hierarchy. The zygote is defined as totipotent, because it gives rise to a complex 
organism. At the blastocyst stage, only the cells of the ICM, ESCs derived from the ICM, and iPS 
cells derived from somatic cells retain the capacity to differentiate into all three primary germ layers, 
the endoderm, mesoderm, and ectoderm, as well as the primordial germ cells, and are defined as 
pluripotent. The developing organs and tissues in a fetus contain partly matured multipotent stem 
cells that have more restricted differentiation potential than pluripotent stem cells. Throughout adult 
life, multipotent stem and progenitor cells continue to reside in various tissues and organs, replacing 
lost or injured cells. Picture modified from image prepared by Bettina Lindroos in the thesis: 
Characterization and Optimization of in vitro culture conditions of adult stem cells for clinical cell 
therapy. Acta Universitatis Tamperensis 1477. Original images were prepared by Catherine Twomey 
for the National Academies Understanding stem cells: An Overview of the Science and Issues, 
http://www.nationalacademies.org/stemcells. 
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2.1.2 Fetal stem cells 
Fetal stem cells can be isolated from various organs and tissues of the fetus or from 
supportive extra embryonic structures of fetal origin (Hemberger et al., 2008). Fetal 
stem cells have been isolated from fetal tissues, including bone marrow, liver, 
blood, lung, spleen, pancreas and kidney, and from several extra embryonic tissues, 
including umbilical cord blood, amniotic fluid and membrane, Wharton’s jelly, and 
placenta (Campagnoli et al., 2001; In ‘t Anker et al., 2003; In ‘t Anker et al., 2004; 
Pappa and Anagnou, 2009). Fetal stem cells exhibit several features of ESCs, such 
as the expression of stem cell markers and their ability to self-renew (Guillot et al., 
2007). The differentiation potential of some specific types of fetal stem cells 
recapitulates features of plasticity residing between pluripotent and multipotent stem 
cells, while other types of fetal stem cells are merely multipotent (Pappa and 
Anagnou, 2009). Fetal stem cells can differentiate into functional haematopoietic 
cells, adipocytes, chondrocytes, osteocytes, cardiomyocytes, hepatocytes, insulin-
secreting β-cells, lung progenitor cells, muscle cells, and neural cells, including 
dopaminergic neurons and glia (Mimeault et al., 2007).   
To date, studies of fetal stem cells have provided important information and new 
insights into the understanding of the biology of stem cells in general and have 
suggested strategies to utilise their therapeutic potential. Several problems, however, 
are associated with the therapeutic use of prenatal fetal stem cells. The stem cells in 
fetal tissues are present in low numbers and need to be greatly expanded in vitro to 
be sufficient for the therapeutic needs of adults. In addition, tissue rejection may 
limit the usefulness of fetal stem cells for human clinical applications. Stem cells 
from extra embryonic sources, mostly of the mesenchymal type, are a particularly 
interesting source of stem cells for regenerative medicine because they show an 
expansion potential superior to that of stem cells isolated from adult tissues, 
demonstrate no teratoma formation, and appear to be less immunogenic (In ‘t Anker 
et al., 2003; Gang et al., 2004; Pappa and Anagnou, 2009). 
2.1.3 Adult stem cells 
Adult stem cells exhibit a limited self-renewal and differentiation capacity that is 
restricted to the cell types of a particular lineage or a closely related family of cells 
(Choumerianou et a., 2008; Hipp and Atala 2008). The major advantage of adult 
stem cells is that they can be used in autologous therapies, thus avoiding any 
immune rejection complications (Mimeault and Batra, 2006; Moore and Lemischka, 
2006; Mimeault et al., 2007). It has been known for decades that bone marrow 
contains two types of stem cells: haematopoietic stem cells, which are committed to 
differentiate into all the haematopoietic cell lineages in blood, and the less-
differentiated stromal mesenchymal cells (Choumerianou et al., 2008). Within the 
last decade, however, adult stem cells have been identified in other organs and 
tissues, including brain, peripheral blood, blood vessels, skeletal muscle, skin, 
adipose tissue, dental pulp, liver, pancreas, eyes, kidneys, lungs, heart, gut, liver, 
ovarian epithelium, prostate, and testis (Presnell et al., 2002; Jiang et al., 2002; 
Mimeault et al., 2007). Besides haematopoietic stem cells, the most characterised 
and widely-used type of adult stem cells are the mesenchymal stem cells (MSCs), 
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which are found in various tissues throughout the body, e.g., bone marrow, skin, fat, 
and muscle. MSCs, which have a broad plasticity and greater differentiation 
potential than many other adult stem cell types, can give rise to a large variety of 
specialised mesenchymal tissues including bone, cartilage, fat, muscle, tendon, 
ligament, and other kinds of connective tissue (Pittenger et al., 1999).  
 
While many adult stem cells, including MSCs, are present at a low frequency (on 
the order of 1 in 10000 cells within the tissue), have limited capacity to divide, and 
are difficult to expand in culture conditions, human adipose stem cells (ASCs) are 
an abundant, readily available population of multipotent progenitor cells that reside 
in adipose tissue and can easily be expanded in vitro (Schaffler and Buchler, 2007; 
Lindroos et al., 2009). Large numbers of ASCs can be retrieved from adipose tissue 
and can be induced to undergo adipogenic, osteogenic, chondrogenic, neurogenic, 
and myogenic differentiation in vitro (Zuk et al., 2001; Schaffler and Buchler, 2007; 
Lindroos et al., 2009). ASCs are typically characterised by their immunophenotype 
in the undifferentiated state and by their differentiation potential towards the 
adipogenic, osteogenic, and chondrogenic lineages in the presence of lineage-
specific growth factors and cytokines (Gimble and Guilak, 2003). Furthermore, 
ASCs exhibit immunoprivileged properties and lack the expression of human 
leukocyte antigen class II (HLA-DR), and thus demonstrate therapeutic applicability 
in pre-clinical studies in diverse fields (Zuk et al., 2001, Lindroos et al., 2009). 
While the current use of adult stem cells is quite limited, mostly due to challenges 
involved in isolation, maintenance, and expansion of these cells, there is great 
potential for the future utilization of these cells in tissue-specific regenerative 
therapies.  
2.1.4 Human embryonic stem cells 
Human ESCs are generally derived from the ICM of 5-day-old blastocysts. Human 
ESC lines can also be created from the whole blastocyst or earlier morula stage 
embryos, albeit at a lower efficiency than those from the ICM of blastocysts 
(Reubinoff et al., 2000; Strelchenko et al., 2004; Chen et al., 2005). The first 
permanent hESC line was established in 1998 from the ICM of a preimplantation 
embryo (Thomson et al., 1998). Since 1998, over 650 hESC lines have been 
registered in the EU (www.hESCreg.eu.). In most cases, excess or poor quality 
embryos donated for research by couples undergoing in vitro fertilization (IVF) 
treatments that would otherwise be discarded are used to create hESC lines (Lei et 
al., 2007; Skottman et al., 2007). The most commonly used method to derive hESC 
lines is isolation of the ICM using pronase and immunosurgery (Thomson et al., 
1998). In immunosurgery, the blastocyst is incubated with mouse antibodies specific 
to human trophoectoderm and guinea pig complement proteins, resulting in lysis of 
the trophoectoderm so that the only surviving cells constitute the ICM (Thomson et 
al., 1998; Hipp and Atala, 2008). Later, other methods using Tyrode’s acid or 
mechanical removal of the zona pellucida instead of pronase, followed by 
mechanical isolation of the ICM, were developed for the derivation of hESC lines, 
thus avoiding contact of the blastocyst with xenogeneic (i.e., animal-derived) factors 
(Genbacev et al., 2005; Ström et al., 2007).  
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Due to ethical restrictions surrounding research with hESCs, new methods are being 
developed to derive hESC lines without destroying human embryos. Human ESC 
lines can also be derived from late (day 6-7) arrested embryos (Zhang et al., 2006) 
and from single blastomeres of an arrested four-cell-stage embryo (Feki et al., 
2008). Arrested embryos have stopped dividing and have unequal or fragmented 
cells and blastomeres. These arrested embryos constitute over half of the embryos 
produced by IVF procedures and are usually discarded. Single cell blastomeres have 
also been used to derive new hESC lines without destroying the embryo 
(Klimanskaya et al., 2006; Eiges et al., 2007).  This alternative method is based on a 
technique used to obtain a single cell embryo biopsy for preimplantation genetic 
diagnosis of genetic defects.  
 
A unique feature of hESCs that discriminates them from other types of stem cells is 
their ability to proliferate in long-term cultures while maintaining their pluripotent 
nature. The undifferentiated stage of hESCs can be monitored based on the 
morphological characteristics of the cells. The basic characteristics of these cells are 
a high nucleus to cytoplasm ratio, prominent nucleoli, and distinct colony 
morphology (Carpenter et al., 2003; Draper et al., 2004). Human ESCs express high 
levels of telomerase, which explains their ability to undergo nearly unlimited self-
renewal (Thomson et al., 1998; Reubinoff et al., 2000). In addition, hESCs are 
defined by alkaline phosphatase (ALP) activity, a normal karyotype, and the 
expression of several transcription factors and cell surface proteins (Thomson et al., 
1998; Reubinoff et al., 2000). The transcription factors POU domain transcription 
factor Oct-4, homeobox protein Nanog, and HMG-box transcription factor Sox2 
form the core regulatory network that ensures the maintenance of pluripotency, 
while other characteristic transcription factors expressed by hESCs include Lin-28, 
Rex-1, and Thy-1. The cell surface antigens most commonly used to identify hESCs 
are the stage-specific embryonic antigen (SSEA)-3 and SSEA-4 and the tumor-
related antigen (TRA)-1-60 and TRA-1-81, as well as cluster of differentiation 
(CD)9 and CD24. Unlike mouse ES cells, however, hESCs do not express SSEA-1 
(Thomson et al., 1998; Reubinoff et al., 2000; Richards et al., 2004; Hoffman and 
Carpenter, 2005a). Furthermore, hESC-specific characteristics include unique 
histone modification and DNA methylation patterns (Bernstein et al., 2006), specific 
expression of a group of microRNAs (Laurent et al., 2008), and a unique cell cycle 
with a shortened G1 phase (Stead et al., 2002) and pluripotency.  
 
The pluripotent nature of hESCs allows them to be differentiated into specialised 
cell lineages of all three embryonic germ layers: ectoderm, endoderm, and 
mesoderm (Thomson et al., 1998; Reubinoff et al., 2000). The differentiation is 
defined by the formation of embryoid bodies (EB) in vitro and teratoma formation 
in vivo when transplanted into severe combined immunodeficient (SCID) mice 
(Thomson et al., 1998; Reubinoff et al., 2000). In vitro, hESCs have been directly 
differentiated into various different cell types, such as neurons (Reubinoff et al., 
2001; Schuldiner et al., 2001; Zhang et al., 2001), oligodendrocytes (Zhang et al., 
2001), dopaminergic neurons (Zhang et al., 2001), astrocytes (Zhang et al., 2001), 
hepatocytes (Hay et al., 2007), osteoblasts (Kärner et al., 2007), chondrocytes (Toh 
et al., 2007), skeletal muscle (Zheng et al., 2006), retinal cells (Haruta et al., 2005), 
keratinocytes (Ji et al., 2006), cardiomyocytes (Kehat et al., 2001), haematopoietic 
cell lineages (Chadwick et al., 2003), endothelial cells (Levenberg et al., 2002), 
insulin producing β-cells (Assady et al., 2001), and germ cells (Clark et al., 2004). 
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Human ESC lines differ from each other due divergences in isolation procedures, 
isolation stage (e.g., morula, epiblast) or individual allelic differences, further 
resulting in divergences in growth rates, differentiation capacity, karyotypic 
stability, and the ability to integrate and function in vivo (Carpenter et al., 2009).  
 
Intense research on hESCs during the last decade indicates that these cells are 
invaluable tools for studying the early events of development, stem cell biology in 
general, as well as basic disease mechanisms, and can be used as an ideal biological 
platform for drug discovery and testing. Most importantly, hESCs possess an 
enormous developmental potential that could be utilised to treat and even cure 
diverse genetic and degenerative disorders in the human body and whose pathology 
remains incurable with the other types of available clinical treatments. There are still 
major challenges including technical limitations regarding the quality of hESC 
culture, efficient differentiation of hESCs to fully functional cell types, the risk of 
teratoma formation, and the potential immunogenicity of hESCs, which need to be 
solved before hESCs can be safely used as a source for cell therapies.  
2.1.5 Human induced pluripotent stem cells 
During cellular differentiation, cells become increasingly more specialised and 
restricted in their developmental potential. Several techniques have been developed 
to de-differentiate adult somatic cells to produce patient-specific pluripotent stem 
cells without the use of embryos. Pluripotency can be induced in somatic cells by 
somatic cell fusion with pluripotent stem cells (Cowan et al., 2005), trans-
differentiation of male germ cells (Kanatsu-Shinohara et al., 2004), parthenogenesis 
(Kim et al., 2007), and somatic cell nuclear transfer (SCNT) where the oocyte 
nucleus is replaced with a nucleus derived from a somatic cell obtained from a 
donor, resulting in ESCs that are genetically identical to the donor (Wakayama et 
al., 2001). In theory, ESCs derived from such a blastocyst would not be rejected 
when transplanted into the donor. A breakthrough in nuclear transfer experiments 
occurred in 1997, when Wilmut and colleagues reported cloning the first mammal, 
the sheep named Dolly, from an adult somatic cell using SCNT (Wilmut et al., 
1997). Although tremendous effort has been put into these methodologies, success 
with human cells is limited. So far, there are no published reports of successful 
derivation of cloned hESC lines by SCNT, and pluripotent cells generated by cell 
fusion, parthenogenesis, and in vitro trans-differentiation of germ cells have an 
abnormal karyotype and imprinting status and thus immune rejection remains an 
issue (Yamanaka, 2008). 
 
A promising new source of pluripotent cells was recently discovered, as lineage-
restricted human somatic cells were reprogrammed by ectopic expression of a 
defined set of pluripotency-related transcription factors to induce the pluripotent 
state. Takahashi and Yamanaka were the first to discover that mouse embryonic 
fibroblasts (MEFs) and adult mouse fibroblasts can be reprogrammed into iPS cells 
(Takahashi and Yamanaka, 2006). They examined 24 genes considered to be 
important for ESCs and identified 4 key genes that are required to bestow ESC-like 
properties on fibroblasts. In the first published report on human cells, Yamanaka 
and his colleagues used retroviral vectors, each carrying Oct-4, Sox2, c-Myc, and 
krupper-like family of transcription factor (Klf) 4, commonly called the Yamanaka 
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factors, to reprogram human dermal fibroblasts (hDFs) to iPS cells (Takahashi et al., 
2007). Simultaneously in 2007, Yu, Thomson, and their colleagues demonstrated 
that retrovirus-mediated transfection of a different set of four transcription factors, 
Oct-4, Sox2, Nanog, and Lin-28, also induced pluripotency in human foreskin 
fibroblasts (hFFs) without introducing any oncogenes (c-Myc) (Yu et al., 2007).  
 
Like ESCs, iPS cells have a compact colony morphology and possess immortal 
growth characteristics in culture. They express markers characteristic to 
pluripotency including Nanog, Oct-4, SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and 
ALP, and exhibit high telomerase activity. Furthermore, iPS cells seem to exhibit 
differentiation potential similar to that of hESCs and can differentiate in vitro and in 
vivo into cells of all three germ layers (Takahashi et al., 2007; Yu et al., 2007. 
Global genome-wide expression analysis demonstrated that DNA and histone 
methylation patterns are similar in human iPS and hESCs and that gene expression 
patterns correlate well between these two cell types, although some differences do 
exist and thus further characterization of iPS cell lines is required to determine the 
full potential of these cells (Maherali et al., 2007; Chin et al., 2009; de Souza, 2010). 
Human ESCs currently remain the gold standard for pluripotent cells, but the 
knowledge accumulated from culturing and differentiating hESCs will likely also 
directly apply to human iPS cells.  
 
As somatic cells are reprogrammed to iPS cells, they shut down the genes specific 
for their own cell type and activate genes that maintain pluripotency. Oct-4, Sox2, 
Nanog, and Lin-28 contribute to the reprogramming, and c-Myc and Klf4 enhance 
the efficiency of clonal recovery (Park et al., 2008). What happens at the molecular 
level during the reprogramming process, however, is not fully understood and is the 
current focus in iPS cell research (Amabile and Meissner, 2009). So far, different 
human somatic cell types, including fibroblasts, keratinocytes, and cell types from 
blood have been reprogrammed to induce pluripotency (Takahashi et al., 2007; Yu 
et al., 2007; Aasen et al., 2008; Haase et al., 2009; Giorgetti et al., 2009). The 
pluripotency induction efficiency often differs between cell types, and it seems that 
the more differentiated the cell type, the more difficult it is to return it to the 
pluripotent state. In addition, in cell types with endogenously high expression levels 
of one or more of the factors that induce pluripotency, such as neural cells that 
strongly express Sox2, pluripotency may be induced with only a subset of factors 
(de Souza, 2010).  
 
The initial methods used to generate iPS cells involved the use of retroviral or 
lentiviral vectors that integrate into the genome to deliver the factors to the cells 
(Takahashi and Yamanaka, 2006; Wernig et al., 2007; Takahashi et al., 2007; Yu et 
al., 2007). Since then, however, the development in this field has been rapid and 
novel strategies have been applied to improve the reprogramming methods and 
efficiency as well as to generate iPS cells without permanent modification of the 
genome. Once reprogramming has occurred, endogenous counterparts of the 
exogenously supplied reprogramming factors are activated, indicating that 
exogenous factors are only required for the induction, not the maintenance of 
pluripotency (Takahashi et al., 2007). The nonintegrating reprogramming methods 
include adenoviruses, plasmid- and episomal vector-based approaches, and delivery 
of reprogramming factors directly as proteins (Shao and Wu, 2010). Other factors 
have been identified that can replace the four traditional transcription factors. Klf2 
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and Klf5 can replace Klf4, Sox1 and Sox3 can replace Sox2, and n-Myc and I-Myc 
can replace c-Myc (Nakagawa et al., 2008).  Nuclear receptor subfamily 5, group A, 
member 2 (Nr5a2) can be used to replace Oct-4 in the reprogramming of murine 
somatic cells and also to enhance the reprogramming process by increasing 
transcription activity (Heng et al., 2010). In addition, small molecules are capable of 
replacing some of the reprogramming factors, e.g., the histone deacetylase inhibitor 
valproic acid can replace Klf4 and c-Myc for reprogramming human fibroblasts 
(Huangfu et al., 2008b) and other small molecules with reprogramming factors 
increase the efficiency of the reprogramming process and promote more complete 
reprogramming (Huangfu et al., 2008a; Lin et al., 2009).  
 
The ability to return mature body cells to a pluripotent state enables the creation of 
patient-specific stem cell lines for the study of basic biology and various disease 
mechanisms, and has wide-ranging potential as a tool for drug discovery as well as 
for treating a number of human degenerative diseases without evoking immune 
rejection. To date, human iPS cells have been used for the study of the 
reprogramming process itself and establishment of disease-specific cell lines and the 
differentiation of these cell lines into the relevant cell types affected by the disease. 
For example, spinal motor neurons, dopaminergic neurons, and cardiomyocytes 
have been differentiated from iPS cell lines derived from patients suffering from a 
slowly progressing form of amyotrophic lateral sclerosis (Dimos et al., 2008), spinal 
muscular atrophy (Ebert et al., 2009), sporadic Parkinson’s disease (Soldner et al., 
2009), and long QT syndrome (unpublished results). Research on iPS cells is still in 
its infancy, and understanding the true potential of these cells requires continued 
investigation and more complete comparisons to ESCs. In 2010, neuronal cells were 
directly induced from mouse fibroblasts by the combined expression of neural-
lineage specific transcription factors (Vierbuchen et al., 2010).  Whether this 
method will work in human somatic cells and how comparable these directly 
differentiated cells are to their in vivo counterparts will need to be investigated.  
2.2 Culture of stem cells 
In vivo, stem cells are generally colocalised with supporting cells within the specific 
regions in each tissue, which are designated as niches. A stem cell niche is a defined 
microenvironment in which the local signals and spatial organization of the cells 
generate location-dependent control over reversing cell-fate decisions, such as self-
renewal and differentiation. The complex interactions via the formation of adherent 
junctions and the secretion of diverse soluble factors between stem cells and 
supportive cells contribute to the cell-fate decisions within the niches under specific 
physiological and pathological conditions. Arrangement of stem and supportive 
cells into niches organises the timing and levels of the signals that the stem cells 
receive, thus directing cell fate. Stem cells may also be found in clusters in the 
absence of a clearly defined niche of supportive cells, however, and still regulate 
cell fate in a spatially organised fashion indicating that cells may be capable of 
forming niches in an autoregulatory manner. In vitro, both exogenously controlled 
parameters, including physical and chemical factors in the culture environment and 
autocrine and paracrine secretion of endogenously produced factors, mediate the 
growth and fate decision of stem cells. These exogenous factors include the type and 
 28 
age of cell: culture environment such as temperature, pH, osmolality, humidity, and 
the oxygen tension as well as nutrients and toxins (Peerani et al., 2007). Cell culture 
media have an important impact on growth and differentiation of stem cells. An 
ideal culture condition would optimally mimic the natural environment of the 
particular cell type in vivo. 
 
The diverse culture conditions utilised for the in vitro expansion and differentiation 
of stem cells influence the gene expression profiles of stem cells and, hence, 
probably many of the cell properties (Skottman et al., 2006). Most stem cell lines 
established to date have been directly or indirectly exposed to xenogeneic products 
during their derivation, expansion, or differentiation in vitro. The exposure of stem 
cells to xenogeneic products increases the risk of graft rejection and severe immune 
response in the recipient (Bradley et al., 2002; Selvaggi et al., 1997). Xenogeneic 
immunogen N-glycoylneuraminic acid (Neu5Gc) for which a preformed antibody 
exists in humans, has been identified from stem cells cultured with xenogeneic 
products (Martin et al., 2005; Heiskanen et al., 2007). More recently, Sakamoto and 
co-workers reported the identification of another predominant immunogen apoB-
100 that was acquired by stem cells from xenogeneic products in the culture 
environment (Sakamoto et al., 2007; Hisamatsu-Sakamoto et al., 2008). Other 
potential risks to the recipient include viral or bacterial infections, prions, and as yet 
unidentified zoonoses (Cobo et al., 2005). Therefore, for research purposes, as well 
as for the clinical application of stem cells, the development of a completely 
defined, xeno-free, and standardised culture conditions is highly desirable. 
2.2.1 Culture of adipose stem cells 
In most cases, the capacity of adult stem cells to divide in vitro is limited, making it 
difficult to generate large numbers of stem cells. Methods are being developed to 
grow large quantities of adult stem cells in cell culture and to manipulate them to 
generate specific cell types so they can be used to treat injury or disease.  
 
ASCs are a rare exception among adult stem cells as they can be isolated in high 
numbers from either liposuction aspirates or subcutaneous adipose tissue fragments 
and can be easily expanded in vitro (Zuk et al., 2001; Lindroos et al., 2009). The 
isolation of ASCs is straightforward utilizing manual mincing and collagenase I 
enzymatic digestion (Zuk et al., 2001). Currently, the standard in vitro expansion of 
ASCs utilises fetal bovine serum (FBS) and various other xenogeneic reagents such 
as trypsin, serum albumin, and growth factors (Lindroos et al., 2009). The species of 
origin and the concentration of the serum affect the proliferation of ASCs 
(Kocaoemer et al., 2007; Mirabet et al., 2008; Herrera and Inman, 2009). In fact, 
replacing FBS with pooled allogeneic human serum (alloHS) and human serum 
derivatives leads to equal or higher proliferation rates and multilineage 
differentiation capacity of ASCs (Katz and Parker, 2006; Kocaoemer et al., 2007; 
Mirabet et al., 2008). When cultured in the presence of serum, ASCs do not require 
any feeder cells or extracellular matrix (ECM) to aid in the attachment. Serum 
composition is largely uncharacterised, containing variable amount of cytokines and 
growth factors, and showing significant lot to lot variability, which may affect the 
reproducibility of the results (Caterson et al., 2002; Herrera and Inman, 2009; 
Lindroos et al., 2009). Autologous human serum (autoHS) is a feasible option for 
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clinical applications, because it eliminates the problem of introducing xenogeneic or 
allogeneic antibodies into the recipient (Mesimäki et al., 2009). The use of 
autologous human serum for clinical applications is hindered, however, due to the 
limited availability of the large quantities needed for in vitro expansion of the cells.  
 
The drawbacks of the use of serum and the risks related to the use of xenogeneic 
products have lead to the development of serum-free media formulations. As a 
result, reduced serum media (Parker et al., 2007), serum-free media (Koller et al., 
1998; Meuleman et al., 2006; Qizhou et al., 2007) and xeno-free media (Lindroos et 
al., 2009) are now available for adult stem cell expansion.  
2.2.2 Culture of human embryonic stem cells 
Human ESCs tend to maintain tight contacts with their neighbors and grow in 
colonies in culture. Human ESCs are difficult to maintain in vitro because they tend 
to follow their natural cell fate and differentiate spontaneously. Most culture 
conditions result in some level of unwanted spontaneous differentiation of hESCs. 
Differentiation is a result of many complex interactions with intrinsic and extrinsic 
factors, including growth factors, ECM molecules and components, environmental 
stressors, and direct cell-to-cell interactions (Peerani et al., 2007). While some 
spontaneously differentiated cells usually appear at the margin and at the centre of 
hESCs colonies, an ideal culture condition provides growth support with minimal 
amounts of differentiated cells. Since the first establishment of permanent hESC line 
in 1998 (Thomson et al., 1998), various culture conditions have been described for 
the derivation and expansion of hESCs. Some of these culture methods are 
presented in Tables 1 and 2.  
Feeder cell-dependent culture conditions  
Initially, the establishment of hESC lines utilised mitotically inactivated MEFs as 
feeder cells and FBS-containing culture medium for both feeder cells and hESCs 
(Thomson et al., 1998). MEFs have a limited lifespan in culture and can only be 
cultured for five to six passages before entering senescence (Choo et al., 2006). To 
eliminate xeno-contamination, human feeder cells have replaced mouse feeder cells 
to support the undifferentiated growth of hESCs (Table 1). Compared to MEFs, 
human feeder cells have an extended lifespan (Amit et al., 2003). Human ESC lines 
can maintain their self-renewal and pluripotency on several types of human feeder 
cells including hFFs (Amit et al., 2003; Hovatta et al., 2003), fetal placental 
fibroblasts (Genbacev et al., 2005), uterine endometrium cells (Lee et al., 2005), 
adult marrow stroma cells (Cheng et al., 2003), fetal or adult muscle and skin cells 
(Richards et al., 2002; Richards et al., 2003), and autologous hESC-derived 
fibroblast cells (hESC-df; Xu et al., 2004; Wang et al., 2005; Stojkovic et al., 2005). 
Recently, basic fibroblast growth factor (bFGF)-secreting hESC-df cells were 
derived enabling hESC cultures to be maintained without exogenous bFGF (Saxena 
et al., 2008; Unger et al., 2009). Although hESC-df cells provide an interesting 
opportunity, differentiation of fibroblast-like cells from hESCs and their use for 
hESC maintenance is very labor intensive and not an optimal choice for 
standardisation and mass production of undifferentiated hESCs.  
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Different types of human feeder cells appear to have different capabilities to support 
the growth of undifferentiated hESCs (Richards et al., 2003; Eiselleova et al., 2008), 
and MEFs seem to support the growth of some hESC lines better than human feeder 
cells (Richards et al., 2002; Richards et al., 2003). The mechanisms by which feeder 
cells form a supportive niche for the maintenance of undifferentiated hESCs in 
culture are not entirely understood, but feeder cells are suggested to provide a 
suitable attachment substrate for hESCs and to secrete important soluble factors 
(Raikwar et al., 2006). To optimise the culture conditions, great effort has been 
made to identify conditioned media (CM) components for hESC self-renewal. High 
throughput screening methods have been used to investigate the protein composition 
of media conditioned by mouse and human feeder cells (Lim and Bodnar, 2002; 
Prowse et al., 2005; Prowse et al., 2007), providing preliminary insight into the 
possible feeder cell-secreted factors that support hESC growth. Human feeder cells 
secrete transforming growth factor beta 1 (TGFβ1), Activin A, bFGF, and low levels 
of bone morphogenic protein 4 (BMP4), while mouse feeder cells secrete 
comparable levels of TGFβ1 and BMP4, higher levels of Activin A, and no bFGF 
(Lim and Bodnar, 2002; Prowse et al., 2005; Prowse et al., 2007; Eiselleova et al., 
2008). Most feeder cells have been exposed to xenogeneic products such as FBS, 
during their isolation and culture. However, the establishment of a xeno-free hFF 
cell line using human serum has been reported (Ellerström et al., 2006; Meng et al., 
2008). Although, several xeno-free medium formulations have been developed for 
the derivation and propagation of primary cell lines, such as fibroblasts, the 
performance of these media for the expansion of fibroblasts is poor (K.R. 
unpublished observations).  
 
Initially, FBS was used in the culture medium for hESCs. FBS, however, had a 
negative effect on hESCs as the colonies undergo excessive differentiation (Amit et 
al., 2000; Amit and Itskovitz-Eldor, 2002). The development of a commercially 
available serum replacement, Knockout™ serum replacement (KO-SR, Invitrogen) 
was a major advancement in the establishment of a serum alternative (Price et al., 
1998). KO-SR supplemented with bFGF supports the prolonged growth of hESCs in 
an undifferentiated state, with a higher growth rate and cloning efficiency than in 
FBS-containing medium (Amit et al., 2003; Richards et al., 2003; Koivisto et al., 
2004). To further examine the mechanisms that support the enhanced growth of 
hESCs in KO-SR-containing medium, the gene expression profiles of hESCs 
cultured under FBS- and KO-SR-containing media formulations were examined 
(Skottman et al., 2006). Although the expression of stem cell markers and their 
differentiation capacity in EBs were similar in both conditions, surprisingly, over 
100 genes were significantly differentially expressed in these conditions. Further, 
many differentially expressed genes in cells cultured in medium containing serum 
included those expressed in differentiated cells. Such changes may have 
fundamental importance for hESCs and as many of the differentially expressed 
genes have no known biological function, further studies are required to clarify the 
true impact of these results. KO-SR supplemented with bFGF also supports the 
derivation of hESC lines (Genbacev et al., 2005; Inzunza et al., 2005) and currently 
KO-SR is widely used for the derivation and culture of hESCs. Although the use of 
KO-SR in hESC culture medium provides more standardised and more defined 
culture conditions compared to FBS-containing conditions, it contains AlbuMAX, a 
lipid-rich bovine serum albumin (BSA) and bovine transferrin and is a xenogeneic 
component (Price et al., 1998).  
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Table 1. Human feeder cell- dependent culture methods for hESCs.  
Feeder-cell source Medium 
components 
M/D References 
Fetal muscle, Fetal skin, 
Adult fallopian tube 
FBS/Human serum M/D Richards et al. 2002  
Adult skin, Adult muscle FBS/KO-SR, bFGF M Richards et al. 2003  
Human foreskin FBS, LIF M/D Hovatta et al. 2003  
Human foreskin KO-SR, bFGF M Amit et al. 2003  
Adult bone marrow stroma KO-SR, bFGF M Cheng et al. 2003  
hESC-derived fibroblasts KO-SR, bFGF M Xu et al. 2004  
Human foreskin KO-SR, bFGF M/D Inzunza et al. 2005  
Placenta KO-SR, bFGF M/D Genbacev et al. 2005  
Uterine endometrium KO-SR, bFGF M/D Lee et al. 2005  
hESC-derived fibroblasts KO-SR, bFGF M/D Wang et al. 2005  
Xeno-free human foreskin Human serum  M/D Ellerström et al. 2006  
Human foreskin HEScGRO  M Chin et al. 2009 
Human foreskin KO-SR XF  M Chin et al. 2009 
 
Abbreviations: M=Maintenance; D=Derivation; HEScGRO=Chemically defined xeno-free medium 
(Millipore); KO-SR XF= Chemically defined xeno-free medium (Invitrogen). Other abbreviations 
are presented beginning at page 13. 
 
Human serum has also been used as a xeno-free alternative for the maintenance and 
derivation of hESCs (Richards et al., 2002). In 2006, Ellerström and co-workers 
reported the establishment of xeno-free hFF feeders for hESC derivation in a 
medium supplemented with human serum and devoid of any animal-derived 
material (Ellerström et al., 2006). In accordance with previously published data 
(Richards et al., 2002), Ellerström et al. (2006) also reported the ability to derive 
hESCs in human serum-containing medium using a xeno-free derivation procedure 
with continuous propagation of undifferentiated cells for more than 30 passages. 
Although human serum provides a xeno-free serum alternative, this source, similar 
to FBS, is plagued by batch variability, a poorly defined composition, and variable 
efficacy in hESC cultures (Richards et al., 2002).  
Feeder cell-free culture conditions  
Significant progress has been made in the development of feeder cell-free culture 
methods for hESC propagation (Table 2). The first feeder cell-free maintenance 
method for existing hESC lines were cultures on Matrigel using CM from MEFs 
(Xu et al., 2001). Matrigel is a complex basement membrane mixture secreted by 
mouse sarcoma cells, composed of several ECM components such as laminin, 
collagen IV, entactin, and heparan sulfate proteoglycan, as well as various growth 
factors. There are previous reports of the use of FBS coating (Vallier et al., 2005; 
Soh et al., 2007) and human serum coating (Stojkovic et al., 2005) as a matrix for 
feeder cell-free propagation of hESCs. Although the media used with the FBS 
coating was defined in both reported studies, the serum used as a coating material 
was not, and therefore more defined matrix materials for the feeder cell-free 
propagation of hESCs are needed. As a step forward, human derived ECM 
components such as laminin or fibronectin have also been used as substrates in 
feeder cell-free culture conditions (Xu et al., 2001; Amit et al., 2004; Li et al., 2005; 
Beattie et al., 2005; Noaksson et al., 2005; Liu et al, 2006; Lu et al., 2006). They 
have, however, proven to be inferior compared to Matrigel in the long-term hESC 
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cultures, thus indicating that other yet unknown factors are needed for successful 
feeder-cell free culture of hESCs. Recently, ECM derived from xeno-free hFFs was 
described to support the maintenance of hESCs for at least 20 passages (Meng et al., 
2008).  
Table 2. Feeder cell-free culture methods for hESCs. 
Substrate hESC medium composition M/D References 
Matrigel/Laminin CM (MEFs), KO-SR, bFGF M Xu et al. 2001 
Matrigel CM (hESC-dF), KO-SR, bFGF  M Xu et al. 2004 
Matrigel KO-SR, bFGF, BIO M Sato et al. 2004  
Fibronectin KO-SR, TGFβ1, bFGF M Amit et al. 2004 
Matrigel KO-SR, Noggin, high bFGF M Xu et al. 2005  
Matrigel/Laminin X-Vivo 10, high bFGF, SCF, FL, LIF M Li et al. 2005 
Laminin X-Vivo 10, high bFGF M Genbacev et al. 2005 
Laminin KO-SR, bFGF, Activin A, KGF, NIC M Beattie et al. 2005  
Fibronectin CM (MEFs), KO-SR, bFGF M Noaksson et al. 2005  
Matrigel PDGF, S1P  M Pebay et al. 2005  
ECM from MEFs KO-SR, Plasmanate, LIF, bFGF M/D Klimanskaya et al. 2005  
Human serum matrix CM (hESC-df), KO-SR, bFGF M Stojkovic et al. 2005  
FBS matrix CDM (Activin A/Nodal, bFGF) M Vallier et al. 2005  
Matrigel KO-SR, Noggin, high bFGF M Wang et al. 2005  
Matrigel/Fibronectin N2, B27, high bFGF M Liu et al. 2006  
Matrigel N2, B27, BSA, bFGF M Yao et al. 2006  
Matrigel/Fibronectin/ 
Fibronectin, Collagen 
HESCO  
(bFGF, Wnt3a, April/BAFF) 
M Lu et al. 2006  
Matrigel KO-SR, bFGF, BDNF, NT3, NT4 M Pyle et al. 2006  
Matrigel/ 
Human ECM mix 
mTeSR1/TeSR1 M/D Ludwig et al. 2006  
Laminin SFM, high bFGF M/D Fletcher et al. 2006  
Matrigel/FBS matrix CDM (Activin A, bFGF, PTN) M Soh et al. 2007  
Matrigel X-Vivo 10, high bFGF, TGFβ1 M Peerani et al. 2007  
Matrigel KO-SR, IGF-II M Bendall et al. 2007 
Matrigel DC-HAIF  
(HRG-β1, Activin A, IGF-I, bFGF) 
M Wang et al. 2007  
None NC-CM and hEL-CM M Bigdeli et al. 2007 
ECM from XF-hFFs HEScGRO, high bFGF, ROCK M Meng et al. 2008 
Fibronectin StemPro M Chin et al. 2009 
Matrigel Stemedia™ NutriStem™ XF/FF M Stemgent 
 
Abbreviations: M=Maintenance; D=Derivation; X-Vivo 10=Xeno-free basal medium; 
CDM=chemically defined medium; HESCO=chemically defined medium; Human ECM 
mix=laminin, fibronectin, vitronectin, collagen; mTeSR1=chemically defined medium, containing 
xeno-derived components; TeSR1=chemically defined xeno-free medium; SFM=Serum-free 
medium; DC-HAIf=chemically defined medium; HEScGRO=Chemically defined xeno-free medium 
(Millipore); Stempro=defined, serum-free medium (Invitrogen); Stemedia™ NutriStem™ XF/FF= 
defined, serum-free medium (Stemgent). Other abbreviations are presented beginning at page 13. 
 
 
KO-SR is also widely used as a culture medium in feeder cell-free methods (Table 
2). The early feeder cell-free studies relied on the use of CM from MEFs containing 
KO-SR (Xu et al., 2001; Noaksson et al., 2005). Later, feeder cell-free propagation 
of hESCs using CM from hESC-derived fibroblasts was described (Xu et al., 2004; 
Stojkovic et al., 2005). CM is usually prepared by overnight incubation with a 
confluent feeder layer and by subsequent filtration prior to its use (Bigdeli et al., 
2007). CM from different feeder cells all differ in their ability to support the growth 
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of undifferentiated hESCs (Xu et al., 2001). Feeder cell-free and matrix-free 
cultures of hESCs directly on plastic surfaces have also been described (Bigdeli et 
al., 2007). These studies used extensive adaptation processes in which hESCs 
cultured on Matrigel were first adapted to neonatal chondrocytes-CM (NC-CM) 
during a 20-day cultivation period and subsequently transferred to cell- and matrix-
free polystyrene dishes where hESCs were cultured for 11 days in the presence of 
NC-CM followed by culture in the presence of human embryonic lung fibroblast 
CM (hEL-CM) for 43 passages. For some unknown reason, the hESCs were 
dependent on the use of NC-CM during the adaptation process.  
 
Feeder cell-free derivation of hESC lines is also possible. ECM from MEFs and 
KO-SR containing medium were used in the first successful feeder cell-free 
derivation (Klimanskaya et al., 2005). Another report described the derivation of 
two hESC lines in a defined culture medium, TeSR1, containing components solely 
derived from recombinant sources or purified from human material, on substrate 
formed by human ECM components: fibronectin, laminin, collagen IV, and 
vitronectin (Ludwig et al., 2006).  One of these lines had karyotype 47XXY, 
however, which is common in human embryos. The second line gained an extra 
chromosome 12 at passage level 40. Currently, the modified formulation, mTeSR1, 
containing xenogeneic components, is one of the most commonly used feeder cell-
free culture systems utilised with Matrigel. Recently, Fletcher and co-workers 
compared different derivation conditions for hESCs (Fletcher et al., 2006). They 
used human laminin, Matrigel, or hDFs as the substrate and KO-SR containing 
medium or serum and xeno-free medium (SFM), which were either conditioned 
with hDFs or used without conditioning. They were able to derive one hESC line 
using nonconditioned SFM and human laminin in xeno-free derivation conditions. 
In response to embryonic cell lifting, the line was transferred on hDFs only 8 days 
after initial derivation on human laminin. For unknown reasons, expression of the 
undifferentiated hESC marker SSEA-4 was gradually lost in this line maintained in 
SFM. 
Chemically defined and xeno-free culture conditions 
To develop a chemically-defined culture environment that maintains 
undifferentiated self-renewal of hESCs, it is necessary to first determine the signals 
and mechanisms governing hESC fate. Over the last few years, a number of 
molecular factors and signalling pathways that play a major role in maintaining 
hESCs self-renewal were identified (Figure 2). One of these important factors is 
bFGF, which seems to act in part by inducing the expression of TGF-β superfamily 
molecules and insulin-like growth factor (IGF)-II (Xu et al., 2005; Bendall et al., 
2007), activation of Gremlin-1, and suppression of BMB4 (Greber et al., 2007). 
Basic FGF is the most commonly used media component required for hESC 
maintenance, both in the presence and absence of fibroblast feeder cells. TGFβ 
superfamily members, namely TGFβ, Activin A, and Nodal, are also important 
regulators of hESC self-renewal by inducing phosphorylation of the intracellular 
mediators Smad2 and/or Smad3 and have been used by several research groups in 
the feeder cell-free culture of hESCs (Amit et al., 2004; Beattie et al., 2005; James 
et al., 2005; Vallier et al., 2005; Peerani et al., 2007). Furthermore, Activin A 
induces the expression of several pluripotency genes, such as Oct-4 and Nanog, and 
stimulatory growth factors, such as Nodal, Wnt3, bFGF, and FGF8 (Xiao et al., 
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2006). More complex is the role of the Wnt family of proteins in hESC self-renewal 
because of conflicting reports regarding its role in hESCs self-renewal (Dravid et 
al., 2005). A proposed Wnt-signalling activator, glycogen synthase kinase-2 
inhibitor, BIO, as well as a combination of Wnt3a, April/BAFF and bFGF have 
been used to supplement feeder cell-free culture of hESCs (Sato et al., 2004; Lu et 
al., 2006). Inhibiting the activity of BMPs with a specific BMP signalling antagonist 
such as Noggin may also enhance the maintenance of hESCs in a pluripotent state 
(Wang et al., 2005; Xu et al., 2005). IGF-II is implicated as a direct mediator of 
hESC growth, being expressed in response to bFGF, and in parallel with 
TGFβ/Nodal/Activin (Bendall et al., 2007). bFGF might drive the expression of 
IGF-II and TGFβ factors from the hESC-df-like cells generally surrounding the 
hESC colonies in both feeder and feeder cell-free cultures. Another study described 
the importance of IGF-I for hESCs self-renewal, as well as a role for heregulin-β1 
(HRG-β1) an human EGF receptor 2/3 ligand (ErbB), and Activin A using a simple 
defined medium (Wang et al., 2007). Neurotrophins (NT; Pyle et al., 2006), 
pleiotrophin (PTN; Soh et al., 2007), and a Rho-associated kinase inhibitor (ROCK) 
(Watanabe et al., 2007) may be used to enhance clonal growth of hESCs by 
inhibiting apoptosis.  
 
 
Figure 2. Molecules regulating pluripotent stem cell renewal. Growth factors such as bFGF, IGF, 
TGF-β1, and Activin A stimulate pluripotent stem cell growth via direct and indirect mechanisms, 
whereas BMP signalling induces premature differentiation.  
  
Besides growth factor proteins, recent reports indicate that lipid molecules, 
abundant in serum and AlbuMAX, which is an essential ingredient within KO-SR 
(Price et al., 1998), are also important regulators for maintaining hESC self-renewal. 
Sphingosine-1-phosphate (S1P) enhances proliferation and prevents apoptosis of 
hESCs (Inniss and Moore, 2006), whereas S1P and platelet-derived growth factor 
(PDGF) synergistically stimulate the self-renewal of hESCs grown on MEFs (Pebay 
et al., 2005; Wong et al., 2007). Albumin-associated lipids present in KO-SR have a 
strong effect on hESC self-renewal (Garcia-Gonzalo and Izpisua Belmonte, 2008). 
In this study, the major lipids bound to the lipid-rich albumin were identified and 
several lipid candidates: lysophosphatidylcholine, lysophosphatidic acid (LPA), 
S1P, prostaglandin (PG) E2, and dexamethasone were tested in the culture of hESCs, 
but the active lipid responsible for the positive effect of AlbuMAX on hESC self-
renewal remains to be discovered. Previously LPA has been shown to inhibit 
neuronal differentiation of hESCs by activating the Rho/ROCK and the PI3/Akt 
pathways (Dottori et al., 2008).  
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Human ESCs can be cultured under feeder cell-free conditions, thus it is possible to 
systematically define and characterise both the required exogenous factors and the 
factors produced by supportive feeder cell layers. Several chemically defined culture 
media with a cocktail of recombinant growth factors and cytokines have been 
developed to sustain undifferentiated propagation of existing hESC lines (Table 2). 
Feeder-cell free culture conditions are attractive with regard to the therapeutic use of 
hESCs and for drug testing because of the absence of other cell types that may 
hamper the utilization of the cells. Feeder cell-free culture of hESCs routinely 
utilises mostly xenogeneic enzymatic cell dissociation, which is considerably faster 
and simpler than mechanical dissection and enables large-scale expansion of hESCs. 
Several reports however indicate that the use of enzymes may increase the risk of 
introducing cytogenetic aberrations during propagation in vitro due to excessive 
and/or frequent dissociation to single cells (Draper et al., 2004; Mitalipova et al., 
2005; Imreh et al., 2006). In contrast, mechanical dissociation allows for selective 
transfer of exclusively undifferentiated cell aggregates and seems to better maintain 
genetic stability (Lei et al., 2007). 
 
Currently, there are at least four commercially available xeno-free culture media, 
HEScGRO (Millipore), developed for the culture of hESC lines with feeder cells; 
KnockOut™ SR Xeno-free (KO-SR XF, Invitrogen) for feeder or feeder cell-free 
culture of hESCs; Stemedia™ NutriStem™ XF/FF (Stemgent); and TeSR2 
(StemCell Technologies) for feeder-cell free culture of hESCs. Whereas TeSR2 and 
Stemedia™ NutriStem™ XF/FF media are designed to be used with Matrigel, KO-
SR XF can be used with a humanised matrix, CELLstart, thus enabling xeno-free 
feeder cell-free culture of hESCs.  
2.2.3 Culture of induced pluripotent stem cells 
Human iPS cells exhibit many features characteristic of hESCs including 
morphology, marker expression with minor differences, and differentiation 
potential; hence, human iPS cells have similar culture requirements as hESCs. 
Similar to hESCs, however, xenogeneic products are present at multiple steps in the 
currently available protocols for iPS cell generation and maintenance. First, the 
primary cultures of human somatic cells to be reprogrammed are usually established 
using FBS-containing media and passaged with xenogeneic enzymes such as 
trypsin. In addition, cell lines used to produce viral supernatants for the 
reprogramming of somatic cells are usually maintained with FBS and trypsin. 
Finally, in the culture of iPS cells, MEFs or human feeder cells are routinely used 
with FBS or KO-SR containing culture medium and cells are dissociated using 
enzymes from animal origin (Takahashi et al., 2007; Yu et al., 2007; Park et al., 
2008; Lowry et al., 2008). Feeder cell-free culture of human iPS cells on Matrigel 
using CM derived from MEFs has also been reported (Aasen et al., 2008).  
 
So far, the derivation of iPS cell lines has relied on the use of MEF feeder cells but 
recently human iPS cells were derived on immortalised human fibroblast feeders 
from their parental line using KO-SR containing medium in the derivation and 
subsequent culture (Unger et al., 2009). Another recent report describes the feeder 
cell-free derivation of human iPS cell lines on Matrigel using MEF-CM or serum 
and feeder layer-free culture medium (Totonchi et al., 2009). More recently, the 
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generation of iPS cells under xeno-free conditions has been reported; xeno-free 
hDFs were derived using human serum and were used as both the source of cells for 
reprogramming as well as autologous feeder cells for the generation and 
maintenance of iPS cells (Rodriguez-Piza et al., 2010). Two different xeno-free 
culture media containing either KO-SR XF or human plasma-derived cell culture 
additive were used for the reprogramming of human fibroblasts to pluripotency and 
subsequent culture of the resulting iPS cells (Rodriguez-Piza et al., 2010). The 
recent advancements in the generation and maintenance of iPS cells should facilitate 
the safe clinical translation of iPS cell-based technology.  
2.2.4 Culture of stem cells under hypoxia 
The growth, differentiation, and fate decisions of stem cells and multipotent 
progenitors are influenced by complex signals in the microenvironment, including 
oxygen availability. Oxygen is a potent signalling molecule that has received 
increasing recognition for its ability to affect fundamental characteristics, such as 
self-renewal and differentiation, of various stem cell types (Covello and Simon, 
2004; Covello et al., 2006).  
 
The response to hypoxia is regulated by hypoxia inducible factors (HIFs), which 
regulate the expression of over 200 genes, including genes involved in 
erythropoiesis, apoptosis, and proliferation. HIFs are transcription factors consisting 
of three oxygen-dependent alpha subunits, HIF-1α, HIF-2α, and HIF-3α, and the 
constitutively expressed beta subunit HIF-1β. Hypoxia-inducible factors exhibit 
reduced stability as the oxygen concentration rises and are rapidly degraded under 
atmospheric oxygen tensions (Semenza, 2000). They regulate transcriptional 
responses as heterodimers with HIF-1β (Wenger and Gassmann, 1997) through 
binding to cis-acting hypoxia-response elements (HREs) on their target genes when 
oxygen tension is low (Wenger and Gassmann, 1997; Greijer et al., 2005).  HIF-3α 
differs from HIF-1α and HIF-2α in that it lacks the C-terminal activation domain 
(CTAD) required for co-activator binding and is thus unable to recruit co-
transcriptional regulators and basal transcriptional machinery to gene targets. HIF-
2α targets the HRE-sequence independently of HIF-1α, suggesting that they have 
functionally diverse roles. Indeed, HIF-1α, the first HIF-α subunit described and 
originally thought to be the global regulator of the hypoxic response (Semenza and 
Wang, 1992), predominantly regulates glycolytic genes (Hu et al., 2003), whereas 
HIF-2α regulates hypoxia-induced erythropoietin (Warnecke et al., 2004; Rankin et 
al., 2007). To date, little is known about which genes are targeted by HIF-3α. The 
contribution of HIF-2α and HIF-3α to the regulation of the hypoxic response, 
however, remains to be fully characterised (Forristal et al., 2009).  
 
Since the first derivation of hESCs was reported (Thomson et al., 1998) it has 
become routine practice to culture these cells under atmospheric oxygen (20% O2). 
Naturally, human embryos grow in vivo in lower oxygen tension environments and 
physiological O2 levels improve in vitro embryo development (Thompson et al., 
1990; Giles and Foote, 1997; Petersen et al., 2005) and increase cell number, 
particularly of the ICM (Harvey et al., 2004; Rinaudo et al., 2006) indicating that 
O2-regulated gene expression supports the maintenance of pluripotent cells. Thus, 
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hESCs, a derivative of embryos, will likely grow more favorably in a reduced O2 
tension (Westfall et al., 2008).  
 
Hypoxic exposure promotes the proliferation of mouse ESCs through cooperation of 
arachidonic acid and PI3K/Akt signalling pathways and increases differentiation via 
suppression of the leukemia inhibitor factor (LIF)- signal transducers and activator 
of transcription (STAT)3 signalling pathway (Jeong et al., 2007; Lee et al., 2007). In 
contrast, there is emerging evidence to suggest that reducing the oxygen 
concentration towards physiological levels is beneficial for the in vitro maintenance 
of hESCs in terms of decreasing the amount of spontaneous differentiation, 
supporting self-renewal (Ezashi et al., 2005; Ludwig et al., 2006; Peura et al., 2007; 
Westfall et al., 2008), and reducing spontaneous chromosomal aberrations (Forsyth 
et al., 2008). The controversy continues, however, as a recent report suggests that 
there are no significant advantages of culturing hESCs under reduced oxygen 
tension (Chen et al., 2009).  
 
The Notch signalling pathway was suggested to be involved in the maintenance of 
self-renewal under hypoxia (Prasad et al., 2009), but although the Notch signalling 
pathway regulates the fate of many types of stem cells, there is currently very little 
evidence for its involvement in controlling the fate of hESCs (Walsh and Andrews, 
2003; Babaie et al., 2007). Oct-4, one of the core transcription factors known to be 
essential for self-renewal, is an HIF-2α-specific target gene (Covello et al., 2006). 
Recently, microarray analysis performed on hESC lines cultured under hypoxia and 
normoxia revealed 149 differentially expressed genes (Westfall et al., 2008). 
Although genes associated with pluripotency, including Oct-4, Sox2 and Nanog 
were mainly unaffected, some genes controlled by these transcription factors, 
including left-right determination factor 1 (LEFTY), showed increased expression 
under hypoxia (Westfall et al., 2008). Another report described the increased 
expression of Sox2, Nanog, and Oct-4 mRNA as well as Oct-4 protein, and 
increased proliferation of hESCs under hypoxic conditions (Forristal et al., 2009). 
Furthermore, they showed that HIF-1α protein was not expressed at a 20% oxygen 
level and displayed only a transient nuclear localization at a 5% oxygen level, 
whereas HIF-2α and HIF-3α displayed nuclear localization following long-term 
culture at a 5% oxygen level and were significantly upregulated compared to cells 
cultured at a 20% oxygen level. Their results also suggested that while HIF-3α 
regulates the expression of both HIF-1α and HIF-2α, it is HIF-2α that regulates the 
pluripotency of hESCs and their proliferation under hypoxic conditions. More 
recently, it was shown that hypoxic conditions improve the efficiency to generate 
iPS cells from mouse and human somatic cells (Yoshida et al., 2009). A 
comprehensive definition of the molecular mechanisms favoring pluripotency under 
hypoxia, however, has yet to be determined.  
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2.3 Clinical grade stem cells 
2.3.1 Stem cells for regenerative medicine 
The basic and clinical research accomplished during the last few years on stem cells 
constitutes a revolution in regenerative medicine by indicating the possibility of 
generating multiple therapeutically useful cell types. Cell therapies based on adult 
stem cells for several disorders have been in use for many decades, beginning in 
1968 with the first successful bone marrow transplant (Gatti et al., 1968; Bach et al., 
1986; Carpenter et al., 2009). Although few cell-based products, such as Carticel, an 
autologous chondrocyte, and products for skin replacement therapies, have received 
the United States Food and Drug Administration (FDA) approval, so far no stem 
cell products have been approved in the EU or US. There are many ongoing clinical 
trials involving the direct application of stem cells (see http://clinicaltrials.gov, 
https://eudract.emea.europa.eu/). Several stem cell products, including human adult 
MSCs for the treatment of graft versus host disease are currently in late-stage 
clinical trials (Carpenter et al., 2009) and human autologous ASCs for repairing 
perianal fistulas are in phase III clinical trials (see http://clinicaltrials.gov). In 
January 2009, the Geron Corporation announced that the FDA had granted approval 
to begin clinical trials of its product GRNOPC1, which contains oligodendrocyte 
progenitor cells derived from hESCs (Geron, 2009a; von Tigerstrom, 2009). This 
clinical trial will involve the administration of GRNOPC1 to patients with recent, 
functionally complete spinal cord injuries. As a Phase I trial, its primary objective is 
to assess the safety of the product, though secondary endpoints will also be used to 
assess efficacy (Geron, 2009a; von Tigerstrom, 2009). The approval of this 
investigational new drug (IND) application is a significant milestone in the clinical 
translation of stem cell research, because it will be the first approved clinical trial of 
an hESC-derived product. The Geron’s IND application, however, was put on 
clinical hold in May 2009, a few months after it was filed (Geron, 2009b; von 
Tigerstrom, 2009). In 2008, the International Society for Stem Cell Research 
(ISSCR) released Guidelines for the Clinical Translation of Stem Cells (ISSCR, 
2008; von Tigerstrom, 2009). These guidelines aim to promote an international 
consensus on important issues surrounding the clinical applications of novel stem 
cell therapies in response to growing concerns relating to “stem cell tourism” where 
unproven stem cell treatments not subjected to adequate testing or review are 
offered in clinics around the world (von Tigerstrom, 2009).   
 
At present, it is unclear which stem cell type will provide the best approach for cell 
therapy. Depending on the clinical scenario, one cell may be more feasible than 
another. Even though tissue progenitor cells have limited growth and differentiation 
potential, they have a lower tendency to form tumors and to produce mixed 
phenotypes and are thus ideal candidates for tissue engineering of organs. On the 
other hand, pluripotent stem cells have the ability to grow indefinitely and 
differentiate into cells of all three germ layers. Ethical concerns regarding the use of 
embryos, the formation of teratomas, and the potential for evoking an immune 
response currently dampen enthusiasm for their clinical potential. The ability to 
reprogram adult somatic cells into iPS cells is a scientific breakthrough, but the use 
of oncogenes, retroviral transduction, and limited understanding hinders their 
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clinical potential. The stem cell field is full of challenges, technical, regulatory, and 
clinical, and there are inherent risks in all cell therapies, whereby the safety of the 
product will have to be balanced against the life-threatening nature of the indication 
and the risk of not having an alternative therapy available (Hipp and Atala 2008).  
2.3.2 Regulatory requirements for cell therapy products 
The use of cells in therapeutic applications requires adherence to the regulatory 
requirements outlined in Europe in several European Commission directives and 
European Medicinal Agency’s (EMEA) guidelines, whereas in the US cell therapies 
are regulated under the FDA’s Good Tissue Practices Final Rule (US 21 C.F.R., Part 
1271; US FDA, 1998). The EU has adopted an advanced therapy medicinal products 
(ATMPs) regulation that specifically applies to cell therapy products (EC 
Regulation 1394; EC Directive 2001/83/EC; EC Regulation 726/2004). The EU 
Directive (2004/23/EC) establishes standards of quality and safety for the donation, 
procurement, testing, processing, storage, distribution, and preservation of human 
tissues and cells. The ATMP regulations define tailor-made technical requirements 
and establish new standards for clinical trials addressing development, manufacture, 
and quality control, as well as non-clinical and clinical development of cell-based 
medicinal products. The regulations in both the EU and US divide procedures 
according to the degree of manipulation involved and the level of risk associated 
with the cell product. Therefore, the interpretation of the regulation is to some 
extend based on the nature of the cell product being manufactured. In the EU, 
minimal manipulation products, such as cryopreservation of cells, will only be 
subjected to limited requirements and may be produced according to defined 
industrial standards, known as good tissue practices (GTPs). More than minimally 
manipulated cell products require elevated control and adherence to current good 
manufacturing practices (cGMPs; EC Directive 2001/83/EC; 2004/23/EC; US 21 
C.F.R., Part 1271). The presumption is that for minimally manipulated cell products, 
the primary concern is with contamination and communicable disease, whereas cells 
that undergo more extensive manipulation will raise a broader range of safety issues 
and questions about whether they will perform the intended function in the human 
recipient (von Tigerstrom, 2009).  
 
GMP is a quality assurance system used in the pharmaceutical industry covering all 
stages of the manufacture from the isolation of cells to storage of the cell product. 
The objectives of GMPs are to identify and standardise the best practices that result 
in safe products with reproducible characteristics, quality, and overall safety, as well 
as protecting the wellbeing of the patient. The quality management framework 
defined under GMP should ensure quality and traceability of raw materials, 
personnel qualifications with defined responsibilities, validation of equipment, 
facility, processes and quality control methods, standard operating procedures for all 
functions, record keeping, error management, standard production and process 
controls to monitor both quality and safety, as well as constant review of the quality 
of the activities by self-auditing (Unger et al., 2008; Carpenter et al., 2009).  
 
The goal of manufacturing a stem cell-based product is the consistent and 
reproducible generation of sufficient numbers of cells in an aseptic environment 
with adequate safeguards and traceability. Consistency of the manufacturing process 
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can be achieved by minimizing variability at all steps of the manufacturing process 
and is related to the use of standardised reagents and source material, reproducible 
expansion and differentiation protocols, and validated in-process and quality control 
tests. Defining the consistency of the cell-based product is inherently challenging 
because, unlike molecules, cells are living entities and change over time. 
Demonstrating of the quality and safety of the stem cell-derived products requires 
evaluation of the starting materials, demonstration of reproducible expansion and 
differentiation in an aseptic environment, and assessment of the product 
characteristics using validated testing methods. Testing the end product is not 
sufficient as the quality must be built into the product by performing testing 
throughout the manufacturing process. Phenotypic features such as identity, viability 
and doubling time, genotypic features such as genomic and epigenetic stability, as 
well as functional assessment including differentiation potential and safety tests 
such as purity, sterility, endotoxins and mycoplasma contamination should be tested 
at critical control points during the manufacturing process. The purity of the cell-
based product consists of the active cell type and contaminants such as supporting or 
accessory cells, undifferentiated cells, or other cells unrelated to the therapeutic 
activity. The manufacturing process should produce product lots containing 
consistent amounts of the active cell type and of the contaminants. The relevant tests 
for the characterization of the final product will depend on the cell population and 
its mechanism of action, but should include the evaluation of identity; genetic 
stability and safety; characterization of in vivo properties, such as biodistribution, 
tumorigenicity, toxicity, and immunogenicity; as well as functional evaluation of the 
cell product, including functional stability. Surrogate measures of efficacy and 
potency should be developed to allow prediction of the activity of the cell-based 
product in vivo (Carpenter et al., 2009). An overview of the manufacturing process 
and quality control of clinical-grade stem cell-based products and operations 
fundamental to cGMP regulations are presented in Figure 3.  
 
Similar to small molecule-based drugs, stem cell products will need to demonstrate 
potency, efficacy and, most importantly, safety in appropriate animal models before 
entering clinical trials on humans (Vogel, 2005; Parson, 2006; Hentze et al., 2007).  
Both in the EU and US, the initiation of clinical trials requires approval by the 
relevant agency. The application for this approval must be supported by preclinical 
data showing sufficient preliminary evidence of safety and efficacy, as well as data 
from any clinical trials already performed (von Tigerstrom, 2009). Many countries 
have an exemption that may allow unapproved products to be administered to 
individual patients outside of a clinical trial on a case-by-case basis, but these 
involve also some oversight by the regulatory agency (EC Directive 2001/83/EC; 
FDA Regulation, 21 C.R.F., Part 312, § 312.34). Generally, these specific 
regulations apply when a patient is seriously ill and the need for access to an 
investigational product can be justified, usually because all conventional therapies 
have failed (von Tigerstrom, 2009). Strengthening long-term monitoring is also 
important in the context of stem cell-based products. The European ATMP 
regulations include specific requirements for post-authorization follow-up and 
traceability (EC Regulation 1394; EMEA 2008; von Tigerstrom, 2009). The 
regulatory framework worldwide regarding human cell-derived products is 
constantly under development and globally there is widespread recognition of the 
need for an internationally unified regulatory framework to ensure high standards of 
quality and safety with respect to cell and tissue transplantation.  
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Figure 3. Outline of a general strategy to generate a clinically compliant cell therapy product and 
operations fundamental to cGMP regulations 
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2.4 Challenges to the clinical use of stem cells 
2.4.1 Culture conditions 
The use of defined and xeno-free conditions is the ultimate goal for studies aimed at 
understanding the regulation of self-renewal and the generation of therapeutically 
useful cell-based products. Reagents used in the production processes need to be 
quality assured and traceable. The reagents currently in use for stem cell derivation 
and propagation, however, have not yet been validated for human or therapeutic use. 
Therefore, it is essential that we use strict fit-for-purpose justifications, selection 
criteria, and product specifications to ensure the highest possible product quality and 
to ensure that suppliers follow an appropriate quality assurance program (Stacey, 
2004; De Sousa et al., 2006). Recently, Crook and co-workers published the 
generation of six clinical-grade hESC lines in ES Cell International Singapore 
(Crook et al., 2007). These lines were established and banked in a clinical-grade 
manufacturing process facility in compliance with international regulatory 
requirements. Interestingly, the lines were derived and propagated using FDA-
approved hFFs initially derived and propagated in cGMP-grade FBS-based medium 
as feeder cells and the hESC lines were derived using cGMP-manufactured KO-SR 
containing medium. Although qualified xenogeneic reagents have previously 
received approval for skin replacement cell therapy by the FDA, the overall risk of 
these topical somatic cell therapy applications is considered extremely low (Hentze 
et al., 2007), which is not the case with stem cell-based therapies. Recently, the 
FDA approved Geron’s hESC-based product using xenogeneic components for 
human clinical trials. Because cells can incorporate animal components, however, 
including the nonhuman sialic acid Neu5Gc and apoB-100, and given the concerns 
about possible infection and immune responses from xenogeneic products, it is 
preferable to maintain the cells in defined, xeno-free conditions. Albeit rare, severe 
anaphylaxis and immune reactions have been reported in patients transplanted with 
human cells exposed to xenogeneic products (Selvaggi et al., 1997; Mackensen et 
al., 2000), which may also adversely impact engraftment and therapeutic efficacy 
(Sakamoto et al., 2007; Hisamatsu-Sakamoto et al., 2008). Therefore, it is likely that 
when defined and xeno-free culture reagents are available in the future, xenogeneic 
components will no longer be acceptable for the production of clinical cell-based 
products from a regulatory point of view. By replacing xenogeneic products with 
defined xeno-free media, the safety, reproducibility, and quality of the cells with 
therapeutic potential may be greatly enhanced.  
2.4.2 Scale up of production processes 
One of the most basic problems is how to generate the very large numbers of cells 
required for tissue replacement. For clinical application of stem cells, culturing 
techniques need to be scaled up for robust mass production of clinically relevant 
quantities of the specified cells. Automated mechanical passaging of hESCs 
incorporating the advantages of mechanical dissection without sacrificing the 
practical benefits of enzymatic passaging has been developed (Joannides et al., 
2006). The first completely automated robotic system enables plating, feeding and 
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harvesting hESCs in MEF co-culture (Terstegge et al., 2007). Suspension culture, 
although difficult to establish with adherence-dependent cells, would offer a robust 
and scalable expansion of stem cells (Cormier et al., 2006). Proof-of-concept has 
also been demonstrated using bioreactors for hESCs (Cameron et al., 2006). Further 
implementation of bioengineering strategies is required to overcome the cell-
manufacturing challenges for future clinical cell-based therapies.  
2.4.3 Differentiation of stem cells 
To realise the full potential of stem cells, it is essential to be able to direct the 
development of these cells along specific pathways and to control their 
differentiation. Embryology offers important insights into key pathways regulating 
pluripotent stem cell differentiation leading to the development of protocols for the 
efficient generation of a broad spectrum of cell types in vitro. The identification of 
precursor populations for many tissues led to the development of multistep 
differentiation protocols for the derivation of individual lineages, where the 
formation of progenitors via a number of intermediate stages is induced by altering 
culture conditions and by adding specific growth factors and cytokines (Hipp and 
Atala, 2008; Mountford, 2008; Murry and Keller, 2008). It is well known that 
different hESC lines and probably iPS cell lines exhibit considerable differences in 
their differentiation capacity (Osafune et al., 2008). In addition, hESCs and iPS cells 
tend to differentiate towards some lineages better than others, as neural lineages can 
be derived with a relative high efficiency (up to 90% of cultures), but a rather low 
percentage of hESCs, only 1% to 20%, differentiates towards the haematopoietic 
lineage (Lowell et al., 2006). 
 
The therapeutic potential of stem cells largely relies on efficient and controlled 
differentiation towards a specific cell type and the generation of homogenous cell 
populations. One concern about the clinical potential of stem cells is their tendency 
to form mixed phenotypes in most differentiation protocols (Hipp and Atala, 2008). 
On the other hand, mixed phenotypes might be a requirement for the efficient 
differentiation of fully mature phenotypes, through a yet largely unknown complex 
interaction between the different cell types. Thus, characterising and understanding 
mixed populations of progenitor stages will be of increasing importance in stem cell 
research. Genetic manipulation of pluripotent cells may be a way to efficiently 
achieve unilineage differentiation (Keller, 2005; Hentze et al., 2007). One 
prerequisite for cell therapy use is the enrichment of the desired cell type from other 
unwanted lineages and the selective elimination of potentially harmful tumorigenic 
cells, which will be discussed later (Hentze et al., 2007).  
 
Even if cells can be reliably differentiated into sufficiently homogenous cultures, 
cells differentiated from pluripotent stem cells tend to resemble fetal rather than 
adult forms of cells. In many cases, maturation is partial and the differentiated cells 
share only some of the characteristics of their endogenous counterparts. While 
lineage-specific gene expression and cell surface markers are commonly used to 
describe a differentiated phenotype, it is difficult to determine whether differentiated 
cells are, for example, bona fide neurons or merely neuronal-like cells. The extent to 
which immature cells will be clinically functional and whether they will mature 
further in vivo remain unknown at this time (Hipp and Atala, 2008; Mountford, 
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2008; Murry and Keller, 2008). Thus, considerably more work is required to 
standardise differentiation methods and to reproducibly produce truly functional cell 
populations for therapeutic use. The next challenge will be to demonstrate the 
functional utility of these cells, both in vitro and in preclinical models of human 
disease (Murry and Keller, 2008). 
2.4.4 Immune rejection 
Allogeneic cell transplantation may result in graft rejection and immune reactions 
and therefore may require lifelong immunosuppression, which can have serious side 
effects, including an increased tumorigenicity risk (Muruve and Shoskes, 2005). The 
major advantage of using iPS and adult stem cells for cell therapy is that they offer 
the potential to generate patient-specific cells that would be recognised as “self” by 
the immune system, thus preventing rejection of cell transplants. These cells, 
however, would likely only be produced after the patient becomes ill, precluding 
their use in the acute phase of the disease. Although cell transplants may not have 
the full antigenicity of solid organs, there is now clear evidence that hESCs are 
immunogenic and will be rejected in an allogeneic setting (Grinnemo et al., 2008). 
Furthermore, once transplanted, hESC derivatives have increased expression of 
major histocompatibility complex (MHC) antigens, which are further modulated by 
inflammatory cytokines such as interferon gamma (Murry and Keller, 2008). 
 
Several methods have been proposed to avoid the problem of immune rejection. The 
first requires the use of SCNT techniques to generate autologous cells and eliminate 
the risk of graft rejection, an as-yet unsuccessful approach in human beings (Wilmut 
et al., 1997; Hentze 2006; Deb and Sarda 2008). Another option would be the 
induction of immune tolerance by genetically engineering hESC lines either by 
overexpressing genes that can suppress the immune system (Deb and Sarda, 2008), 
by deletion of MHC molecules or other immune effectors (Hentze et al., 2007; 
Mountford 2008), or by engineering hESC progeny to secrete locally 
immunosuppressive molecules (Murry and Keller, 2008). These methods are 
technically challenging and some would be clinically problematic, e.g., cells lacking 
MHC class I surface expression are targeted by natural killer cells (Hentze 2007; 
Deb and Sarda 2008). An alternative approach will be co-transplantation of the graft 
with haematopoietic stem cells generated from the same hESC line as used for tissue 
replacement, potentially inducing lifelong tolerance to the graft (Beilhack et al., 
2003). This technique has been used in solid organ transplants where patients have 
previously received bone marrow transplantation, and these patients did not require 
immune suppression (Menendez et al., 2005; Priddle et al., 2006; Hentze et al., 
2007). Yet another option would be to generate an hESC bank covering most 
histocompatibility antigen combinations to provide an acceptably well-matched 
graft for the majority of the population. It is estimated that several hundred thousand 
up to one million lines would be needed (Hyslop et al., 2005; Taylor et al., 2005; 
Rao and Auerbach, 2006). As only several hundreds lines have been generated so 
far, this is clearly going to be an impractical solution based on current technology 
and knowledge. Even with such banks immunosuppressive drugs would still be 
needed in most cases for most donor-patient combinations (Hentze et al., 2007; Deb 
and Sarda, 2008). Further, transplantation of allogeneic cells into immune-
privileged sites such as the brain, may ameliorate the adverse effects of a MHC-
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mismatch, although the protection might only be short term (Hentze et al., 2007; 
Deb and Sarda, 2008). Another straightforward approach useful for indications 
where cells do not have to undergo functional engraftment would be encapsulation 
of the graft with immune-inert material (Hentze et al., 2007). Although none of 
these approaches appears to be a complete solution for all indications, it is probable 
that a combination of different strategies will eventually facilitate successful 
transplantation of an allogeneic cell therapy product. The immunogenicity of each 
cell product however, must be tested at the appropriate site (Carpenter et al., 2009) 
2.4.5 Epigenetic changes 
Pluripotent cell lines can differ from each other in their genomic expression profiles 
through epigenetic regulations (Deb and Sarda, 2008). Epigenetic changes are 
associated with preimplantation embryos used for the derivation of the ESC lines 
and prolonged culture of pluripotent cells (Eggan et al., 2002; Draper et al., 2004; 
Allergrucci et al., 2007). In preimplantation embryos, epigenetic modifications such 
as DNA methylation and histone modifications are widely involved in the regulation 
of imprinted and non-imprinted genes. These events are often vulnerable to the 
external environment or culture conditions. It is possible that pluripotent cells can 
get rapidly reprogrammed into unpredictable genetic changes (Deb and Sarda, 
2008). Most existing pluripotent cell lines have been established under different 
culture conditions, which may cause variations in epigenetic profiles over and above 
that inherited from in vitro production of the embryo (Wrenzycki and Niemann, 
2003). A DNA methylation profile for hESC was determined, and a set of 25 sites 
from 23 genes was also identified that could be used to distinguish normal hESCs 
from differentiated cells (Bibikova et al., 2006). More studies on various existing 
pluripotent cell lines are required to identify the epigenetic markers for 
pluripotency. There is also a need for optimization of procedures that would 
minimise culture-induced genomic instability (Deb and Sarda, 2008). Periodic 
monitoring of epigenetic stability, by evaluating histone modification and DNA 
methylation, should be assessed after expansion of pluripotent cells in culture before 
the clinical use of pluripotent cell lines (Harrison et al., 2007; Spivakov and Fisher, 
2007; Carpenter et al., 2009).  
2.4.6 Chromosomal abnormalities 
Selection and adaptation of hESCs is a poorly understood phenomenon (Deb and 
Sarda, 2008). Genomic instability of hESCs in long-term culture has been 
extensively investigated but less so with adult stem cells. Several reports indicate 
that hESCs acquire chromosomal abnormalities or karyotypic aberrations during 
prolonged culture in parallel with epigenetic changes (Mitalipova et al., 2005; Baker 
et al., 2007; Deb and Sarda, 2008; Carpenter et al., 2009). The acquisition of 
chromosomal abnormalities may be related to the laboratory manipulations of cells. 
More specifically, Draper et al., showed that trisomies 12 and 17 were observed 
when colonies were disaggregated to single cells, whereas manual passaging of 
cultures contributed to the long-term maintenance of normal karyotypes (Draper et 
al., 2004). Another report by Baker et al. demonstrates clear evidence for the 
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accumulation of specific chromosomal aberrations within several established hESC 
lines over time, indicating that hESCs become chromosomally abnormal and 
“culture adapted” in a reproducible, non-random nature over time. They also found 
a bias for gains of chromosomes 12, 17, and X, which is similar to the chromosomal 
change seen in breast cancer and testicular germ cell tumor seminomas and non-
seminomas (Baker et al., 2007). Recently, two groups identified recurrent 
chromosomal abnormalities in hESCs maintained over long-term in culture, 
including amplification at 20q11.21, which is associated with oncogenic 
transformation (Lefort et al., 2008; Spits et al., 2008). Karyotypic changes often 
enhance the proliferative capacity of hESCs while shortening the population 
doubling time (Enver et al., 2005), and may result in a reduced tendency for 
apoptosis (Kristal et al., 2004) and a reduced capacity for differentiation, which is 
difficult to assess quantitatively. Therefore, reliable methods to monitor abnormal 
karyotype acquisition will be a crucial quality control assay for all cell lines to be 
used for research and especially for therapeutic purposes (Carpenter et al., 2009). 
2.4.7 Tumorigenicity 
Following transplantation, pluripotent stem cell based therapies involve the risk of 
tumor formation, such as teratomas comprising all three germ layers arising from an 
undifferentiated population of the transplanted cells or from an unstable cell product 
that may de-differentiate or transform the cells to produce a tumor (Carpenter et al., 
2009). The immunosuppressive capacity of the adult stem cells may in some cases 
favor the growth of the tumor cells and, in contrast to hESCs, adult-sourced cell 
populations have already accumulated pro-oncogenic mutations, a situation that 
could be further exacerbated by in vitro culture selection of transformed cells with a 
higher growth rate (Hentze et al., 2006; Cousin et al., 2009). In the induction of 
pluripotent stem cells the introduction of c-Myc should be avoided for clinical 
application because c-Myc is associated with the development of tumors (Nakagawa 
et al., 2008). Another concern besides using oncogenes is that iPS cells contain 
retroviral integrations that could also increase the risk of tumorigenesis (Takahashi 
et al., 2007). Currently, the only way to ensure that teratomas do not form is to 
differentiate the stem cells in advance, enrich for the desired cell type, and screen 
for the presence of undifferentiated cells (Hentze et al., 2007). 
 
As even a single undifferentiated cell in a differentiated transplant could carry 
tumor-forming potential, it seems that pluripotent cells should be at least partially 
differentiated before use in transplantation, but the extent to which they should be 
differentiated is a topic of much debate. Longer in vitro differentiation of pluripotent 
cells seems to reduce the risk of teratoma formation after transplantation (Brederlau 
et al., 2006). As the differentiation stage increases, however, the proliferative 
capacity of pluripotent cells is diminished such that mature cells are unable to 
proliferate. The majority of lineages have an identifiable precursor or progenitor cell 
population that can undergo extensive proliferation and expansion, but are no longer 
pluripotent. Thus, this partial differentiation stage may be an ideal population to use 
for cell therapy as the risks of teratoma and random differentiation are reduced and, 
as the cells still continue to proliferate, fewer cells would be required. Additionally, 
it may be that the in vivo environment would be far more effective in correctly 
inducing terminal differentiation than anything that can be reproduced in vitro. As 
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these precursor populations often closely resemble tissue-specific somatic stem cells 
that naturally repair tissue-damage, it may be that transplanted precursor populations 
would respond to in vivo signals and develop into the most appropriate cell type 
(Puceat and Ballis, 2007). Additionally, some injuries and diseases may require the 
replacement of a number of related lineages; for example, spinal cord injury results 
in the loss of neurons and astrocytes and also reduces myelination by 
oligodendrocytes (McDonald, 2004; Zhang et al., 2007). Therefore, a precursor 
population that could regenerate all the lineages may be a preferred option to single 
cell types. There is also the possibility, however, of tumors deriving from a 
progenitor cell that could stop the differentiation of the progenitor cells and 
proliferate in vivo (Puceat and Ballis, 2007). Such a scenario was reported for 
neuronal progenitors grafted in rat brain (Roy et al., 2006). Previously, teratomas 
were not observed in over 200 animals transplanted with an hESC-derived purified 
cardiomyocyte population (Laflamme et al, 2007), but more differentiated tumor-
like growth might occur (Murry and Keller, 2008). A deeper understanding of the 
teratoma formation process should aid in the development of safer cell therapies and 
may help elucidate the basic principles of tumor initiation. Recent results suggest 
that continued expression of survivin, an anti-apoptotic oncofetal gene, upon 
differentiation in vivo may contribute to teratoma formation by hESCs (Blum et al., 
2009). 
 
The removal of all undifferentiated cells from the graft could be achieved by 
genetically engineering cells to express a suicide gene system. The expression of the 
suicide gene could be driven by the promoter of a gene such as Oct-4 that is only 
expressed in undifferentiated cells. This technology has been used in gene therapy 
systems (Doss et al., 2004). Alternatively, pluripotent cells can be genetically 
engineered so that a negative selection can be carried out based on a compound that 
is toxic to undifferentiated cells under certain culture conditions (Billon et al., 
2002). Other methods include the expression of a genetic label such as green 
fluorescent protein (GFP) or a unique cell surface marker specific for either 
undifferentiated cells or differentiated progeny that enables cell isolation by 
fluorescence activated cell sorting (FACS; Strulovici et al., 2007; Murry and Keller, 
2008). The principal drawback to genetic selection is the necessity of inserting a 
selection cassette into the host genome, which may increase the risk of 
tumorigenesis (Murry and Keller, 2008). While adequate technologies for screening 
and generating a pure population of differentiated stem cells are available, it is not 
yet known whether they are capable of eliminating each and every potential tumor 
forming pluripotent cell. Therefore, it is likely that a tumor assay for preclinical 
safety studies will be needed to test specific therapeutic stem cell-based 
formulations in the relevant environment (Hentze et al., 2007; Carpenter et al., 
2009).  
2.4.8 Other host factors 
One major issue that needs to be considered before the administration of functional 
cell populations in vivo, is the type and number of cells delivered at the site of 
engraftment. In addition, transplanted cell death remains a major limitation for the 
treatment of many injuries and diseases. Current evidence suggests that cell-death 
pathways are initiated by multiple stresses associated with transplantation, including 
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ischemia, loss of matrix attachments, and inflammation (Murry and Keller, 2008). 
Most circumstances where regenerative therapy would be required would involve 
administration of the cells into a site of previous injury or disease where the local 
environment may be altered by the diseased state or by the presence of scarring or 
other lesions, and these intrinsic conditions could be hostile to the new graft (Nistor 
et al., 2005). Simply administration of stem cell-derived grafts into these zones 
would probably not result in any beneficial effect and other manipulations would be 
required to treat these established injuries before the graft could be effective (Deb 
and Sarda, 2008). Even if the environment is not hostile, it will still be necessary for 
the transplanted cells to integrate into the existing tissue and make the correct 
connections required to re-establish organ function (Mountford, 2008). Ideally, the 
presence of a clinical cell product should be traceable in vivo. Hence, sensitive 
techniques are required to measure the function as well as tracking the location and 
migration of the transplanted cells. There are a few techniques available for in vivo 
tracking of cells, including magnetic resonance imaging, radionuclide labeling and 
reporter gene imaging, but all of these techniques have their limitations and no 
method is currently sufficient to fulfill the more stringent requirements needed for 
human studies (Hentze et al., 2007). 
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3. Aims of the study 
The general aim of the thesis was to develop and optimise defined and xeno-free 
culture conditions for stem cells supporting feasible proliferation while maintaining 
the characteristics and differentiation capacity of the different cell types and meeting 
the regulatory requirements set by the directives of the European Union for the 
clinical application of stem cells. In addition, the molecular mechanisms regulating 
the self-renewal and pluripotency of stem cells were studied. The specific aims of 
the thesis are outlined below. 
 
 
1) To assess the applicability of an automated cell culturing, imaging, and 
analysis system for evaluating undifferentiated growth dynamics of hESCs 
maintained in different culture media. 
 
2) To evaluate different xeno-free culture media for maintaining hESCs and to 
assess stem cell characteristics by comparing morphological characteristics, 
stem cell marker expression profiles and differentiation capacity. 
 
3) To develop and optimise culture conditions for expanding stem cells according 
to the regulatory standards. To assess the applicability of the defined and 
xeno-free culture medium RegES in the derivation and expansion of new 
hESC lines and to evaluate stem cell characteristics by comparing the 
morphological characteristics, proliferation rate, stem cell marker expression 
profile, and differentiation capacity with those of hESC lines derived and 
expanded in conventional culture medium. 
 
4) To evaluate the applicability of the defined and xeno-free culture medium 
RegES for the expansion of ASCs and to assess stem cell characteristics by 
comparing the morphological characteristics, proliferation rate, stem cell 
marker expression profile, and multipotentiality with those of ASCs expanded 
in allogeneic human serum. 
 
5) To evaluate the applicability of the defined and xeno-free culture medium 
RegES for the expansion of iPS cells and to assess stem cell characteristics by 
comparing the morphological characteristics, stem cell marker expression 
profile, and differentiation capacity to those of iPS cells maintained in 
conventional culture medium. 
 
6) To elucidate the stem cell characteristics as well as the molecular mechanisms 
regulating the self-renewal and pluripotency of hESCs under hypoxic 
conditions by assessing morphological characteristics, proliferation rate, stem 
cell marker expression profile, and signalling pathways. 
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4. Materials and methods 
4.1 Ethical approval  
The hESC lines used in these studies were derived at either the Karolinska Institutet 
(HS lines, Hovatta et al., 2003, Inzunza et al., 2005) or at the Regea – Institute for 
Regenerative Medicine (Regea lines, Rajala et al., 2010; Skottman unpublished 
data). The studies were conducted with the permission of the National Authority for 
Medicolegal Affairs to perform research with human embryos (Dnro 
1426/32/300/05) and in accordance with the Karolinska Institutet Ethics Committee 
to derive and culture hESCs, with the Ethics Committee of the Pirkanmaa Hospital 
District to culture, characterise, and differentiate hESCs derived at Karolinska 
Institutet (R05051) and to derive, culture, characterise, and differentiate new hESC 
lines at Regea (R05116). Donated embryos were received from Turku and Tampere 
University Hospital IVF clinics (IV). An informed consent form was signed by both 
partners after receiving an oral and written description of the study. The donors did 
not receive financial compensation. Animal experiments were performed at the 
animal facilities of Karolinska University Hospital or at Turku Center for Disease 
Modeling and Department of Physiology, Institute of Biomedicine, University of 
Turku in accordance with the approval of the institution’s Ethics Committee (IV). 
ASCs were isolated from adipose tissue samples collected from female donors 
undergoing elective surgical procedures at the Department of Plastic Surgery, 
Tampere University Hospital with the permission of the Ethics Committee of 
Pirkanmaa Hospital District (IV). Human iPS cells were derived and characterised 
at the University of Helsinki, with the permission of the Ethics Committee of the 
University of Helsinki (IV). 
4.2 Cell culture (I-IV) 
4.2.1 Derivation of human embryonic stem cell lines (IV) 
Surplus poor-quality embryos that could not be used for infertility treatment were 
obtained as donations from couples undergoing IVF treatment at Tampere 
University Hospital. In study IV, the mechanical derivation of the hESC lines from 
blastocyst-stage embryos with a hardly visible ICM was performed using a specially 
made flexible metal needle and surgical knife (Ström et al., 2007). In study IV, 
derivation of the cell line Regea 06/015 was performed from an arrested embryo 
(around day 3-4) that did not undergo blastocyst formation, by removing the zona 
pellucida and plating the remaining cells on top of hFF cells.   
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4.2.2 Culture of human embryonic stem cells (I-IV) 
In study I, hESCs were cultured in either conventional hES medium or in xeno-free 
X-vivo 10 medium. Conventional hES medium contained Knockout- Dulbecco’s 
modified Eagle’s medium (KO-DMEM) basal medium supplemented with 20% 
KO-SR, 2 mM Glutamax, 0.1 mM β-mercaptoethanol, 0.1 mM MEM with non-
essential amino acids (NEAA), 1% penicillin-streptomycin, and 8 ng/ml bFGF. X-
vivo 10 medium contained X-Vivo 10 basal medium and 0.12 ng/ml TGFβ1 
otherwise supplemented as the hES medium without KO-SR. In study II, several 
xeno-free serum replacements and culture media were tested in the culture of 
hESCs. Conventional hES medium was used as a control medium. Xeno-free serum 
replacements Lipumin 10x, SerEx 10x, SR3, and Serum Substitute Supplement 
(SSS) were tested at 10% and 20% concentrations, and Plasmanate  at 20% and 40% 
concentrations in KO-DMEM; X-vivo 10 medium (described above); X-Vivo 20 
medium containing X-Vivo 20 basal medium; human serum medium containing 
KO-DMEM, 10% or 20% heat inactivated, sterile filtered human serum, 50 mg/L L-
ascorbic acid 2-phosphate; and self-made TeSR1 medium (Ludwig et al., 2006). All 
were supplemented as the hES medium without KO-SR. 
 
In study IV, hESC lines Regea 06/015, 07/046, and 08/013 were derived using a 
defined xeno-free culture medium RegES. All other hESC lines were derived using 
conventional hES medium. Xeno-free commercially available HEScGRO medium 
without any supplementation was compared to RegES medium for hESC culture. In 
study III, lipids and lipid derivatives were evaluated in the xeno-free RegES culture 
medium. KO-DMEM, DMEM low glucose, DMEM high glucose, and DMEM/F12 
basal media, and the addition of IGF-II, IGF-I, or HRG-β1 was also evaluated in the 
xeno-free RegES culture medium. RegES culture media with an osmolarity of 260 
mOsm, 290 mOsm, 320 mOsm, or 350 mOsm, were evaluated.  
 
In studies I-IV, commercially available hFFs (CRL-2429, ATCC) cultured in 
Iscove's modified Dulbecco's medium (IMDM) with L-glutamine and 25 mM 
HEPES supplemented with 10% FBS and 1% penicillin-streptomycin were used for 
hESC culture. Confluent hFF monolayers were mitotically inactivated by irradiation 
(40 Gy) and plated at a density of 3.8 x 104 cells/cm2. In study IV, hESC line Regea 
06/015 was derived on hFF feeder cells (C-12300 PromoCell) cultured in IMDM 
with L-glutamine and 25 mM HEPES supplemented with 10% human serum, 0.1 
mM NEAA, and 1% penicillin-streptomycin. 
 
In studies I-IV, the hESCs were cultured in a humidified incubator (+37oC, 5% 
CO2). The growth of hESCs was monitored under a microscope and culture media 
were changed six times per week. The hESCs were mechanically passaged every 6 
to 7 days to new mitotically inactivated hFFs. In study IV, single-cell enzymatic 
passaging (SCED) was performed for hESCs using TrypLE Select and an 8 to 12 
day splitting interval (Ellerström et al., 2007). The hESCs were frozen using RegES 
medium supplemented with 10% dimethyl sulfoxide (DMSO). 
 
In study II, feeder cell free culture of hESCs was performed on 12-well plates 
(CellBIND Surface, Corning, NY), containing 10 µg/cm2 human collagen IV, 0.2 
µg/cm2 human vitronectin, 5 µg/cm2 human fibronectin, and 5 µg/cm2 human 
laminin coating mixture. The feeder-free hESC cultures were passaged 
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mechanically every 7 to 10 days and plated onto new 12-well plates containing the 
coating mixture. For feeder-free culture experiments, hES medium and 20% human 
serum containing culture medium were supplemented with 80 ng/ml bFGF and the 
TeSR1 medium was supplemented with 100 ng/ml bFGF. 
4.2.3 Culture of human induced pluripotent stem cells (IV) 
Human iPS cell lines FiPS 5-7 and FiPS 6-14 were derived and characterised at the 
University of Helsinki. Human cDNAs of Oct-4, Sox2, Nanog, Klf4, and Lin-28, 
were amplified by direct PCR from hESC cDNA, and cloned into a pMXs retroviral 
vector. 293-GPG packaging cells were transfected with each pMXs-cDNA vector 
separately using Fugene HD. The next day, fresh MEF-CM medium was added. 
Viral supernatant was collected 3 times at days 4, 5, and 6 post-transfection, 
combined, and then filtered. The hFF cell line CCCD-1112Sk (ATCC) was plated 
on gelatin-coated petri dishes and incubated overnight. Cells were then infected with 
equal parts of hES medium and fresh virus-containing supernatant twice at 24-h 
intervals. At day 3, infected cells were harvested and re-seeded on a Mitomycin C-
treated MEF layer. The following day, the medium was changed to hES medium. 
Twenty to 30 days post-transduction, ES-like colonies were picked, expanded, and 
characterised as previously described for hESCs (Mikkola et al., 2006). FiPS 5-7 
was generated using Oct-4, Sox2, Nanog, and Lin-28 encoding retroviruses, while 
FiPS 6-14 was generated using the same factors plus Klf4. Human iPS cell lines 
were cultured as described for hESCs using hFF feeder cells, mechanical passaging, 
and hES or RegES culture media.  
4.2.4 Culture of human adipose stem cells (IV) 
Isolation of ASCs from adipose tissue samples was performed by mincing the 
adipose tissue manually into small fragments and digesting them with 1.5 mg/mL 
collagenase type I in a shaking water bath at 37 oC (Gimble and Guilak, 2003; Zuk 
et al., 2001). To separate the ASCs from the surrounding tissue, the digested tissue 
was centrifuged and filtered in sequential steps. The isolated cells were expanded in 
DMEM/F-12 1:1, supplemented with 1% GlutaMAX, 1% antibiotic/antimycotic 
(a/a; 100 U/mL penicillin, 0.1 mg/mL streptomycin, and 0.25 μg/mL amphotericin 
B) and 10% alloHS (alloHS medium). For testing defined xeno-free conditions, 
ASCs at passage 3-4 were transferred to RegES culture medium in flasks with pre-
coated CELLstart. TrypLE Select was used to detach the ASCs from the culture 
plate.  
4.2.5 Automation of imaging and analysis of human embryonic stem 
cells (I) 
Human ESC lines were cultured and monitored using a time-lapse imaging system 
Cell-IQ® (Chipman Technologies Ltd, Tampere, Finland). The system comprised a 
thermal chamber in which two well plates, ranging in size from 6- to 96-well plates, 
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were set into an integrated plate holder and incubator gases were directly transferred 
into the plates. Two different gases could be piped onto a single plate. The chamber 
included a green LED light source below and microscopic phase-contrast optics (10 
×) above the well plates. A charge-coupled device camera was used for imaging. 
The system was connected to a computer through which the imaging was controlled 
with Cell-IQ® Imagen software. The plate holder could be moved in the xy-axis (± 
1 µm) to enable complete control of plate movement. The areas of interest were 
selected and imaged in each well in single squares (500 × 670 µm) or in stitched 
grid squares of 2×2 up to 7×7 (ranging in size from 1000 × 1340 µm to 3500 × 4690 
µm of imaged area). The system utilised a motorised z stage (± 0.4 µm) and a 
dynamic Z-stack (user defined) system, resulting in all-in-focus images. Single 
captured images were stored in separate folders as JPEG-files. These images could 
be opened and transformed into a movie format for further analysis. This allows for 
user-defined cell recognition programs utilizing machine vision technology to be 
built with analysis software.   
 
We developed a new hESC colony area analysis method. The system recognises 
every pixel in each image and assigns the pixel to one of the user-defined classes. 
The colony area measurement classes were 1) background feeder layer, 2) 
undifferentiated area, and 3) differentiated area. The total analysed area in one 
image is usually 360448 pixels = (768-(2*32)) × (576-(2*32), wehre 768 is the 
image width and 576 is the image height. A 32 pixel-wide strip from the image 
edges was not analysed due to methodological limitations. The area analysis method 
results in total number of square pixels for each of the classes in each time-lapse 
image and that number can be converted to a micrometer scale.  
 
The hESCs were cultured either in hES or X-Vivo 10 medium. The hESC colonies 
were mechanically divided and seeded as small aggregates onto 12-well plates 
(CellBIND surface) containing gamma-irradiated hFFs. On days 1 through 3 after 
passaging of hESCs, the plates were transferred to the monitoring equipment. Using 
the instrument's imaging software, the images from selected plate positions were 
recorded as grid images and stored in separate folders in JPEG format (Tarvainen et 
al., 2002). Each region of interest was monitored every 40 to 60 minutes. Colonies 
were monitored until day 7 after passage.  
4.2.6 Culture of human embryonic stem cells under hypoxic versus 
normoxic conditions (III) 
Human ESCs were cultured in hypoxic (5% O2) and normoxic (21% O2) conditions 
using Cell-IQ, an automated cell culturing system (Chipman Technologies, 
Tampere, Finland). Both conventional hES culture medium and serum- and xeno-
free culture medium RegES were used. The cells were exposed to a 2-week culture 
period under normoxic or hypoxic conditions before analysis. Cells were 
manipulated under normoxic conditions and O2 exposure of hESCs cultured under 
hypoxic conditions was kept to a minimum. 
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4.3 Differentiation of stem cells (IV) 
4.3.1 Cardiomyocyte differentiation of human embryonic stem cells 
and induced pluripotent stem cells 
Cardiomyocyte differentiation was carried out by co-culturing Regea 08/013 hESCs, 
maintained in RegES (p46) and in hES (p52) media, with mouse visceral 
endodermal-like (END-2) cells (Pekkanen-Mattila et al., 2009). Undifferentiated 
hESC colonies were dissected mechanically into aggregates containing a few 
hundred cells and placed on the top of plated END-2 cells in hES culture medium 
without KO-SR and bFGF. Differentiating cell colonies were monitored daily by 
microscopy and the medium was changed after 5 days of culturing. After 12 days, 
10% KO-SR was added to the medium. Differentiation was performed in 12-well 
plates with 15 hESC colony pieces per well. The beating areas were dissociated by 
collagenase II treatment. The cells were plated on 0.1% gelatin coated cell culture 
plates in medium containing 7.5% FBS.  
4.3.2 Neuronal differentiation of human embryonic stem cells and 
induced pluripotent stem cells 
Human ESC (Regea 08/013) colonies were maintained in RegES (p53) and in hES 
(p58) culture media and mechanically dissociated into small clusters containing 
~3000 cells. Clusters were transferred into 6-well ultra-low attachment plates 
(Nunc) and cultured as floating aggregates, e.g., neurospheres, for up to 20 weeks in 
neural differentiation medium consisting of 1:1 DMEM/F-12:Neurobasal media 
supplemented with 2 mM Glutamax, 1xB27, 1xN2, 25 U/ml penicillin-
streptomycin, and 20 ng/ml bFGF (Hicks et al., 2009). Medium was changed 3 
times/week and the spheres were mechanically passaged weekly.  
4.3.3 Differentiation of adipose stem cells 
ASCs at passage 3 were transferred in RegES medium to be analysed for their 
capacity to differentiate toward the adipogenic, osteogenic, and chondrogenic 
lineages with ASCs expanded in alloHS medium as the reference. The osteogenic 
differentiation analyses were performed on ASCs seeded onto 12-well plates at a 
density of 2.5 x 103 cells/cm2 in RegES medium supplemented with 150 μM L-
ascorbic acid 2-phosphate, 10 mM β-glycerophosphate, and 100 nM dexamethasone 
in culture vessels pre-coated with CELLstart. The control cultures were maintained 
in RegES medium without supplements in pre-coated culture vessels. The cultures 
were maintained for 14 days and osteogenic differentiation was detected by alkaline 
phosphatase (ALP) activity staining. 
 
Adipogenic differentiation was induced by culturing ASCs for 2 weeks in 
adipogenic RegES medium with an initial seeding density of 2 x 104 cells/cm2 in 
culture vessels pre-coated with CELLstart. For adipogenic induction, RegES 
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medium supplemented with 33 μM biotin, 1 μM dexamethasone, 100 nM insulin, 
and 17 μM pantothenate was used while the control cultures were maintained in 
RegES without adipogenic supplements. The cultures were analysed using an Oil 
red O stain as an indicator of intracellular lipid accumulation.  
 
Chondrogenic differentiation capacity analysis was assessed using a micromass 
culture technique (Denker et al., 1995; Zuk et al., 2001). Briefly, 1 x 105 cells were 
seeded onto a 24-well culture plates in a 10 μl volume, and allowed to adhere for 3 h 
in an incubator prior to the addition of chondrogenic RegES medium containing 1% 
ITS+1, 50 μM L-ascorbic acid 2-phosphate, 55 μM sodium pyruvate, and 23 μM L-
proline. The control cultures were maintained in RegES without chondrogenic 
supplements. Chondrogenesis was confirmed at day 14 by Alcian blue staining. 
4.4 Characterization of stem cells 
4.4.1 Morphology (I-IV) 
Cell morphology and growth was monitored using a stereomicroscope (Nikon 
SMZ800) or a phase-contrast microscope (Nikon T2000S). In study I, to cross-
validate the growth data of the colonies obtained from the Cell-IQ analyses, all 
colonies were photographed using a Nikon Eclipse TE2000-S phase-contrast 
microscope and Eclipse Net software (version 1.20), enabling manual hESC colony 
area measurements.  
 
In study III, lipids and lipid derivatives were evaluated with the RegES culture 
medium. General morphology and the size and thickness of the undifferentiated 
hESC colonies were evaluated before each passage based on visual inspection. The 
colonies were classified into four categories: excess differentiation, poor 
morphology; uneven colony edges, thin and/or small colonies, poor morphology; 
satisfying morphology, some colonies with uneven edges, colonies of medium 
thickness and size; and excellent morphology, even, thick and big colonies. In 
addition, the hESC colonies were classified into three categories; undifferentiated, 
partly differentiated, and differentiated (Figure 4). The number of each colony type 
was calculated before each passage. Later, a percentage value for each colony type 
of the total amount of colonies was calculated.   
 
 
 
Figure 4. Classification of hESC colonies. Representative images of undifferentiated (A), partly 
differentiated (B) and differentiated (C) colony morphology. Scale bar 200 µm. 
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4.4.2 Immunocytochemistry (I-IV) 
The cells were fixed in culture dishes with 4% paraformaldehyde (PFA) in 
phosphate-buffered saline (0.01 M PBS, pH 7.4) for 20 min at room temperature, 
followed by washing with PBS (2×5 min). The cells were permeabilised and 
blocked with 0.1% Triton X-100, 1% BSA, and 10% normal donkey serum in PBS 
for 45 min at room temperature and then washed once with 0.1% Triton X-100, 1% 
BSA, and 1% normal donkey serum in PBS. The primary antibodies used for hESCs 
and iPS cells were specific for Nanog (1:200), Oct-4 (1:200), Sox2 (1:200), SSEA-4 
(1:200), SSEA-1 (1:200), SSEA-3 (1:800), TRA-1-60 (1:200), and TRA-1-81 
(1:200).  
 
In study IV, the primary antibodies used for differentiated cardiomyocytes were 
anti-cardiac troponin T (cTnT; 1:2000) and anti-ventricular myosin heavy chain 
(vMHC; 1:100). Differentiated neural cells were immunostained after 9 weeks of 
differentiation. For immunocytochemical staining, neurospheres were plated on 
human laminin-coated wells in the absence of bFGF and fixed after allowing the 
cells to grow for 3 days. The primary antibodies used for differentiated neural cells 
were polyclonal rabbit anti-microtubule-associated protein-2 (MAP-2; 1:600) for 
neuronal cells and polyclonal sheep anti-glial fibrillary acidic protein (GFAP; 
1:600) for astrocytes. 
 
The cells were incubated with primary antibody solution overnight at 4°C. The cells 
were washed (3×5 min) with 1% BSA in PBS and probed with secondary 
antibodies: rhodamine red-conjugated anti-mouse at 1:400 and Alexa Fluor-488 at 
1:800 or Alexa Fluor-568 at 1:400 conjugated to anti-goat or anti-mouse, and FITC 
conjugated to anti-rabbit or anti-sheep. Cells labelled only with secondary 
antibodies were used as negative controls. After incubation, the cells were washed 
with PBS (3×5 min) and mounted in Vectashield mounting medium containing 4',6-
diamidino-2-phenylindole (DAPI). The labelled cells were photographed with an 
Olympus IX51 phase contrast microscope with fluorescence optics and an Olympus 
DP30BW camera. 
 
In study IV, the in vitro osteogenic differentiation capacity was determined 14 days 
after the initiation of differentiation by ALP staining as described previously (Haimi 
et al., 2008; Haimi et al., 2009 and Lindroos et al., 2009). The cell cultures were 
fixed with a 4% PFA solution and stained with the leukocyte ALP kit according to 
the Sigma Procedure No. 86 (#86R-1KT). ALP staining was confirmed as a purple 
staining visualised by microscopy.  
 
The adipogenic differentiation culture was maintained for 14 days and subsequently 
fixed with 4% PFA, pretreated with 60% isopropanol, and stained with a 0.5% Oil 
red O solution in 60% isopropanol. After fixation and staining, the wells were rinsed 
with distilled water and visualised by microscopy. Adipocytes were identified as 
cells with red-stained lipid vesicles.  
 
The chondrogenic differentiation cultures were maintained for 14 days and were 
subsequently fixed with 4% PFA, and stained with 1% Alcian blue stain. Cells 
stained with Alcian blue verified the presence of sulphated proteoglycans within the 
chondrogenic cell pellet. 
 59
4.4.3 Flow cytometry (I-IV) 
Human ESCs and iPS cells were analysed by flow cytometry using antibodies 
against SSEA-1, SSEA-4 (I,II), PE-conjugated SSEA-4 (III,IV), Oct-4-PE, and 
TRA-1-81-FITC. For the SSEA-1 and SSEA-4 primary antibodies, a PE-conjugated 
antibody was used as the secondary antibody.  
 
In study IV, ASCs cultured for 1 week in RegES medium were analysed by flow 
cytometry using monoclonal antibodies against CD90- APC, CD45-FITC, CD34-
APC, human leucocyte antigen class one (HLA-ABC)-PE, HLA-DR-PE, and 
CD105-PE. In study IV, hESC samples cultured in hES and RegES media were 
from 7 day old colonies, iPS cell samples cultured in hES medium from 6-day-old 
colonies, and samples cultured in RegES medium from 7-day-old (5-7) or 8-day-old 
colonies (6-14). Both undifferentiated and differentiated cells present in the culture 
dish were included in the analyses. In studies I-IV, Alexa Fluor 488 and PE-
conjugated secondary antibodies were used as isotype controls. The samples were 
analysed by FACS (FACSAria®, BD Biosciences). The acquisition was set for 10 
000 events per sample. The data were analysed using FACSDiva Software version 
4.1.2.  
4.4.4 Cell proliferation assay (III, IV) 
Cell proliferation of the hESC lines was determined using a colorimetric 
immunoassay based on bromodeoxyuridine (BrdU) incorporation during DNA 
synthesis. The enzyme linked immunosorbent assay (ELISA) was performed 
according to the manufacturer’s instructions. The hESC colonies at day 5 were 
labelled with BrdU-labelling solution overnight at 37°C. The hESCs (105 cells/well) 
were added to a 96-well plate with 8 replicates per cell line. Cells that were not 
labelled with BrdU were used as a background control. Absorbance of the samples 
was measured at 450nm using a Viktor 1429 Multilabel Counter. 
 
In study IV, the cell viability and proliferation activity of the ASCs were assessed 
using a PreMix WST-1 Cell Proliferation Assay System. The ASCs (n=7 donor cell 
samples, with 4 replicates per cell line) at passage 3 were seeded on 48-well plates 
at a density of 4500 cells/cm2 in RegES medium, and the proliferation was 
determined at 1, 4, 7, and 11 days. Briefly, the cell culture medium was removed 
and DPBS and PreMix WST-1 were added at a ratio of 10:1. The well plate was 
incubated for 4 hours in 37oC and the cell proliferation activity was measured at 450 
nm using a Viktor 1429 Multilabel Counter. 
4.4.5 RNA isolation and reverse transcription (II-IV) 
Total RNA was isolated using an RNeasy Plus Mini Kit according to the 
manufacturer’s instructions. The concentration and quality of isolated RNA was 
determined using a ND-1000 Spectrophotometer. Complementary DNA was 
synthesised from 50 ng of total RNA using a Sensiscript Reverse Transcription Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions. 
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4.4.6 RT-PCR (II, III) 
The expression of ectoderm (PAX-6, Sox1), endoderm (α-fetoprotein (AFP), 
Sox17), and mesoderm (α-cardiac actin, brachyury/T) development in EBs was 
confirmed using the primers listed in Table 3.  β-actin was used as a housekeeping 
control. Negative controls contained sterilised water instead of the cDNA template. 
The RT-PCR reactions were performed in an Eppendorf Mastercycler as follows: 
denaturation at 95°C for 3 min; 40 cycles of denaturation at 95°C for 30 s, annealing 
at 57°C for 30 s, and extension at 72°C for 1 min; followed by a final extension at 
72°C for 5 min. The PCR products were analysed by electrophoresis on a 1.5% 
agarose gel containing 0.4 μg/ml ethidium bromide and 50 bp DNA standard. 
Table 3. Complete list of primers used for RT-PCR in all publications. 
Name Primer sequence Size (bp) Study 
Oct-4 F 5´ CGTGAAGCTGGAGAAGGAGAAGCTG 3´ 
R 5´ AAGGGCCGCAGCTTACACATGTTC 3´ 
245 
 
 IV 
Nanog F5´ TGCAAATGTCTTCTGCTGAGAT 3’ 
R5’ GTTCAGGATGTTGGAGAGTTC 3’ 
286 IV 
AFP F 5´ GCTGGATTGTCTGCAGGATGGGGAA 3´ 
R 5´ TCCCCTGAAGAAAATTGGTTAAAAT 3´ 
216 II,IV 
Brachyury/T F 5´ GCTTCAAGGAGCTCACCAAT 3´ 
R 5´ CACCGCTATGAACTGGGTCT 3´ 
425 IV 
Musashi F 5´ AGCTTCCCTCTCCCTCATTC 3´ 
R 5´ GAGACACCGGAGGATGGTAA 3´ 
161 IV 
Nestin F 5´ CAGCTGGCGCACCTCAAGATG 3´  
R 5´ AGGGAAGTTGGGCTCAGGACTGG 
208 IV 
PAX-6 
 
F 5´ AACAGACACAGCCCTCACAAACA 3´ 
R 5´ CGGGAACTTGAACTGGAACTGAC 3´ 
174 
 
IV 
OTX2 F5’ CGCCTTACGCAGTCAATGGG 3’ 
R5’ CGGGAAGCTGGTGATGCATAG 3’ 
641 IV 
MAP-2 F 5´ AATAGACCTAAGCCATGTGACATCC 3´ 
R 5´ AGAACCAACTTTAGCTTGGGCC 3´ 
132 IV 
NF-68 F 5´ GAGTGAAATGGCACGATACCTA 3´ 
R 5´ TTTCCTCTCCTTCTTCACCTTC 3´ 
473 II,IV 
GFAP F 5´ GCTCGATCAACTCACCGCCAACA 3´ 
R 5´ GGGCAGCAGCGTCTGTCAGGTC 3´ 
207 IV 
Olig1 F 5´ TTGCATCCAGTGTTCCCGATTTAC 3´ 
R 5´ TGCCAGTTAAATTCGGCTACTACC 3´ 
389 IV 
GAPDH 
 
F 5´ AGCCACATCGCTCAGACACC 3´ 
R 5´ GTACTCAGCGGCCAGCATCG 3´ 
302 
 
II,IV 
β-Actin F5’ GTCTTCCCCTCCATCGTG 3’ 
R5’ GGGGTGTTGAAGGTCTCAAA 3’ 
302 IV 
α-cardiactin F5’ GGAGTTATGGTGGGTATGGGTC 3’ 
R5’ AGTGGTGACAAAGGAGTAGCCA 3’ 
486 II,IV 
AFP F5’ AGAACCTGTCACAAGCTGTG 3’ 
R5’ GACAGCAAGCTGAGGATGTC 3’ 
672 IV 
Sox17 F5’ CGCACGGAATTTGAACAGTA 3’ 
R5’ CACACGTCAGGATAGTTGCAG 3’ 
166 IV 
Sox1 F5’ AAAGTCAAAACGAGGCGAGA 3’ 
R5’ AAGTGCTTGGACCTGCCTTA 3’ 
158 IV 
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In study IV, RT-PCR was performed for neural cells (≥10 spheres/sample). The 
RT-PCR primer set contained GAPDH as a housekeeping control; Oct-4 and Nanog 
for undifferentiated hESCs; α-fetoprotein for endodermal lineage; brachyury/T for 
mesodermal lineage; Musashi, Nestin, and PAX-6 for neuroectodermal cells; MAP-
2, NF-68, and OTX2 for neuronal cells; GFAP for astrocytes; and Olig1 for 
oligodendrocyte precursor cells (listed in Table 3). The RT-PCR reactions were 
performed in an Eppendorf Mastercycler with an initializing step at 95°C for 3 min; 
35 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 30 s, extension at 
72°C for 1 min; and a final extension at 72°C for 5 min. The PCR products were 
analysed by electrophoresis on a 1.5% agarose gel containing 0.4 μg/ml ethidium 
bromide and 50 bp DNA standard. 
4.4.7 Quantitative PCR (III-IV) 
In studies III and IV, both undifferentiated and differentiated hESCs and iPS cells 
in the culture plate were included in the quantitative RT-PCR analyses. Quantitative 
RT-PCR was performed with the Applied Biosystems Gene Expression Assays 
listed in Table 4. All samples and the no-template controls were analysed in 
triplicate. Quantitative RT-PCR was performed with an Applied Biosystems 7300 
Real-Time PCR system using the following conditions: 40 cycles of 50°C for 2 min, 
95°C for 10 min, and 95°C for 15 s, followed by 60°C for 1 min. The data were 
analysed with a 7300 System SDS Software. The cycle threshold (Ct) values were 
determined for every reaction. Relative quantification was calculated using the 2-∆∆Ct 
method (Livak and Schmittgen, 2001). All data were normalised to the expression 
of the housekeeping gene GAPDH.  
Table 4. Complete list of primers for undifferentiated hESCs and iPS cells for qRT-PCR in all 
publications. 
Name Assay ID Size (bp) Study 
GAPDH Hs99999905_m1 122     III, IV 
Nanog Hs2387400_g1 109 III, IV 
Oct-4 Hs00999632_g1 77 III, IV 
DNMT3B Hs01003405_m1 80 III, IV 
TDGF1 Hs023339496_m1 102 III, IV 
GDF3 Hs00220998_m1 65 III, IV 
GABRB3 Hs01115771_m1 72 III, IV 
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In study III, the molecular mechanisms activated by low O2 tension were 
investigated using a customised PathwayFinder™ RT²Profiler™ real-time PCR 
Array (CAPH-0616, SABiosciences) including genes from the different signalling 
pathways listed in Table 5. cDNA was synthesised from 1.0 µg of total RNA using 
the RT2 First Strand Kit according to the manufacturer’s instructions. Quantitative 
RT-PCR was performed with an Applied Biosystems 7300 Real-Time PCR system 
using the following conditions: 1 cycle of 95oC for 10 min, 40 cycles of 95°C for 15 
s, followed by 60°C for 1 min. The data were analysed with a 7300 System SDS 
Software. The Ct values were determined for every reaction. Relative quantification 
was calculated using the 2-∆∆Ct method. All data were normalised to the expression 
of the housekeeping genes.  
Table 5. Signal transduction and growth factor pathways analysed in publication III. 
Pathway Gene 
Mitogenic EGR1, FOS, JUN 
Hedgehog BMP2, BMP4, EN1, FOXA2, PTCH1, WNT1, WNT2 
Wnt CCND1, JUN, LEF1, MYC, PPARG, TCF7, VEGFA, WISP1 
TGF-β CDKN1A, CDKN1B, CDKN2A, CDKN2B 
Survival pathway: 
PI3 kinase/Akt 
Jak/Src 
NFκB 
 
BCL2, CCND1, FN1, JUN, MMP7, MYC 
BCL2, BCL2L1 
BCL2A1, BIRC2, BIRC3, NAIP, TERT 
P53 BAX, CDKN1A, Fas, GADD45A, IGFBP3, MDM2, TP53I3 
CREB CYP19A1, EGR1, FOS 
Jak-Stat CXCL9, IL4, IL4R, IRF1, MMP10, NOS2A 
Retinoic acid EN1, HOXA1, RPB1 
Insulin CEBPB, FASN, GYS1, HK2, LEP 
Insulin signalling ELK1, FOS, FOXO1, JUN 
Phospholipase C BCL2, EGR1, FOS, ICAM1, JUN, NOS2A, PTGS2, VCAM1 
Calcium and PKC CSF2, FOS, IL2, JUN, MYC, ODC1, PRKCA, PRKCE, TFRC  
EGF ELK1, FOS, JUN, STAT1, STAT3, STAT5A 
IGF-1 ELK1, FOS, JUN 
PDGF ELK1, FOS, JUN, STAT1, STAT3, STAT5A 
G-protein coupled R CREB1, ELK1, FOS, JUN, NFATC1  
Notch CREBBP, HDAC1 
MAPK: 
Erk1/Erk2 
P38 signalling 
 
ELK1, MYC, STAT3 
ATF2, CREB1, ELK1, MAX, MEF2A, MYC, STAT1 
Hypoxia signalling: 
Response to stress 
Transcription factors 
and regulators 
Signal transduction 
Cell cycle 
Cell proliferation 
Growth factors 
 
IL1A, IL6, NOS2A, NOTCH1, RARA 
CREBBP, RARA, HIF1A-HIF3A, PPARA, NOTCH1 
 
CREBBP, HIF1A-HIF3A, IGFBP1, IL1A, IL6, LEP, RARA, VEGFA 
BAX, HK2, IGF2, IL1A, VEGFA 
DCTN2, IGF2, IL1A, IL6, MT3, NPY, RARA, VEGFA 
IGF2, IGFBP1, IL1A, IL6, VEGFA 
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4.4.8 Karyotyping (IV) 
Karyotype analysis was performed using the G-banding technique by Medix 
Laboratories Inc, Helsinki, Finland. In brief, hESCs were treated with colchicine for 
2 hours, and cells in metaphase were analysed using conventional light microscopy 
(Olympus, BX 50). Karyotypes were determined using IKAROS-software designed 
for chromosome analysis (MetaSystems). A total of 20 cells in metaphase were 
analysed for each cell line. 
4.4.9 Analysis of pluripotency in vitro (II, IV) 
The EBs formed by mechanically dissecting the hESC and iPS cell colonies were 
cultured without feeder cells in TeSR1 (II), RegES, or hES (IV) culture medium 
without bFGF for 4 weeks before RNA isolation. The medium was changed every 2 
to 3 days. RNA isolation, reverse transcription, and RT-PCR from EBs were 
performed as described above.  
4.4.10 Analysis of pluripotency in vivo (IV) 
The in vivo pluripotency of the hESC line Regea 06/015, Regea 07/046, Regea 
08/013 and Regea 06/040 was tested as previously described (Inzunza et al., 2004; 
Inzunza et al., 2005). In brief, the cells were harvested from the culture plates using 
dispase or TrypLe Select and mechanical treatment. Five colonies (103 to 104 hESC) 
were washed twice in PBS and subsequently implanted beneath the testicular capsule 
of a young (6-8 week-old) SCID/beige male mouse (C.B.-17/GbmsTac-scid-bgDF 
N7, M&B, Ry, Denmark) or in the case of Regea 08/013, a male nude mouse (Hsd; 
Athymic Nude-Foxn1nu, Harlan). Three animals were used for each cell line. 
Teratoma growth was determined by palpation once per week, and the mice were 
killed by cervical dislocation 8 to 9 weeks after implantation. Immunohistochemical 
studies of Regea 08/013 cell line teratomas were performed on paraffin sections. 
The dewaxed and rehydrated sections were treated in a pressure cooker in 1 mM 
EDTA, pH 8, (Desmin and HNF3β) or 10 mM sodium citrate buffer, pH 6, (NCAM) 
for 5 minutes to reveal antigenic sites, cooled at room temperature for 2 hours, and 
rinsed in PBS. After rinsing in PBS the sections were incubated with the following 
primary antibodies: rabbit anti-desmin, mouse anti-HNF3β, or rabbit anti-NCAM. 
Primary antibodies were diluted (1:1000, 1:3000, and 1:800 respectively) in PBS 
containing 0.05% Tween® and incubated overnight at +4°C. The next day, after 
several rinses with PBS, endogenous peroxidase was inactivated with 1% hydrogen 
peroxide in PBS for 20 minutes. After rinsing several times with PBS, the sections 
were incubated with secondary antibodies (conjugated to horseradish peroxidase) 
for 30 minutes at room temperature. Slides were rinsed with PBS, and the color was 
developed with diaminobenzidine substrate. Sections were lightly counterstained 
with Mayer’s haematoxylin, dehydrated, and mounted. 
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4.5 Statistical analysis (I, III, IV) 
In study I, statistical analyses were performed with SPSS for Windows software 
(V9.0) using a nonparametric test (the Kruskall-Wallis test) followed by post hoc 
analysis (the Mann-Whitney U-test). P-values less than 0.05 were considered 
significant. Differences between the hESC lines and culture conditions were tested 
using Wilcoxon's signed rank test. 
 
In study III, the values of surface marker expression and proliferation of hESCs, 
expressed as mean ± SD, were compared between the hypoxic and normoxic 
conditions using Student’s t test. In the proliferation analysis, comparisons were 
made between hypoxic and normoxic conditions for all cell lines, cell lines cultured 
only in the hES medium, and cell lines cultured only in the RegES medium. P 
values less than 0.05 were considered significant. The data were analysed using 
SPSS for Windows (v 14.0). 
 
In study IV, mixed models ANOVA was used for the proliferation data analysis of 
ASCs between the different culture media compositions within each separate 
experiment setup to account for the correlation of multiple measurements within 
donors. The Mann-Whitney U test was applied to assess the surface marker 
expression of ASCs between different culture conditions. The surface marker 
expression of ASCs was analysed using the Wilcoxon signed-rank statistic, which 
was used for pairwise comparison between the different culturing conditions. A p  
value of less than 0.05 was considered statistically significant. The analyses were 
performed using SPSS for Windows (v 13.0). 
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5. Results 
5.1 Automation of imaging and analysis (I) 
In the present study, an automated culturing, imaging, and analysis system, Cell-
IQ®, was used to study the growth dynamics of hESCs during one passaging 
interval. We developed an hESC colony area analysis method based on the area 
measurement of the background feeder layer, undifferentiated colony area, and 
differentiated colony area. The average size of the HS237 and HS293 colonies, 
excluding totally differentiated and non-growing hESC colonies, at day 6 was 0.99 
mm2 (± 0.61, n = 24), with 91% undifferentiated cells and 9% differentiated cells. 
To validate the results of the automated analysis, flow cytometry analysis and 
immunocytochemical staining analysis were performed. Flow cytometry analysis of 
the pooled HS237 colonies (n = 143), with a total of 3.0 million cells at day 7, 
revealed that an average-sized colony of 1.04 mm2 contained ~21,000 cells (n = 29). 
Based on the flow cytometry analysis, 81% of the HS237 cells were positive for 
SSEA-4, which was consistent with the automated area protocol result, indicating 
that 86.9% of the HS237 colony area (n = 29) was undifferentiated. 
Immunocytochemical staining of the colonies showed that these colonies were 
positive for Nanog and that SSEA-1 was expressed in only a small proportion (3%) 
of the cells.  
 
After validating the automated analysis protocol, we further examined the growth 
parameters of the HS237 and HS293 cell lines. The average colony size did not 
differ between HS237 (0.79 ± 0.32 mm2) and HS293 (1.20 ± 0.80 mm2) cell lines at 
day 6. The growth rates of the undifferentiated areas (from days 5 to 6) of HS237 
(215 ± 94 μm2/min) and HS293 (328 ± 187μm2/min) were also similar.  HS293 
colonies contained more undifferentiated areas than HS237 colonies (P < 0.01).  
 
The automated culturing, imaging and analysis system was also used to evaluate two 
different culture media, conventional hES culture medium and an X-vivo 10-based, 
xeno-free culture medium. Both HS237 and HS293 cell lines grew better in hES 
medium than in X-vivo 10 medium. Average colony size for both HS237 and 
HS293 was smaller in the X-vivo 10 medium than in the hES medium (0.44 ± 0.31 
vs. 0.99 mm2 ± 0.61, P < 0.01), and the undifferentiated colony area was smaller in 
colonies cultured in the X-vivo 10 medium (64%) than in the hES medium (91%, P 
<0.01).  
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5.2 Evaluation of xeno-free media formulations (II) 
5.2.1 Feeder cell-dependent culture of human embryonic stem cells 
(II) 
In this study, we evaluated nine commercially available or published xeno-free 
medium formulations (Lipumin™, SerEx, SSS, SR3, X-Vivo10, X-Vivo 20, 
Plasmanate, TeSR1, and human serum) for their ability to maintain hESC 
proliferation and self-renewal. Conventional hES medium was used as a control in 
all experiments.  
 
The hESC lines HS181 and HS237 cultured in the xeno-free media formulations 
either differentiated or their proliferation decreased substantially. The results were 
consistent for both hESC lines and across repeated experiments. Differentiation of 
the hESCs began during the adaptation process with all test media except TeSR1 
and human serum media, as indicated by the change in colony morphology. More 
specifically, the differentiated colonies became thinner, and lost their angular shape 
and sharp edges. Differentiation was confirmed by immunocytochemical staining 
analysis; hESC colonies cultured with the test media showed an increased 
expression of a marker characteristic of differentiated hESCs (SSEA-1), but lacked 
the expression of a marker characteristic of undifferentiated hESCs (Nanog). In the 
presence of X-Vivo 10, SSS, SerEx, and TeSR1, colony growth was reduced. With 
X-Vivo 10, X-Vivo 20, SR3, and Lipumin™, hFF morphology was spherical and 
underwent premature detachment. Except in TeSR1 and human serum media, the 
hESCs were all differentiated when the adaptation process was complete and it was 
impossible to passage the colonies further. TeSR1 medium was unable to maintain 
hESC self-renewal beyond 7 passages. An in vitro differentiation analysis was 
performed for the hESCs cultured in TeSR1 medium. Despite the detection of 
ectoderm (NF-68) and mesoderm (α-cardiac actin) -specific markers, an endoderm 
(α-fetoprotein) -specific marker was not detected, indicating defective pluripotency 
of hESCs cultured in TeSR1 medium.  
 
The hESCs cultured in 10% and 20% human serum medium underwent excessive 
differentiation during the first passages of the adaptation phases, which was 
observed as a change in the hESC colony morphology. More specifically, the 
colonies were thinner and lost their angular shape and defined borders. Human 
serum medium-10% was able to maintain the growth of undifferentiated hESCs for 
9 passages. At the end of the passage 10, all colonies had completely differentiated, 
which was confirmed by immunocytochemical staining with Nanog and SSEA-1. 
As the colonies in 20% human serum medium were passaged further, they began to 
regain their undifferentiated morphology. Moreover, at passage 11 the colonies had 
mainly an undifferentiated morphology, although they were notably thinner than the 
hESCs cultured in hES medium. At passage 11, the hESCs cultured in 20% human 
serum medium were stained with Nanog, Oct-4, SSEA-4, and SSEA-1 
immunofluorescent antibodies. Some of the colonies did not express hESC-specific 
markers or SSEA-1, and hESCs cultured in hES medium strongly expressed Nanog 
and did not express SSEA-1. Flow cytometry analysis demonstrated that only 35% 
of the hESCs cultured in 20% human serum medium and 80% of the hESCs 
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cultured in hES medium were positive for SSEA-4. Despite the excessive 
differentiation at the beginning of the experiment, our results indicate that a 
population of cells was able to adapt to the culture conditions with human serum. 
5.2.2 Feeder cell-free culture of human embryonic stem cells (II) 
Control hES, TeSR1, and 20% human serum medium were used to evaluate the self-
renewal of hESC line HS237 in feeder cell-free culture conditions using the 
previously described xeno-free ECM coating mixture (Ludwig et al., 2006). From 
the beginning of the experiment, it was obvious that the attachment of hESCs to the 
ECM mixture was defective. Specifically, of the hESC colony pieces plated with 
each medium, only 30% attached in TeSR1 medium, 55% in 20% human serum 
medium, and 68% in hES medium. In addition, of the attached colony pieces, only 
30% formed colonies in TeSR1 medium, while 75% formed colonies in 20% human 
serum medium and hES medium. After the second passaging, only occasional 
colony formation was observed in hES medium and in 20% human serum medium 
while no colony formation was observed in TeSR1 medium, indicating that none of 
these medium formulations was able to maintain hESC self-renewal in the absence 
of a feeder cell layer. 
5.3 Development and optimization of xeno-free medium 
formulation (III) 
We developed a basic defined and xeno-free serum replacement formulation 
(RegES) based on human serum albumin (HSA), transferrin, amino acids, vitamins, 
antioxidants, trace minerals, and growth factors including bFGF and insulin. The 
initial evaluation of the xeno-free RegES medium revealed that the colonies were 
thinner and the growth of the hESCs was slower than in hESC lines cultured in the 
conventional hES medium. A new hESC line, Regea 06/015, was successfully 
derived by using the first version of the xeno-free RegES medium and hFFs cultured 
in human serum medium. Subsequently, the growth of the Regea 06/015 cell line 
decreased and at passage 7 it was transferred to hES medium. The cell line was 
karyotypically normal and exhibited normal hESC characteristics, including stem 
cell marker expression and pluripotency as determined by EB analysis and teratoma 
formation.  
5.3.1 Evaluation of basal media, glucose concentration, and 
osmolarity 
To evaluate different basal media we tested DMEM/F12, DMEM low D-glucose (1 
g/L), DMEM high D-glucose (4.5 g/L) and KO-DMEM basal media formulations 
with the hESC line HS401 for 5 passages. DMEM/F12 and DMEM low D-glucose 
resulted in excess differentiation of hESCs, whereas only minor differences in the 
proliferation and colony morphology were observed with KO-DMEM and DMEM 
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high D-glucose. In the presence of DMEM/F12 and both DMEM formulations, the 
hFFs exhibited an altered spherical morphology, whereas in KO-DMEM the hFFs 
exhibited the normal elongated morphology. Of the different basal media, KO-
DMEM had the best performance with the RegES concentrate, indicating that a high 
D-glucose concentration and reduced osmolarity of KO-DMEM were more suitable 
for hESC culture.  
 
To further optimise the formulation, we evaluated an osmolarity in the range of 260 
to 350 mOsm in the hESC culture for 5 passages. An osmolarity of 260 mOsm 
induced the formation of small uneven colonies and although the morphology of the 
colonies was improved at an osmolarity of 290 mOsm, the colony size remained 
small. An osmolarity of 350 mOsm clearly restricted the growth of the colonies. The 
best performance was obtained with an osmolarity of 320 mOsm resulting in normal 
colony morphology with defined borders and adequate size. 
5.3.2 Effect of specific lipids and lipid derivatives 
As AlbuMAX, a lipid-rich BSA, is the only non-chemically-defined component of 
KO-SR, we studied whether the addition of lipids or lipid derivatives could further 
enhance the performance of the xeno-free formulation. To assess the general 
morphology, as well as the size and thickness of the undifferentiated colonies, we 
performed visual evaluation of the colonies before each passage. The results 
indicated that conjugated linoleic acid (CLA), eicosapentaenoic acid (EPA), 
palmitoleic acid, linoleic acid, linoleic-oleic-arachidonic acid mix, and especially 
retinol improved the morphology of the undifferentiated colonies in both hES and 
RegES culture media. In addition, myristic acid, alfa-linoleic acid, docosahexaenoic 
acid, S1P, and PGE2 resulted in poor morphology and induced rapid differentiation 
in both types of culture media. 
 
Besides evaluating the morphology of the undifferentiated colonies, the hESC 
colonies were classified into three categories; undifferentiated, partially 
differentiated, and differentiated. The number of each colony type was counted 
before each passage, enabling the calculation of a percentage value for each colony 
type of the total amount of colonies. In RegES culture medium, the number of 
undifferentiated colonies increased and the number of differentiated colonies 
decreased in the presence of CLA, EPA, and stearic acid compared with colonies 
cultured in the control hES medium. In addition, the number of undifferentiated 
colonies increased in the presence of retinol, a linoleic-oleic-arachidonic acid mix, 
DL-isoproterenol, palmitoleic acid, and linoleic acid compared with the colonies 
cultured in the Albumax-RegES medium.  
 
According to the morphology and the level of different colony types, retinol, CLA, 
and EPA improved colony morphology and decreased the number of differentiated 
colonies in both culture media. 
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5.3.3 Retinol and Activin A increase the proliferation and expression 
of stem cell markers 
The effects of retinol were further evaluated in the xeno-free RegES medium. An 
ELISA-based cell proliferation assay demonstrated that retinol (0.5 µM, 2.0 µM, 
and 3.5 µM) stimulated the proliferation rate of hESCs by 5%, 34%, and 37%, 
respectively. In addition, it was noticed that the colony size increased in the 
presence of retinol. Quantitative RT-PCR analysis on hESCs cultured for 10 
passages with or without retinol demonstrated that while a less than 2-fold increase 
in the gene expression of Oct-4, GDF3, DNMT3B, and TDGF1 was detected, 
retinol (0.5 µM, 2.0 µM, and 3.5 µM) increased the expression of Nanog, by 4, 23, 
and 25-fold, respectively. Furthermore, flow cytometry analysis of hESCs cultured 
for 10 passages with and without 2.0 µM retinol showed that retinol induced the 
expression of hESC-specific markers SSEA-4 from 38% to 63% and TRA-1-81 
from 37% to 54%. To assess whether increased expression of the Nanog mRNA 
results in protein synthesis, immunocytochemical analysis was performed on hESCs 
cultured without and with retinol (0.5 µM, 2.0 µM, and 3.5 µM). The analysis 
revealed enhanced staining for Nanog in the presence of retinol (Figure 5). 
 
 
 
Figure 5. Fluorescence microscopy images of hESCs cultured without (A) and with 0.5 µM (B), 2.0 
µM (C), and 3.5 µM (D) retinol for 12 passages showing the expression of Nanog (red) and DAPI 
(blue). Scale bar: 200 µm. 
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Growth factor Activin A was also evaluated in the xeno-free RegES medium. An 
ELISA-based cell proliferation assay performed for hESCs cultured with or without 
Activin A demonstrated that Activin A (5 ng/ml and 10 ng/ml) stimulated the 
proliferation rate of hESCs by 68% and 63%, respectively (Figure 6A). Flow 
cytometry analysis of hESCs cultured with and without Activin A (5 and 10 ng/ml) 
showed that Activin A increased the expression of the hESC-specific markers 
SSEA-4 and TRA-1-81 (Figure 6B). 
 
 
 
Figure 6. Activin A induced proliferation and stem cell marker expression. A) Cell proliferation 
analysis of hESCs cultured without and with 5 and 10 ng/ml Activin A for two passages. B) FACS 
analysis of hESCs cultured without and with 5 and 10 ng/ml Activin A for two passages. 
5.3.4 Insulin induces the expression of stem cell markers 
To assess whether insulin is an important component of the xeno-free medium 
formulation, we tested both IGF-I and IGF-II as well as a combination described by 
Wang et al., 2007 containing 10 ng/ml Activin A, 200 ng/ml IGF-I, and 10 ng/ml 
HRG-β1 for the ability to maintain the proliferation and undifferentiated growth of 
hESCs without insulin. Without insulin and in the presence of IGF-I, IGF-II, and the 
combination of 10 ng/ml Activin A, 200 ng/ml IGF-I, and 10 ng/ml HRG-β1 less 
compact and thinner colonies with less clearly defined borders, as well as increased 
differentiation of hESCs was detected. The cultures could not be maintained beyond 
5 passages due to difficulties in the mechanical passaging of the thin and fragile 
colonies. When a combination of Activin A, IGF-I, and HRG-β1 was evaluated in 
the RegES formulation containing insulin, the colonies exhibited better morphology 
and proliferation, but were thinner compared to colonies cultured in the RegES 
formulation containing only insulin. Quantitative RT-PCR of hESCs cultured with 
or without insulin for 10 passages showed that a less than 2-fold increase in the gene 
expression of Nanog, Oct-4, GABRB3, GDF3, and DNMT3B were detected. Flow 
cytometry analysis of hESCs cultured with or without insulin for 10 passages 
showed that insulin increased the expression of stem cell markers Oct-4 from 27% 
to 64%, SSEA-4 from 67% to 100%, and TRA-1-81 from 39% to 75%. 
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5.4 The effect of oxygen tension on the self-renewal of 
human embryonic stem cells (III) 
5.4.1 Cell proliferation and morphology under hypoxia 
Hypoxic culture improved the hESC colony morphology in both RegES and hES 
culture media, resulting in more compact colonies with clearly defined borders and 
larger colony size. Under hypoxia in both culture conditions, only minor 
spontaneous differentiation was detected within cell colonies, whereas under 
normoxic conditions, spontaneous differentiation of hESCs at the center began 
within 5 days after passaging. An ELISA-based cell proliferation assay 
demonstrated that hypoxia increased the proliferation rate of hESCs maintained in 
the conventional hES culture medium by 42% (p=0.001) and in the RegES culture 
medium by 54% (p<0.001).  
5.4.2 Hypoxia induces the expression of stem cell markers 
No significant differences in the gene expression profiles of stem cell markers (Oct-
4, Nanog, TDGF1, DNMTB3, GABRB3, and GDF3) were detected between hESCs 
cultured either in hES or RegES medium and maintained under hypoxic and 
normoxic conditions. To investigate the effect of O2 tension on the translational 
expression of stem cell markers, flow cytometry analysis was performed on hESCs 
cultured under normoxic and hypoxic conditions. No significant differences were 
detected in the stem cell marker expression (Oct-4, SSEA-4) of hESCs cultured 
either in hES or RegES medium and maintained under hypoxia and normoxia at day 
6. At day 8, however, flow cytometry analysis showed an increase in the expression 
of stem cell markers Oct-4 from 52% to 69% (p<0.05), SSEA-4 from 74% to 91%, 
and TRA-1-81 from 73% to 84% under hypoxia in both culture conditions. 
5.4.3 Hypoxia alters the gene expression of several signalling 
pathways 
To further investigate the possible molecular mechanisms activated by low O2 
tension, a customised quantitative real-time PCR array including genes from 
different signalling pathways was performed. Of the genes analysed, eight genes 
were upregulated and three genes were downregulated in hESCs cultured under 
hypoxic conditions in both culture media. In addition, 8 genes were upregulated in 
hESCs cultured under hypoxic conditions in the hES culture medium, whereas 2 
genes were upregulated and 21 genes were downregulated in hESCs cultured in the 
RegES culture medium. The calcium and PKC pathway (CSF2, IL2, FOS, PRKCE, 
and TFRC) and several hypoxia signalling-related genes (DCTN2, PPARA, 
VEGFA) were altered under hypoxia in both culture conditions. The retinoic acid 
pathway was downregulated under hypoxia in hESCs cultured in the RegES culture 
medium.  
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5.5 Validation of the xeno-free medium formulation (IV) 
5.5.1 Comparison of the RegES medium to HEScGRO (IV) 
We compared the xeno-free RegES medium with the commercially available xeno-
free HEScGRO medium specifically developed for hESC cultures using feeder cells. 
In the hESC line HS401, in contrast to RegES, the morphology of the hESC 
colonies revealed that the HEScGRO medium induced excess differentiation already 
during the adaptation process. After completion of the adaptation process, the 
HEScGRO medium was not able to maintain the undifferentiated growth of hESCs. 
The experiment was repeated two times. 
5.5.2 Derivation, culture, and characterization of human embryonic 
stem cells (IV) 
The optimised RegES medium was used to derive two hESC lines (Regea 07/046 
and Regea 08/013). Both hESC lines exhibited characteristic hESC colony 
morphology, normal diploid karyotype, and were continuously cultured in RegES 
medium for over 80 passages. When stem cell marker expression levels were 
compared to the control hESC line Regea 06/040 derived and cultured in hES 
medium, both Regea 07/046 and Regea 08/013 cell lines exhibited higher 
expression levels of SSEA-4 (difference 8% and 2%, respectively) and TRA-1-81 
(difference 10% and 11%, respectively). In qRT-PCR no significant differences (> 
2-fold) in the expression levels of markers Nanog, Oct-4, GABRB3, GDF3, 
DNMT3B, and TDGF1 were detected between hESC lines derived in RegES and in 
control hESCs. Cell proliferation ELISA analysis showed that the cell proliferation 
rates of Regea 07/046 (A=0,286) and Regea 08/013 (A=0,272) were comparable to 
that of control cell line Regea 06/040 (A=0,287) cultured in hES medium.  
5.5.3 Differentiation potential of human embryonic stem cells (IV) 
The differentiation potential of the hESC lines derived and maintained in RegES 
medium was evaluated in vitro for EB-differentiation assay and in vivo for the 
teratoma formation analysis. The EB-derived cells from the hESC lines Regea 
07/046 and 08/013 expressed markers from the three embryonic lineages; endoderm, 
ectoderm, and mesoderm, and structures from all these germ layers were also 
detected in the teratomas. In addition, we evaluated the in vitro differentiation 
potential of hESC line Regea 08/013 to cardiomyocytes and neural cell lineages. 
The cardiac and neural differentiation efficiency was similar in hES and RegES 
medium. Spontaneously beating cells that were positively stained with cardiac 
troponin T and vMHC markers exhibited a striated pattern. Neural cell 
differentiation was verified by the expression of neural precursor markers, neuronal 
markers and astrocytic markers in RT-PCR and the neuronal (MAP-2) and glial 
(GFAP) fate of the cells was confirmed with immunocytochemical staining.  
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5.5.4 Culture and characterization of induced pluripotent stem cells 
(IV) 
In the present study, we cultured two iPS cell lines on hFFs in RegES medium. Both 
iPS cell lines were maintained in RegES medium for over 20 passages. The 
morphology of the cells was similar to that of the cells cultured in hES medium. In 
qRT-PCR no significant differences (over 2-fold) in the expression levels of stem 
cell markers Nanog, Oct-4, GABRB3, GDF3, DNMT3B, and TDGF1 were detected 
between iPS cell lines maintained in RegES and in hES medium. Only a 1% 
difference was detected in the flow cytometry analysis of both SSEA-4 and TRA-1-
81 of iPS cell line 5-7 cultured in RegES and in hES medium, however, iPS cell line 
6-14 maintained in hES culture medium exhibited higher expression of SSEA-4 
(difference 17%) and TRA-1-81 (difference 21%) than iPS cells maintained in 
RegES medium. 
 
 
 
Figure 7. Analysis of pluripotency of the iPS cell lines maintained in xeno-free RegES medium. 
Differentiated cardiomyocytes from iPS lines 5-7 (A) and 6-14 (B) stained positive for cardiac 
troponin T (red) and vMHC (green), DAPI (blue). C) Higher magnification of vMHC staining. D) 
Most of the cells migrating out from the neurospheres stained positive for neuronal marker MAP-2 
(green) and for astrocytic marker GFAP (red), DAPI (blue). E) RT-PCR analysis of neurospheres 
shows expression of neural precursor markers. 
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5.5.5 Differentiation potential of induced pluripotent stem cells (IV) 
An in vitro EB differentiation assay demonstrated that both iPS cell lines cultured in 
RegES medium maintained their ability to differentiate into all three germ layers. 
The two iPS cell lines also differentiated in vitro into cardiomyocytes and neural 
cell lineages (Figure 7). Cardiomyocyte differentiation was confirmed based on the 
spontaneously beating cells exhibiting a striated pattern by immunocytochemical 
staining of cardiac troponin T and vMHC markers. Neural cell differentiation was 
verified by the expression of neural precursor markers, neuronal markers, and 
astrocytic marker in RT-PCR. No oligodendrocyte precursor marker Olig1 was 
detected in either cell line, while cell line 5-7 expressed Nanog and cell line 6-14 
expressed endodermal marker α-fetoprotein after neuronal differentiation. The 
neuronal (MAP-2) and glial (GFAP) fate of the cells was confirmed in 
immunocytochemical staining.  
5.5.6 Culture and characterization of adipose stem cells (IV) 
ASCs isolated from adipose tissue samples were used to assess the performance of 
RegES medium for the culture of mesenchymal stem cells. AlloHS medium was 
used as a control in all experiments. Seven ASC lines were used for the WST-1 
proliferation analysis performed at several time points (1, 4, 7, and 11 days). At day 
4, hESC cultures with the RegES medium exhibited higher proliferation rates 
compared to the alloHS medium (p=0.035). Subsequently, ASCs continued to 
proliferate at a higher proliferation rate in RegES medium compared to alloHS 
medium at day 7 (p=0.022) and day 11 (p=0.018). Flow cytometric characterization 
of four cell lines was performed to compare surface marker expression 
characteristics of ASCs expanded in RegES and alloHS medium. The flow 
cytometry analysis revealed positive expression (>50% positive expression) for 
ASCs cultured in both culture conditions for the adhesion molecule CD105 and 
extracellular matrix protein CD90, while lacking the expression (<4%) of CD34 and 
CD45, markers of haematopoietic cell lineage. Additionally, no expression (<1%) of 
MHC Class II isotype HLA-DR was observed for ASCs cultured in alloHS or 
RegES media and only modest expression (10%) of MHC Class I isotype HLA-
ABC was observed in ASCs expanded in RegES. While both culture conditions 
maintained the characteristic surface marker expression profile of ASCs, statistical 
analysis revealed significant differences in the expression of sialomucin-like 
adhesion molecule CD34 (p=0.043), leukocyte common antigen CD45 (p=0.017), 
adhesion molecule CD105 (p=0.020), and MHC Class I isotype HLA-ABC 
(p=0.021) of ASCs cultured in alloHS and RegES media. 
5.5.7 Multipotential differentiation capacity of adipose stem cells (IV) 
The multilineage differentiation potential of ASCs expanded in RegES medium was 
examined by culturing ASCs at passage 3 under conditions supporting osteogenic, 
adipogenic, and chondrogenic differentiation (Figure 8). The osteogenic induction 
was evident after 14 days of culture in osteogenic RegES medium and was 
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confirmed by ALP activity staining. Also, adipogenic differentiation was detected in 
osteogenic induction cultures with RegES. Already during the first week of 
adipogenic induction, accumulation of small lipid droplets was visible within the 
ASCs in adipogenic RegES medium. At day 14, ASCs in RegES adipogenic 
induction cultures proliferated rapidly and grew in a layered manner, with lipid 
droplets forming in several layers. Adipogenic differentiation was verified by oil red 
O staining as an indicator of intracellular lipid accumulation. In the chondrogenic 
induction cultures, ASCs expanded in chondrogenic RegES medium began to 
aggregate and form condensed pellets within 2 to 3 days after induction of 
chondrogenesis. The size of the condensing pellets grew rapidly, indicating profuse 
production of ECM. At day 14 cells stained with Alcian blue verified the presence 
of sulphated proteoglycans within the chondrogenic cell pellet. 
 
 
 
Figure 8. Multilineage differentiation potential of ASCs cultured in RegES and in control alloHS 
medium. ALP staining confirming osteogenic differentiation, oil red O staining confirming 
adipogenic differentiation, and Alcian blue staining confirming chondrogenic differentiation of 
ASCs. Scale bar 200 µm (osteogenesis and chondrogenesis) or 100 µm (adipogenesis).  
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6. Discussion 
6.1 Automated culture, monitoring and analysis (I) 
Generally, monitoring cell cultures requires time-consuming microscopy, manual 
imaging and image processing without automated data analysis. In the present study, 
an automated culturing, imaging and analysis system, Cell-IQ®, was used to 
develop an hESC colony area analysis method aimed at studying the growth 
dynamics of hESCs and enabling the comparison of different culture conditions. 
Traditionally, the growth rates of hESC colonies are manually counted from a single 
cell suspensions as doubling time during the exponential growth phase (Choo et al., 
2006) or as an expansion of the area of single colony from photomicrographs 
(Koivisto et al., 2004). The automated culturing, imaging, and analysis system 
utilizing machine vision technology enables automatic observation, recording, and 
analysis of intact living cells. To validate the automated hESC colony area analysis 
method, the results of the automated analysis were validated using flow cytometry 
and immunocytochemical staining analysis. Based on this study, the automated 
monitoring system allowed for the reliable area measurement of live, intact cell 
colonies. There were no differences in the growth rates, amount of spontaneous 
differentiation, or in areas of undifferentiated and differentiated cells between the 
hESC colonies cultured in a standard incubator or in the automated system.  
 
Using the developed analysis method, we examined the growth dynamics of two 
hESC lines. No differences in the average colony size and the growth rates between 
cell lines HS237 and HS293 were detected. It is not yet known, however, whether 
the size of the mechanically passaged cell aggregate influences the size of the 
resulting colony. To minimise variations in the cell aggregate size, the same person 
performed the mechanical passaging throughout the experiment. More 
undifferentiated areas were detected in the colonies of the HS293 cell line than in 
the colonies of HS237 cell line. Human ESC lines exhibit natural variation in 
growth rates and in their tendency to differentiate spontaneously in culture 
(Carpenter et al., 2009). In addition to analyzing the growth dynamics of hESCs, the 
automated monitoring system enabled the observation of hESC behavior, revealing 
more information than would be possible to discover by conventional microscopy 
observation. For example, the hESC colonies attached to the feeder cells on days 1 
to 2 after passaging, and outgrowth of the hESC colonies began on day 3. Typically, 
spontaneous differentiation of undifferentiated colonies started 6 to 8 days after 
passaging in the center of the colonies and at day 7, the hESC colonies had reached 
a size where they needed to be passaged. Moreover, events such as apoptosis, cell 
division, cellular movement, and the number of single cells can be continuously 
observed and recorded in this system.  
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The automated culturing, imaging, and analysis system was also used to evaluate 
two different culture media for the culture of hESCs, the conventional hES culture 
medium and an X-vivo 10-based xeno-free culture medium. The results showed that 
in both HS237 and HS293 cell lines the average colony size and the undifferentiated 
colony area was smaller in colonies cultured in the xeno-free X-Vivo 10 medium 
indicating that hESCs from both cell lines grew better in hES medium. Based on this 
study, the automated cell culturing, imaging, and analysis system provides a useful 
tool for evaluating hESC cultures, allowing for continuous comparison of the effects 
of different culture media or different growth factor concentrations on cell growth 
and behavior. The analysis software of the system is relatively slow, however, 
allowing for the comparison of only few parameters in each experiment. 
Automation of culturing, monitoring, and analysis is essential for fast and reliable 
optimization of culture methods and differentiation protocols as well as for the 
robust mass production of clinically relevant quantities of the specific cell types for 
clinical application of stem cells.   
6.2 Evaluation of xeno-free media formulations (II) 
In this study, nine commercially available or published xeno-free media and serum 
replacements were systematically evaluated and compared to the conventional hES 
medium in hESC culture. Although these products have theoretical promise as 
serum alternatives in hESC culture, our results indicate that all the xeno-free 
formulations, except TeSR1 and human serum medium, were unable to maintain the 
undifferentiated growth of hESCs on human feeder cells. More specifically, the cells 
began to differentiate during the adaptation to the xeno-free test media and upon 
completion of the adaptation process, excess differentiation of the hESCs was 
evident. The loss of pluripotent cells was confirmed by the expression of SSEA-1 
and loss of expression of Nanog. Moreover, colony growth rates decreased in the 
presence of X-Vivo 10, SSS, SerEx, and TeSR1. In addition, in the X-Vivo 10, X-
Vivo 20, SR3, and Lipumin™ test conditions, the morphology of the hFFs was 
considerably altered, showing spherical appearance and premature detachment. 
Feeder cells are an important part of the culture niche, and therefore this might have 
had a critical effect on the excess differentiation observed among the hESCs.  
 
The use of commercially available X-Vivo 10 medium was described previously by 
three research groups (Genbacev et al., 2005; Li et al., 2005; Peerani et al., 2007) for 
feeder cell-free culture of hESCs. Genbacev et al. used a high concentration of 
bFGF; Peerani et al. used TGFβ1 in addition to high bFGF concentration, and Li et 
al. supplemented X-Vivo 10 medium with a high bFGF concentration, stem cell 
factor (SCF), recombinant human flt3 ligand, and LIF. LIF, however, does not 
promote the self-renewal of hESCs (Thomson et al., 1998; Reubinoff et al., 2000; 
Humphrey et al., 2004). In addition, we used a low bFGF concentration (8 ng/ml) 
that is generally employed with feeder cell-dependent cultures and TGFβ1 in 
combination with X-Vivo 10 basal medium. It is unlikely that a higher bFGF 
concentration would have produced better results with these formulations, as a high 
bFGF concentration with feeder cell-dependent cultures generally results in a lower 
growth rate and colonies that grow upward instead of spreading, i.e., colonies that 
do not resemble the characteristic hESC colony morphology (K.R unpublished 
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observations). Besides the undesired effect on hFFs in some test conditions, it is 
impossible to evaluate what caused the excess differentiation of hESCs in the 
presence of these xeno-free formulations because as proprietary formulas, their 
constituents are unknown. It is probable that, rather than containing harmful 
components for hESCs, these formulations lack essential cues needed for the 
maintenance of hESC self-renewal.  
 
Previously, Ludwig and co-workers reported feeder cell-free derivation and culture 
of hESCs using defined medium (TeSR1) including protein components solely from 
recombinant sources or purified from human material and ECM mix coating from 
human sources (Ludwig et al., 2006). They were able to derive two hESC lines in 
these xeno-free conditions, although neither one maintained a stable karyotype. 
Because the xeno-free formulation of TeSR1 was not commercially available when 
our study was conducted, we manufactured the medium according to the published 
report for our experiment. Based on our study, the TeSR1 medium was unable to 
maintain hESC self-renewal beyond 7 passages on human feeder cells. One obvious 
reason may be that TeSR1 was specifically developed to feeder cell-free culture of 
hESCs. Interestingly, albeit a low bFGF concentration was used, the hESC colonies 
cultured in TeSR1 medium did not have the characteristic hESC colony morphology 
or growth, but rather grew upward, resulting in plump colonies, which complicated 
the manual passaging. Based on EB-differentiation analysis an endoderm-specific 
marker was not detected, indicating defective pluripotency of hESCs cultured in 
TeSR1 medium.  
 
In this study, we also evaluated medium containing human serum for the culture of 
hESCs. Previously, Richards and co-workers (Richards et al., 2002) derived an 
hESC line using 20% human serum medium and were able to propagate hESCs in 
an undifferentiated state for 10 passages. It was later observed, however, that 
prolonged use of human serum beyond the tenth passage led to the increased 
differentiation of hESCs (Richards et al., 2003). Based on the present study, the 
hESCs cultured in 10% and 20% serum medium underwent excessive differentiation 
during the initial adaptation phases and we were able to maintain hESCs in 10% 
human serum medium for only 9 passages. Similar results have been described 
before by Koivisto and co-workers who showed that hESCs underwent extensive 
spontaneous differentiation within a few passages in medium containing human 
serum (Koivisto et al., 2004). Interestingly, despite the excessive differentiation in 
the beginning of our experiment, the differentiation of hESCs decreased during 
subsequent passages, and although the hESC colonies were notably thinner in the 
presence of human serum than the hESCs cultured in hES medium, our results 
indicate that a population of cells was able to adapt to the culture conditions with 
human serum. More recently, however, Ellerström and co-workers derived and 
propagated an hESC line in 20% human serum medium for over 20 passages 
without excessive differentiation (Ellerström et al., 2006). The difference in the 
results may be due to different methods for preparing the serum, which yielded a 
different quality of the human serum used in the experiments, thus resulting in 
different effects on cell growth (Tallheden et al., 2005). The use of human serum in 
hESC culture medium is a xeno-free alternative to KO-SR, but like FBS, human 
serum is largely undefined and contains variable amounts of cytokines and growth 
factors, such as PDGF, epidermal growth factor (EGF) and BMPs that may 
influence hESC fate (Bieback et al., 2009). Human serum shows significant lot-to-
 81
lot variability that may affect reproducibility, which means that each lot should be 
carefully tested prior to use (Caterson et al., 2002; Herrera and Inman, 2009). 
Commercial human sera are pooled from a heterogeneous group of donors. Pooling 
sera from selected donors might provide more homogenous sera for hESCs culture. 
In fact, Ellerström and co-workers used pooled blood from 15 donors and prepared 
the sera by using a previously described method (Tallheden et al., 2005; Ellerström 
et al., 2006), resulting in superior quality human serum. Nevertheless, yet another 
concern with the use of human serum is the potential transmission of serious 
pathogens like HIV, which has a long latent preclinical period and could go 
undetected in routine donor screenings (Mallon et al., 2006). By weighing the 
advantages and disadvantages, however, it can be concluded that the optimal 
approach for the xeno-problem of KO-SR would be the use of a defined serum 
replacement comprising purified human or recombinant components.  
 
Control hES, TeSR1, and 20% human serum medium were used to evaluate the self-
renewal of hESCs on feeder cell-free culture conditions using the previously 
described xeno-free ECM coating mixture (Ludwig et al., 2006). The attachment 
and colony formation in all these media, however, were poor. After the second 
passaging, only occasional colony formation was observed in hES and in 20% 
human serum medium, while no colony formation was observed in TeSR1 medium, 
indicating that none of these medium formulations was able to maintain self-renewal 
of hESCs in the absence of a feeder cell layer. Of note, other than the published 
report by Ludwig et al., no other reports describing the use of the xeno-free 
formulation of the TeSR1 medium have been published. Although published in 
2006, only recently has the xeno-free TeSR1 medium formulation been made 
commercially available, indicating that it required several years of optimization 
before being ready for the market. 
6.3 Optimization of xeno-free medium formulation (III, IV) 
Due to the lack of commercially available xeno-free medium specifically developed 
for hESC culture, we developed a basic defined and xeno-free serum replacement 
formulation (RegES) comprising HSA, transferrin, amino acids, vitamins, 
antioxidants, trace minerals, and growth factors, including bFGF and insulin. 
Despite the fact that we were able to derive a new hESC line, Regea 06/015, using 
the xeno-free RegES medium and hFF cultured in human serum (IV), the initial 
evaluations of the xeno-free RegES medium showed that the hESC colonies 
exhibited a thinner appearance and the growth rate of the colonies was slower than 
in the hESC lines cultured in the conventional hES medium, indicating that the 
formulation was not yet optimal for the culture of hESCs. Nevertheless, the first 
successful derivation of a new hESC line exhibiting a normal karyotype and hESC 
characteristics, including pluripotency in xeno-free conditions, demonstrated a vital 
proof-of-principle that our formulation was on the right track. 
 
In this study, we identified essential nutrients and growth factors required for the 
undifferentiated growth of hESCs. To optimise the performance of the xeno-free 
RegES medium, we evaluated different basal media combined with RegES 
concentrate (III). Based on this study, KO-DMEM had the best performance with 
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the RegES concentrate. Furthermore, from the results obtained, the following 
conclusion can be drawn. First, the undesired spherical morphology of the feeder 
cells observed with DMEM/F12 and in both DMEM formulations might have 
affected hESC self-renewal. Second, as the performance of DMEM high D-glucose 
was notably superior to DMEM low D-glucose, the high D-glucose concentration 
was beneficial to hESCs. Finally, DMEM/F12 also containing high D-glucose 
concentration might contain some detrimental component(s) for hESCs. Glucose is 
not just an energy source, but it also induces a variety of cellular signals. In fact, 
early human development in vitro is enhanced in medium lacking glucose 
(Conaghan et al., 1998). Therefore, as many of the differentiation protocols typically 
utilise media containing high glucose concentrations, such as DMEM/F12, the effect 
of glucose on the differentiation of hESCs into specific cell types should be further 
investigated. While we have demonstrated that glucose is important for the growth 
of hESCs, to our knowledge there are no previously published reports on the 
influence of glucose concentration on hESCs. High glucose levels increase the 
proliferation of mouse ESCs through the induction of peroxisome proliferator-
activated receptor δ (PPARδ), which is at least partially mediated through the 
induction of cyclooxygenase-2 expression and PGE2 (Kim and Han, 2008). Thus, 
the possible influence of the glucose on hESC self-renewal requires further 
investigation. 
 
In addition to a high D-glucose concentration, the osmolarity of KO-DMEM was 
reduced to better mimic the natural environment of embryonic tissue. To further 
assess the optimal osmolarity, we evaluated an osmolarity range of 260-350 mOsm 
in the hESC culture for 5 passages. The optimal osmolarity for hESCs was 
approximately 320 mOsm, higher or lower osmolarity altered the morphology and 
restricted the growth of hESCs. In contrast to our results, Ludwig and coworkers 
previously reported that the optimal osmolarity for feeder cell-free hESCs culture is 
350 mOsm, which in our experiment clearly restricted hESC growth (Ludwig et al., 
2006). 
 
Relatively few reports have been published on the effects of lipid-mediated 
signalling for the self-renewal of hESCs. Recently, Garcia-Gonzalo and co-workers 
demonstrated that the albumin-associated lipids present in KO-SR have a strong 
positive effect on hESC self-renewal (Garcia-Gonzalo and Izpisua Belmonte, 2008). 
Although they were able to indentify the major lipids bound to albumin and 
evaluated several lipid candidates, including lysophosphatidylcholine, LPA, S1P, 
PGE2, and dexamethasone in hESC culture, the active lipid remains to be 
determined. We also observed a superior effect of AlbuMAX on hESC self-renewal 
and evaluated many different lipids and lipid derivatives in hESC culture. Based on 
our study, especially retinol, CLA and EPA improved the colony morphology and 
increased the number of undifferentiated colonies in both hES and RegES culture 
media (III). The optimal performance of AlbuMAX may be due to synergism 
between the different lipids (Garcia-Gonzalo and Izpisua Belmonte, 2008), and 
therefore lipids with positive effects on hESC self-renewal should be further 
evaluated to determine optimal combinations and concentrations. Consistent with 
the data reported by Garcia-Gonzalo and co-workers (Garcia-Gonzalo and Izpisua 
Belmonte, 2008), in our experiment S1P neither stimulated self-renewal or 
proliferation nor prevented apoptosis, as described previously (Pebay et al., 2005; 
Inniss and Moore, 2006; Wong et al., 2007). In contrast, S1P induced excessive cell 
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death in both hES and RegES culture media. Although PGE2 has been reported to be 
involved in the increase of proliferation of mouse ESCs in response to high glucose 
concentration (Kim and Han, 2008), in our experiment and consistent with previous 
results (Garcia-Gonzalo and Izpisua Belmonte (2008), PGE2 resulted in poor 
morphology and excess differentiation in both culture media. 
 
In the present study, we further evaluated the effects of retinol on hESC self-
renewal. Retinol increased the proliferation of hESCs and induced the expression of 
the hESC-specific markers SSEA-4 and TRA-1-81. Consistent with the data 
obtained with mouse ESCs (Chen and Khillan, 2008; Chen et al., 2007), addition of 
retinol to the RegES formulation induced a high transcriptional expression of 
Nanog, a key transcription factor for self-renewal. Furthermore, based on this study, 
immunocytochemical analysis revealed increased expression of Nanog in the 
presence of retinol. Nevertheless, the increase in the translational expression of 
Nanog in response to retinol should be confirmed by flow cytometry analysis. In 
contrast to mouse ESCs, however, our results demonstrated that with hESCs the 
optimal effective concentration of retinol was ≥ 2.0 µM, while with mouse ESCs 0.5 
µM retinol, an amount far less than the physiological concentration of retinol (1-2 
µM), suppresses ESC differentiation (Chen et al., 2007; Goodman, 1984). While we 
detected no noteworthy difference between 2.0 µM and 3.5 µM retinol 
concentration, the retinol concentration of 0.5 µM did not increase the proliferation 
or the expression of Nanog to the extent detected with higher concentrations. 
Nevertheless, compared with published data with mouse ESCs (Chen et al., 2007; 
Chen and Khillan, 2008), our results indicate that retinol mediates hESC self-
renewal via the overexpression of Nanog. Retinol plays an important role in a 
variety of essential biological functions, including vision, reproduction, growth, and 
development, and is typically associated with cell differentiation via its potent 
metabolite retinoic acid (Blomhoff and Blomhoff, 2006). The retinol-induced 
expression of Nanog in mouse ESCs is independent of retinoic acid, as well as of 
the JAK-Stat3, BMP2/4, and Wnt/β catenin signalling pathways (Chen et al., 2007; 
Chen and Khillan, 2008). Retinol was recently reported to regulate the self-renewal 
of mouse ESCs by activating PI3 kinase directly via IGF-II receptor/IRS-1, 
suggesting a growth factor like function of this molecule (Chen and Khillan, 2010). 
Whether this is also the mechanism of action in hESCs, however, remains to be 
elucidated.   
 
In the present study, growth factor Activin A, which has long been known for its 
role in endodermal differentiation and cell growth (Sulzbacher et al., 2009), was 
also evaluated in the xeno-free RegES medium. Based on this experiment, Activin 
A stimulated the proliferation of the hESCs and increased the expression of the 
hESC-specific markers SSEA-4 and TRA-1-81. Previously, it has been shown that 
Activin A maintains the pluripotency of hESCs in the absence of feeder layers 
(Beattie et al., 2005; Vallier et al., 2005). Further, both mouse and human feeder 
cells secrete Activin A, although mouse feeder cells secrete higher levels 
(Eiselleova et al., 2008). 
 
We also studied whether insulin is an important component of the xeno-free RegES 
medium formulation or whether it could be replaced with IGF-I, IGF-II or a 
combination of IGF-I, Activin A, and HRG-β1. IGF-II may act as a direct mediator 
of hESC growth, being expressed in response to bFGF and in parallel with 
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TGFβ/Nodal/Activin (Bendall et al., 2007). Basic FGF drives the expression of IGF-
II and TGF-β factors from the hESC-derived fibroblast-like cells that generally 
surround the hESC colonies in both feeder and feeder cell-free cultures (Bendall et 
al., 2007).  Based on our results, however, IGF-II could not replace insulin in the 
xeno-free RegES formulation. In addition, although Wang and co-workers 
suggested that insulin-initiated insulin receptor and IGF-I receptor signalling as well 
as low levels of bFGF are not sufficient to maintain hESC self-renewal (Wang et al., 
2007), our results showed that insulin cannot be replaced with IGF-I alone, or a 
combination of Activin A, IGF-I, and HRG-β1, at least when the hESCs are cultured 
on a feeder cell layer. Human ESCs cultured without insulin and in the presence of 
the IGF-I, IGF-II, or a combination of Activin A, IGF-I, and HRG-β1, exhibited thin 
colonies with less clearly defined borders, as well as increased differentiation. Our 
results suggest that distinct signalling pathways mediate, at least in part, the effects 
of insulin and IGF-I or II in hESCs. Flow cytometry analysis of hESCs cultured 
with or without insulin showed that insulin increased the expression of the stem cell 
markers Oct-4, SSEA-4, and TRA-1-81, indicating that insulin was an important 
component of the xeno-free RegES formulation. 
6.4 Hypoxia mediated self-renewal (III) 
In the present study, we evaluated the effects of hypoxic conditions on the self-
renewal of hESCs cultured in hES or RegES medium. Although the hypoxia system 
used in the present study was not optimal due to the need to manipulate the cells 
under normoxic conditions, exposure to hypoxic conditions prevented spontaneous 
differentiation, significantly increased proliferation, and supported hESC self-
renewal, consistent with previous reports (Ezashi et al., 2005; Ludwig et al., 2006; 
Peura et al., 2007; Westfall et al., 2008; Forristal et al., 2009). The transcriptional 
expression of common genes associated with pluripotency was not significantly 
affected by hypoxia, which is consistent with previous reports (Forsyth et al., 2008; 
Westfall et al., 2008), however increased transcriptional expression of the stem cells 
markers Nanog, Oct-4 and Sox2 under hypoxia was recently reported (Forristal et 
al., 2009). The differences in the observed responses may be due to differences in 
hESC lines and culture conditions, including various degrees of hypoxia, exposure 
to normoxia during manipulation of the cells, culture media, feeder cells, and 
passaging methods. Furthermore, consistent with previous reports, there were no 
statistically significant differences detected in the transcriptional expression of 
hypoxia-inducible factors HIF-1α, HIF-2α, and HIF-3α under hypoxia (Forsyth et 
al., 2008; Westfall et al., 2008; Forristal et al., 2009). Investigation of the 
transcriptional expression of genes relating to different signalling pathways revealed 
that several hypoxia signalling-related genes and the calcium and PKC pathway 
were activated, probably in relation to the altered carbohydrate metabolism under 
hypoxic conditions. The retinoic acid pathway, generally associated with hESC 
differentiation (Inanç et al., 2008), was downregulated under hypoxia in hESCs 
cultured in only the RegES culture medium. Further analyses of the genetic 
mechanisms controlling self-renewal under hypoxia and verification of the results at 
the translational level are needed.  
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Although no statistically significant differences were detected in the translational 
expression of SSEA-4 and TRA-1-60, our results showed a consistent increase in 
the expression of these markers under hypoxia in all of the hESC lines. Consistent 
with previous reports, however, Oct-4 protein expression was significantly increased 
under hypoxic conditions, indicating a possible mechanism for hypoxia-induced 
self-renewal and the prevention of spontaneous differentiation (Covello et al., 2006; 
Forristal et al., 2009). Forristal and colleagues also proposed a model for HIF-
mediated regulation of hypoxia-induced effects where HIF-3α regulates the 
expression of both HIF-1α and HIF-2α, and suggested that HIF-2α regulates hESC 
pluripotency and proliferation under hypoxic conditions (Figure 9).   
 
 
 
Figure 9. A proposed model depicting hypoxia induced transcriptional activity. In cells in which the 
Oct-4 locus is accessible as a result of open chromatin, its transcription is induced directly by HIF-
2α/HIF-1β dimers in response to hypoxia. 
6.5 Validation of xeno-free medium fromulation (IV) 
In the present study (IV), the optimised xeno-free RegES medium was validated for 
use with hESC, iPS cell, and ASC cultures. Furthermore, RegES medium was 
compared to the first commercially available xeno-free medium, HEScGRO, 
specifically developed for hESC cultures on feeder cells. In contrast to a previous 
report in which hESCs were successfully maintained in HEScGRO medium for 10 
passages on human feeder cells (Chin et al., 2009), we found HEScGRO medium to 
be inferior to RegES medium in terms of the amount of spontaneous hESC 
differentiation. HEScGRO is proprietary; therefore, it is not possible to evaluate the 
cause of the excess differentiation of hESCs in our experiment. HEScGRO contains 
20 ng/ml bFGF, which is a much higher concentration than that in RegES medium 
(8 ng/ml). Feeder-cell free culture of hESCs using matrix from xeno-free hFFs 
together with HEScGRO supplemented with 100 ng/ml bFGF and ROCK inhibitor 
have also been described (Meng et al., 2008). 
 
To date only two successful derivations of new hESC lines under xeno-free 
conditions have been described either by using XF-hFFs and human serum 
(Ellerström et al., 2006), or xeno-free ECM matrix and TeSR1 medium (Ludwig et 
al., 2006). The two hESC lines derived by using xeno-free ECM matrix and TeSR1 
medium were karyotypically unstable (Ludwig et al., 2006). In study IV, we 
successfully derived new hESC lines (Regea 07/046 and Regea 08/013) in optimised 
 86 
RegES medium on human feeder cells. Both cell lines were karyotypically normal. 
Furthermore, we continuously maintained these cell lines for over 80 passages in 
xeno-free conditions, which is far more than previously described (Ludwig et al., 
2006; Ellerström et al., 2006). When compared to the hESC lines initially derived 
and maintained in conventional hES medium, these cell lines cultured in hES and 
RegES exhibited almost equal proliferation rates and transcriptional expression of 
stem cell markers. Although no statistically significant differences in the 
translational expression of stem cell markers were detected between these cell lines, 
both cell lines derived and maintained in RegES medium exhibited a modestly 
higher expression of SSEA-4 and TRA-1-81 compared to the hESC line cultured in 
hES medium.  
 
When new xeno-free culture conditions are designed it is important to demonstrate 
that the differentiation potency is maintained. In the present study, we also 
demonstrated that structures from all three germ layers were detected when these 
hESC lines were differentiated in vitro and in vivo. Nevertheless, the direct 
differentiation of these hESC lines towards cardiomyocyte and neural cell lineages 
demonstrated that these cell lines efficiently differentiate to spontaneously beating 
cardiomyocytes and neural cells. Our results demonstrate that xeno- and serum-free 
derivation of hESCs is possible and these cells can be further differentiated to 
specific functional cell types. 
 
Although the RegES medium was initially developed for the culture of hESCs, we 
further evaluated its performance in the culture of two iPS cell lines (IV). The cell 
lines retained their characteristic morphology for more than 20 passages. 
Furthermore, no significant differences in the transcriptional expression of stem 
cells markers of the iPS cell lines maintained in RegES medium were detected 
compared to the control cell line maintained in hES medium. Moreover, no major 
differences in the translational expression of stem cell markers were detected 
between iPS cell line 5-7 maintained in RegES or in hES medium, while for 
unknown reasons iPS cell line 6-14 cultured in RegES exhibited lower expression of 
SSEA-4 and TRA-1-81 than iPS 6-14 cells maintained in hES medium. Both iPS 
cell lines generated structures from each germ layer when differentiated in vitro in 
EBs and differentiated to spontaneously beating cardiomyocytes and neural cells. 
Human somatic cells were recently reprogrammed to pluripotency using KO-SR XF 
or human plasma-derived cell culture additive and CellStart matrix (Rodriquez-Piza 
et al., 2010), or human serum and hDFs (Unger et al., 2009). Our results indicate 
that the xeno-free generation of human iPS cell lines is also possible by using 
RegES medium and further studies to address this question should be performed.  
 
RegES medium was further evaluated for its ability to expand ASCs. The RegES 
medium supported significantly higher proliferation rates than ASCs cultured in 
alloHS medium, which is consistent with previous reports on ASCs expanded in 
xeno-free formulations compared to human serum (Lindroos et al., 2009). 
Furthermore, ASCs maintained their characteristic surface marker expression profile 
under xeno-free culture conditions although there were significant differences in the 
surface marker expression of ASCs cultured in human serum and RegES media 
(IV). Different culture conditions affect the cell surface marker expression of ASCs 
(Lindroos et al., 2009). Nevertheless, irrespective of culture condition, the surface 
marker expression profiles presented in study IV are consistent with previous results 
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for ASCs (Gimble and Guilak 2003; Gronthos et al., 2001; Strem et al., 2005; 
Zannettino et al., 2008), with the expression of markers verifying the mesenchymal 
origin of cells, and the absence of markers of the haematopoietic origin of cells.  
 
Moreover, ASCs exhibited multipotentiality towards osteogenic, chondrogenic, and 
adipogenic lineages in RegES medium (Figure 10). As previously described with 
other xeno-free media (Lindroos et al., 2009), the osteogenic differentiation capacity 
of ASCs cultured in RegES medium is less intense than that in alloHS medium, with 
simultaneous adipogenic differentiation occurring in the osteogenic induction 
cultures. One reason for this may be the superior cell proliferation rates in RegES 
medium, leading to cultures becoming rapidly confluent, which may support 
spontaneous trans-differentiation (Schilling et al., 2007; Liu et al., 2007; Lindroos et 
al., 2009) or due to dexamethasone supplementation of the osteogenic medium 
(Oshina et al., 2007). Also consistent with a previous report on other xeno-free 
media (Lindroos et al., 2009), RegES medium supported adipogenic and 
chondrogenic differentiation of ASCs. The differentiation protocols require further 
development with xeno-free media for optimal differentiation results. 
 
 
 
Figure 10. The differentiation potential of the ASCs in RegES and HS medium conditions. The 
thickness of the arrow indicates the differentiation potential towards each lineage. RegES=xeno-free 
culture medium; AlloHS= allogeneic human serum 
6.6 Future perspectives 
Since the discovery of stem cells, diverse culture conditions have been utilised for 
different types of stem cells. Most existing stem cell lines have been exposed to 
undefined xenogeneic products during in vitro establishment and expansion of the 
cells, which makes these cell lines undesirable for clinical applications. 
Furthermore, undefined products, such as FBS or human serum show significant 
batch-to-batch variability that may affect reproducibility of the results. At present, 
FBS or human serum is used for the in vitro expansion of adult stem cells. Various 
culture conditions have been described for the culture of hESCs, although the most 
widely used are KO-SR media employed with either human or mouse feeder cells 
and feeder cell-free culture utilizing Matrigel as a substrate and mTeSR1 medium.  
 
Over the last few years, a number of molecular factors and signalling pathways that 
play a major role in maintaining self-renewal have been identified. Determining the 
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synergistic effects of these molecules and the convergence of independent signalling 
pathways affecting the growth and maintenance of stem cells will enable a better 
mechanistic understanding of stem cell regulation. Considerable progress has been 
made towards the generation of defined and xeno-free culture conditions for stem 
cells. An overview of the progress and anticipated future development in stem cell 
culture conditions are summarised in Figure 11. Currently, there are at least four 
commercially available xeno-free culture media for the culture of hESCs; 
HEScGRO (Millipore), developed for the culture of hESC lines with feeder cells; 
KnockOut SR Xeno-free (Invitrogen), which can be used with or without feeder 
cells; Stemedia™ NutriStem™ XF/FF (Stemgent) and TeSR2 (StemCell 
Technologies) for the culture of hESC lines in feeder-cell free conditions. Because 
human iPS cells have similar culture requirements with hESCs, the xeno-free 
culture media developed for hESCs will probably be applicable also for the culture 
of human iPS cells. A few xeno-free media have also been developed for the 
expansion of adult stem cells such as CellGro SCGM (CellGenix) and StemPro 
MSC FFM Xeno-Free (Invitrogen). In the present study, we also demonstrated that 
hESCs, iPS cells, and ASCs could be maintained in the same defined xeno-free 
medium formulation for a prolonged period of time while maintaining their 
characteristics. Furthermore, so far RegES is the only defined, xeno-free medium 
described that maintains the differentiation potential of stem cells both in vitro and 
in vivo after long-term culture. 
 
 
Figure 11. An overview of the history and future culture methods for ASCs and hESCs. 
 
 
The new xeno-free products present an important advancement in the field of stem 
cell culture. Although all stem cell lines share the expression of characteristic stem 
cell markers, different culture conditions influence gene expression and therefore 
many of the cell properties (Skottman et al., 2006). The use of completely defined 
conditions will allow for a better understanding of stem cell regulations and provide 
more reproducible results. Nevertheless, it is essential to fully validate these 
products before they are brought to market. Future studies should focus on 
validating xeno-free culture conditions for long-term culture; maintaining the key 
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features of self-renewal, pluripotency, and genetic stability; as well as derivation, 
reprogramming, or isolation of new stem cell lines as a full proof-of-principle. 
These studies should also maximise proliferation rates, improve the efficiency of 
subcloning of these cells, and provide for scale-up to a manufacturing level. This is 
highly important not only for clinical use of these cells, but also for reliable research 
using these cells. Moreover, as many of the current differentiation protocols utilise a 
variety of undefined products, the xeno-free products should be tested as a base for 
differentiation protocols. The use of defined products in the differentiation protocols 
will facilitate the discovery of molecular mechanisms underlying the differentiation 
to various cell types and the reproducibility of differentiation processes.  
 
Stem cells are invaluable tools for research and are a potential resource for 
regenerative therapies. As the number of potential applications for stem cell 
transplantation in the treatment of various degenerative diseases is rapidly 
increasing and several clinical trials using adult stem cells are ongoing as well as the 
first trial using hESCs is under way for acute spinal cord injuries, a strong focus on 
the safety and quality of stem cell transplants is needed. As the regulatory 
framework is constantly developing, we can only anticipate the future requirements 
for stem cell-based therapies. Although qualified xenogeneic reagents have 
previously received approval by the FDA, given the potential for infections and 
immune responses from xenogeneic products, it is preferable to maintain clinical-
grade cells in defined, xeno-free conditions. By replacing xenogeneic products with 
defined xeno-free media formulation, the safety, reproducibility, and quality of the 
cells with therapeutic potential may be significantly enhanced. The basic RegES 
culture medium described in the present study has the potential to be further 
optimised for the xeno-free establishment, culture, and differentiation of various 
stem cell types and can ultimately serve as a platform for the production of clinical-
grade stem cells and their derivatives for safer clinical cell therapy treatments. 
Additional pre-clinical safety and efficacy studies are also needed before the 
promise of the xeno-free products can be fully realised.  
 
Although stem cells have the capacity to generate specific cell types and therefore 
may appear to be a panacea for cell and tissue replacement, there are still major 
challenges; including efficient differentiation of stem cells to fully functional cell 
types; changes in their epigenetic profiles, chromosomal aberrations during their 
establishment and maintenance; post-transplantation challenges like risk of tumors, 
genetic instability, and potential immunogenicity. It is clear that stem cells represent 
an equally large opportunity and challenge for the future of regenerative therapy. 
This new field of biology has been established with great enthusiasm, and huge 
amounts of work are being undertaken to dissect the basic biology and 
characteristics of these cells. Such understanding will undoubtedly uncover ways to 
harness their potential and bring the use of these unique cells into routine clinical 
practice. 
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7. Conclusions 
The aim of this thesis was to develop and optimise defined and xeno-free culture 
conditions for stem cells to support feasible proliferation while maintaining the 
characteristics and differentiation potential of the cell types and meeting the 
regulatory standards for the clinical application of stem cells. Furthermore, these 
studies provided new insights into the molecular mechanisms that regulate the self-
renewal and pluripotency of stem cells. The results of these studies led us to the 
following conclusions: 
 
• The automated culturing, imaging, and analysis system Cell-IQ® enabled 
reliable analysis of the undifferentiated growth dynamics of hESCs, 
revealing more information than conventional microscopic observation. The 
system is applicable for the comparison of morphology and growth of hESCs 
in different culture conditions (I).  
 
• None of the xeno-free medium formulations evaluated in study (II) were 
able to maintain the self-renewal of hESCs on human feeder cells. A portion 
of hESCs was able to adapt to 20% human serum medium, but it was inferior 
to the conventional hES culture medium. Pooling sera from selected 
individuals and optimization of the serum preparation method may yield 
better quality human serum, decreasing the batch-to-batch variability, and 
increasing the reproducibility of the results. In the feeder cell-free culture of 
hESCs on a xeno-free matrix, the attachment and colony formation in 20% 
human serum medium, TeSR1, and hES medium were inadequate, indicating 
that none of these medium formulations was able to maintain hESC self-
renewal in the absence of a feeder cell layer. 
 
• Human ESC characteristics and proliferation were enhanced in the presence 
of KO-DMEM basal media, high glucose concentration, and osmolarity of 
320 mOsm, together with xeno-free serum replacement RegES (III). 
Specific lipids enhanced the growth and/or self-renewal of hESCs and could 
be used to supplement the xeno-free RegES medium.  
 
• The addition of retinol in the RegES formulation (III) accelerated 
proliferation of hESCs and the expression of stem cell markers, especially 
Nanog, indicating that similar to mouse ESCs, retinol may mediate hESC 
self-renewal via Nanog overexpression. Activin A stimulated the 
proliferation of hESCs and increased the expression of stem cell markers. 
IGF-I, IGF-II or a combination of Activin A, IGF-I, and HRG-β1 could not 
effectively replace insulin in the xeno-free RegES culture medium. The lack 
of insulin in the xeno-free RegES medium resulted in a thin cell morphology 
and decreased the expression of stem cell markers. 
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• Exposure to hypoxic conditions prevented spontaneous differentiation, 
supported self-renewal, and significantly increased the proliferation of 
hESCs (III). Although no major differences were detected in the expression 
of common genes associated with pluripotency or the hypoxia-inducible 
factors HIF-1α, HIF-2α, and HIF-3α, several hypoxia signalling-related 
genes and the calcium and PKC pathway were activated in both hES and 
RegES culture conditions. The retinoic acid pathway was downregulated by 
hypoxia in hESCs cultured in the RegES culture medium. Translational 
expression did not differ significantly, but the expression of SSEA-4 and 
TRA-1-60 consistently increased under hypoxia in all hESC lines. Oct-4 
expression was significantly increased under hypoxic conditions, indicating 
a possible mechanism for hypoxia-induced self-renewal and the prevention 
of spontaneous differentiation. 
 
• Xeno-free RegES medium enabled the derivation of new hESC lines on 
human feeder cells (IV). These hESC lines were karyotypically stable over 
very long-term (> 80 passages) culture, and exhibited a feasible proliferation 
rate, characteristic stem cell marker expression, and pluripotency 
comparable to that of control hESC line. 
 
• Xeno-free RegES medium enabled long-term (> 20 passages) culture of 
human iPS cells on a human feeder layer (IV) while maintaining 
characteristic stem cell marker expression. The iPS cell line 6-14 showed a 
lower expression of stem cell markers SSEA-4 and TRA-1-81 than iPS cells 
maintained in control hES medium. Nevertheless, pluripotency was 
maintained in both iPS cell lines cultured in RegES medium.  
 
• The xeno-free RegES medium induced significantly higher proliferation 
rates of ASCs than alloHS medium, and maintained the multipotentiality 
towards osteogenic, chondrogenic, and adipogenic lineages, as well as the 
characteristic surface marker expression profile of ASCs. There were, 
however, significant differences in the surface marker expression of the 
ASCs cultured in alloHS and RegES media, (IV).  
 
• The results indicate that the basic xeno-free RegES medium is applicable for 
further optimization of xeno-free establishment, culture, and differentiation 
of various stem cell types and can ultimately serve as a platform for the 
production of clinical-grade multi- and pluripotent stem cells and their 
derivatives for safer clinical cell therapy treatments. 
 92 
Acknowledgements 
This study was carried out in Regea – Institute for Regenerative Medicine, 
University of Tampere during the years 2005-2010. I wish to thank all those who 
during these years have helped me. 
 
My deepest gratitude I owe to my supervisor Docent Heli Skottman PhD, who gave 
me the opportunity to work in this great project under her excellent supervision. 
Thank you for allowing me to be involved in many interesting projects and tasks 
during these years. I greatly admire her for her enthusiasm, expertise and 
confidence. 
 
I am also profoundly thankful to my second supervisor Professor Outi Hovatta, MD, 
PhD for giving me valuable advice, inspiration and infusing me with courage.  
 
Professor Arto Urtti, Associate Professor Anna Veiga and Associate Professor 
Melissa Carpenter are warmly thanked for their constructive criticism and valuable 
comments on the thesis, despite the strict timetable.  
 
To the members of my follow-up group, Professor Riitta Suuronen, MD, DDS and 
also the head of Regea, Docent Katriina Aalto-Setälä, MD, PhD and Professor Timo 
Ylikomi MD, PhD, I owe my sincere thanks for the productive discussions and 
valuable advice during the years of my PhD studies.  
 
I owe my gratitude to my co-authors Suvi Aivio, Samer Hussein, Jose Inzunza, 
Timo Otonkoski, Sarita Panula, Harri Pihlajamäki, and Björn Rozell and to my 
collaborators Seppo Auriola, Marjut Borgenström, Catharina Ellerström, Heini 
Huhtala, Reijo Itkonen, Anna Mårtensson, Elin Sjöqvist, Glyn Stacey, Reimund 
Strehl and Tony Winslöf, for their contribution to this work. Special thanks to 
Joydeep Goswami for his advice and cheerful discussions. 
 
I owe special thanks to my workmates at former GMP group, especially Heidi 
Hongisto for your friendship and help that you have given me during these years 
and Outi Melin, Niina Ikonen and Hanna Koskenaho for outstanding technical 
assistance in the laboratory. I warmly thank also Miia Juntunen, Anna-Maija 
Honkala, and Maarit Partikainen for helping me with the laboratory work regarding 
RegES optimization. Special thanks belong also to all my dear colleagues, we have 
had fun together. 
 
My beloved friends, Miia & Sami, Sari & Jarno, Suvi & Jarno, Heta & Vesa and my 
many team-mates are dearly thanked for their friendship, for their care and for 
keeping in touch. Thank you for giving my life plenty of joy and happiness! 
 
 93
I wish to thank my family; especially my husband Mikko, for taking care of our 
home and Max when I have been in the “science world”. I am grateful for your love 
and care. I would like to cordially thank my parents, Anita and Markku, and my 
brother Juha for the endless encouragement and support, my grandmother, Saimi, I 
regret for not being able to visit as often as I had wanted, you truly are my role 
model, and last but not least the always happy Max, for insisting me to play and take 
long walks with you and keeping me in touch with the reality. 
 
This study was financially supported by TEKES, the Finnish Funding Agency for 
Technology and Innovation, Academy of Finland, the competitive research funding 
of the Pirkanmaa Hospital District, Finnish Defense Forces, KAUTE foundation, 
Konkordia foundation and the City of Tampere. 
 
Tampere, March 2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 94 
8. References 
 Aasen T, Raya A, Barrero M, Garreta E, Consiglio A, Gonzalez F, Vassena R 
(2008): Efficient and rapid generation of induced pluripotent stem cells from 
human keratinocytes. Nat Biotechnol 26:1276-1284. 
 
 Allegrucci C WY, Thurston A, Denning CN, Priddle H, Mummery CL, Ward-van 
Oostwaard D, Andrews PW, Stojkovic M, Smith N, Parkin T, Jones ME, 
Warren G, Yu L, Brena RM, Plass C, Young LE (2007): Restriction 
landmark genome scanning identifies culture-induced DNA methylation 
instability in the human embryonic stem cell epigenome. Hum Mol Genet 
16:1253-1268. 
 
 Amabile G, Meissner, A. (2009): Induced pluripotent stem cells: current progress 
and potential for regenerative medicine. Trends Mol Med 15:59-68. 
 
 Amit M, Carpenter MK, Inokuma MS, Chiu CP, Harris CP, Waknitz MA, 
Itskovitz-Eldor J, Thomson JA (2000): Clonally derived human embryonic 
stem cell lines maintain pluripotency and proliferative potential for 
prolonged periods of culture. Dev Biol 227:271-8. 
 
 Amit M, Itskovitz-Eldor J (2002): Derivation and spontaneous differentiation of 
human embryonic stem cells. J Anat 200:225-32. 
 
 Amit M, Margulets V, Segev H, Shariki K, Laevsky I, Coleman R, Itskovitz-Eldor 
J (2003): Human feeder layers for human embryonic stem cells. Biol Reprod 
68:2150-6. 
 
 Amit M, Shariki C, Margulets V, Itskovitz-Eldor J (2004): Feeder layer- and 
serum-free culture of human embryonic stem cells. Biol Reprod 70:837-45. 
 
 Assady S, Maor G, Amit M, Itskovitz-Eldor J, Skorecki KL, Tzukerman M (2001): 
Insulin production by human embryonic stem cells. Diabetes 50:1691-7. 
 
 Atala A (2006): Recent developments in tissue engineering and regenerative 
medicine. Curr Opin Pediatr 18:167-171. 
 
 Babaie Y, Herwig R, Greber B, Brink TC, Wruck W, Groth D, Lehrach H, Burdon 
T, Adjaye J (2007): Analysis of Oct4-dependent transcriptional networks 
regulating self-renewal and pluripotency in human embryonic stem cells. 
Stem Cells 25:500-510. 
 
Bach JF, Boitard C (1986): Experimental models of type-I diabetes. Pathol 
Immunopathol Res 5:384-415. 
 95
 
 Baker D, Harrison NJ, Maltby E, Smith K, Moore HD, Shaw PJ, Heath PR, Holden 
H, Andrews PW (2007): Adaptation to culture of human embryonic stem 
cells and oncogenesis in vivo. Nat Biotechnol 25:207-215. 
 
 Beattie GM, Lopez AD, Bucay N, Hinton A, Firpo MT, King CC, Hayek A (2005): 
Activin A maintains pluripotency of human embryonic stem cells in the 
absence of feeder layers. Stem Cells 23:489-95. 
 
Beilhack G, Scheffold, YC, Weissman, IL, Taylor, C, Jerabek, L, Burge, MJ, 
Masek, MA, Shizuru, JA (2003): Purified allogeneic hematopoietic stem cell 
transplantation blocks diabetes pathogenesis in NOD mice. Diabetes 52:59-
68. 
 
 Bendall S, Stewart M, Menendez P, George D, Vijayaragavan K, Werbowetski-
Ogilvie T, Ramos-Mejia V, Rouleau A, Yang J, Bosse M, Lajoie G, Bhatia 
M (2007): IGF and FGF cooperatively establish the regulatory stem cell 
niche of pluripotent human cells in vitro. Nature 7157:1015-1021. 
 
 Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, 
Meissner A, Wernig M, Plath K, Jaenisch R, Wagschal A, Feil R, Schreiber 
SL, Lander ES (2006): A bivalent chromatin structure marks key 
developmental genes in embryonic stem cells. Cell 125:315-26. 
 
 Bibikova M, Chudin E, Wu B, Zhou L, Garcia EW, Liu Y, Shin S, Plaia TW, 
Auerbach JM, Arking DE, Gonzalez R, Crook J, Davidson B, Schulz TC, 
Robins A, Khanna A, Sartipy P, Hyllner J, Vanguri P, Savant-Bhonsale S 
(2006): Human embryonic stem cells have a unique epigenetic signature. 
Genome Res 16:1075-83. 
 
 Bieback K, Hecker A, Kocaomer A, Lannert H, Schallmoser K, Strunk D, Kluter H 
(2009): Human alternatives to fetal bovine serum for the expansion of 
mesenchymal stromal cells from bone marrow. Stem Cells 27:2331-41. 
 
 Bigdeli N, Andersson M, Strehl R, Emanuelsson K, Kilmare E, Hyllner J, Lindahl 
A (2007): Adaptation of human embryonic stem cells to feeder-free and 
matrix-free culture conditions directly on plastic surfaces. J Biotechnol 
133:146-153. 
 
 Billon N, Jolicoeur C, Ying QL, Smith A, Raff M (2002): Normal timing of 
oligodendrocyte development from genetically engineered, lineage-
selectable mouse ES cells. J Cell Sci 115:3657-65. 
 
Blomhoff R, Blomhoff HK (2006): Overview of retinoid metabolism and function. J 
Neurobiol 66:606-630. 
 
Blum B, Bar-Nur O, Golan-Lev T, Benvenisty N (2009): The anti-apoptotic gene 
survivin contributes to teratoma formation by human embryonic stem cells. 
Nat Biotechnol 27:281-287. 
 
 96 
 Bradley JA, Bolton EM, Pedersen RA (2002): Stem cell medicine encounters the 
immune system. Nat Rev Immunol 2:859-71. 
 
 Brederlau A, Correia AS, Anisimov SV, Elmi M, Paul G, Roybon L, Morizane A, 
Bergquist F, Riebe I, Nannmark U, Carta M, Hanse E, Takahashi J, Sasai Y, 
Funa K, Brundin P, Eriksson PS, Li JY (2006): Transplantation of human 
embryonic stem cell-derived cells to a rat model of Parkinson's disease: 
effect of in vitro differentiation on graft survival and teratoma formation. 
Stem Cells 24:1433-40. 
 
 Cameron C, Hu WS, Kaufman DS (2006): Improved development of human 
embryonic stem cell-derived embryoid bodies by stirred vessel cultivation. 
Biotechnol Bioeng 94:938-948. 
 
 Campagnoli C RI, Kumar S, Bennett PR, Bellantuono I, Fisk NM (2001): 
Identification of mesenchymal stem/progenitor cells in human first-trimester 
fetal blood, liver, and bone marrow. Blood 98:2396-2402. 
 
 Carpenter MK, Rosler E, Rao MS (2003): Characterization and differentiation of 
human embryonic stem cells. Cloning Stem Cells 5:79-88. 
 
Carpenter MK, Frey-Vasconcells J, Rao MS (2009): Developing safe therapies from 
human pluripotent stem cells. Nat Biotechnol 27:606-613. 
 
 Caterson EJ, Nesti LJ, Danielson KG, Tuan RS (2002): Human marrow-derived 
mesenchymal progenitor cells: isolation, culture expansion, and analysis of 
differentiation. Mol Biotechnol 20:245-56. 
 
 Chadwick K, Wang L, Li L, Menendez P, Murdoch B, Rouleau A, Bhatia M 
(2003): Cytokines and BMP-4 promote hematopoietic differentiation of 
human embryonic stem cells. Blood 102:905-915. 
 
Chen H, Qian K, Hu J, Liu D, Lu W, Yang Y, Wang D, Yan H, Zhang S, Zhu G 
(2005): The derivation of two additional human embryonic stem cell lines 
from day 3 embryos with low morphological scores. Hum Reprod 20:2201-
6. 
 
Chen L, Yang M, Dawes J, Khillan J (2007): Suppression of ES cell differentiation 
by retinol (vitamin A) via the overexpression of Nanog. Differentiation 
75:682-93. 
 
 Chen L, Khillan J (2008): Promotion of feeder-independent self-renewal of 
embryonic stem cells by retinol (vitamin A). Stem Cells 26:1858-64. 
 
 Chen H, Kuo H, Chen W, Wu F, Yang Y, Ho H (2009): A reduced oxygen tension 
(5%) is not beneficial for maintaining human embryonic stem cells in the 
undifferentiated state with short splitting intervals. Hum Reprod 1:71-80. 
 
 97
 Chen L, Khillan JS (2010): A novel signaling by vitamin A/retinol promotes self 
renewal of mouse embryonic stem cells by activating PI3K/Akt signaling 
pathway via insulin-like growth factor-1 receptor. Stem Cells 28:57-63. 
 
 Cheng L, Hammond H, Ye Z, Zhan X, Dravid G (2003): Human adult marrow cells 
support prolonged expansion of human embryonic stem cells in culture. 
Stem Cells 21:131-42. 
 
 Chin A, Padmanabhan J, Oh SK, Choo AB (2009): Defined and serum-free media 
support undifferentiated human embryonic stem cell growth. Stem Cells Dev 
[Epub ahead of print] 
 
Chin MH, Mason MJ, Xie W, Volinia S, Singer M, Peterson C, Ambartsumyan G, 
Aimiuwu O, Richter L, Zhang J, Khvorostov I, Ott V, Grunstein M, Lavon 
N, Benvenisty N, Croce CM, Clark AT, Baxter T, Pyle AD, Teitell MA, 
Pelegrini M, Plath K, Lowry WE (2009): Induced pluripotent stem cells and 
embryonic stem cells are distinguished by gene expression signatures. Cell 
Stem Cell 5:111-123. 
 
 Choo A, Padmanabhan J, Chin A, Fong WJ, Oh SK (2006): Immortalized feeders 
for the scale-up of human embryonic stem cells in feeder and feeder-free 
conditions. J Biotechnol 122:130-41. 
 
 Choumerianou DM, Dimitriou H, Kalmanti M (2008): Stem cells: promises versus 
limitations. Tissue Eng Part B Rev 14:53-60. 
 
 Clark AT, Bodnar MS, Fox M, Rodriquez RT, Abeyta MJ, Firpo MT, Pera RA 
(2004): Spontaneous differentiation of germ cells from human embryonic 
stem cells in vitro. Hum Mol Genet 13:727-39. 
 
 Cobo F, Stacey G, Hunt C, Cabrera C, Nieto A, Montes R, Cortes J, Catalina P, 
Barnie A, Concha A (2005): Microbiological control in stem cell banks: 
approaches to standardisation. Appl Microbiol Biotechnol 68:456-66. 
 
 Conaghan J, Hardy K, Leese H, Winston R, Handyside A (1998): Culture of human 
preimplantation embryos to the blastocyst stage: a comparison of 3 media. 
Int J Dev Biol 7:885-893. 
 
 Cormier J, zur Nieden NI, Rancourt DE, Kallos MS (2006): Expansion of 
undifferentiated murine embryonic stem cells as aggregates in suspension 
culture bioreactors. Tissue Eng 12:3233-3245. 
 
 Cousin B, Ravet E, Poglio S, De Toni F, Bertuzzi M, Lulka H, Touil I, Andre M, 
Grolleau JL, Peron JM, Chavoin JP, Bourin P, Penicaud L, Casteilla L, 
Buscail L, Cordelier P (2009): Adult stromal cells derived from human 
adipose tissue provoke pancreatic cancer cell death both in vitro and in vivo. 
PLoS One 4:e6278. 
 
 98 
 Cowan CA, Atienza J, Melton DA, Eggan K (2005): Nuclear reprogramming of 
somatic cells after fusion with human embryonic stem cells. Science 
309:1369-73. 
 
 Covello K, Simon M (2004): HIFs, hypoxia, and vascular development. Curr Top 
Dev Biol 62:37-54. 
 
Covello K, Kehler J, Yu H, Gordan JD, Arsham AM, Hu CJ, Labosky PA, Simon 
MC, Keith B (2006): HIF-2alpha regulates Oct-4: effects of hypoxia on stem 
cell function, embryonic development, and tumor growth. Genes Dev 
20:557-570. 
 
 Crook J, Peura T, Kravets L, Boesman A, Buzzard J, Horne R, Hentze H, Dunn N, 
Zweigerdt R, Chua F, Upshall A, Colman A (2007): The generation of six 
clinical-grade human embryonic stem cell lines. Cell Stem Cell 1:490-4. 
 
Deb K, Sarda K (2008): Human embryonic stem cells: preclinical perspectives. J 
Transl Med 6:7. 
 
 De Sousa P, Galea G, Turner M (2006): The road to providing human embryo stem 
cells for therapeutic use: the UK experience. Reproduction 132:681-689. 
 
 de Souza N (2010): Primer: induced pluripotency. Nat Methods 7:20-21. 
 
 Denker A, Nicoll S, Tuan R (1995): Formation of cartilage-like spheroids by 
micromass cultures of murine C3H10T1/2 cells upon treatment with 
transforming growth factor-beta 1. Differentiation 59:25-34. 
 
 Dimos J, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft, 
GF, Saphier G, Leibel R, Goland R, Wichterle H, Henderson CE, Eggan K 
(2008): Induced pluripotent stem cells generated from patients with ALS can 
be differentiated into motor neurons. Science 321:1218-1221. 
 
 Doss M, Stauch T, Gross U, Renz M, Akagi R, Doss-Frank M, Seelig HP, Sassa S 
(2004): The third case of Doss porphyria (delta-amino-levulinic acid 
dehydratase deficiency) in Germany. J Inherit Metab Dis 27:529-536. 
 
 Dottori M, Leung J, Turnley A, Pebay A (2008): Lysophosphatidic acid inhibits 
neuronal differentiation of neural stem/progenitor cells derived from human 
embryonic stem cells. Stem Cells 5:1146-1154. 
 
 Draper JS, Moore HD, Ruban LN, Gokhale PJ, Andrews PW (2004): Culture and 
characterization of human embryonic stem cells. Stem Cells Dev 13:325-36. 
 
 Dravid G, Ye Z, Hammond H, Chen G, Pyle A, Donovan P, Xu X, Cheng L (2005): 
Defining the role of Wnt/beta-catenin signaling in the survival, proliferation, 
and self-renewal of human embryonic stem cells. Stem Cells 10:1489-1501. 
 
 99
 Ebert AD YJ, Rose FF Jr, Mattis VB, Lorson CL, Thomson JA, Svendsen CN 
(2009): Induced pluripotent stem cells from a spinal muscular atrophy 
patient. Nature 457:277-280. 
 
 EC. Regulation (EC) No 1394 of the European Parliament and of the Council on 
advanced therapy medicinal products and amending Directive 2001/83/EC 
and Regulation (EC) No 726/2004.  
 
 EC. (2001): Directive 2001/83/EC of the European Parliament and of the Council 
of 6 November 2001 on the Community Code Relating to medicinal 
Products for Human Use.  
 
 EC. (2004): Directive 2004/23/EC of the European Parliament and of the Council 
of 31 march 2004 on setting standards of quality and safety for the donation, 
procurement, testing, processing, preservation, storage, and distribution of 
human tissues and cells.  
 
 Eggan K, Rode A, Jentsch I, Samuel C, Hennek T, Tintrup H, Zevnik B, Erwin J, 
Loring J, Jackson-Grusby L, Speicher MR, Kuehn R, Jaenisch R (2002): 
Male and female mice derived from the same embryonic stem cell clone by 
tetraploid embryo complementation. Nat Biotechnol 20:455-459. 
 
 Eiges R, Urbach A, Malcov M, Frumkin T, Schwartz T, Amit A, Yaron Y, Eden A, 
Yanuka O, Benvenisty N, Ben-Yosef D (2007): Developmental study of 
fragile X syndrome using human embryonic stem cells derived from 
preimplantation genetically diagnosed embryos. Cell Stem Cell 1:568-577. 
 
 Eiselleova L, Peterkova I, Neradil J, Slaninova I, Hampl A, Dvorak P (2008): 
Comparative study of mouse and human feeder cells for human embryonic 
stem cells. Int J Dev Biol 52:353-363. 
 
 Ellerstrom C, Strehl R, Moya K, Andersson K, Bergh C, Lundin K, Hyllner J, 
Semb H (2006): Derivation of a xeno-free human embryonic stem cell line. 
Stem Cells 24:2170-6. 
 
Ellerström C, Strehl R, Noaksson K, Hyllner J, Semb H (2007): Facilitated 
expansion of human embryonic stem cells by single-cell enzymatic 
dissociation. Stem Cells 25:1690-6. 
 
 EMEA. (2008): Guideline on safety and efficacy follow-up-risk management on 
advanced therapy medicinal products.  
 
 Enver T, Soneji S, Joshi C, Brown J, Iborra F, Orntoft T, Thykjaer T, Maltby E, 
Smith K, Dawud RA, Jones M, Matin M, Gokhale P, Draper J, Andrews PW 
(2005): Cellular differentiation hierarchies in normal and culture-adapted 
human embryonic stem cells. Hum Mol Genet 14:3129-40. 
 
 Ezashi T, Das P, Roberts RM (2005): Low O2 tensions and the prevention of 
differentiation of hES cells. Proc Natl Acad Sci U S A 102:4783-4788. 
 
 100 
Feki A, Bosman A, Dubuisson JB, Irion O, Dahoun S, Pelte MF, Hovatta O, Jaconi 
ME (2008): Derivation of the first Swiss human embryonic stem cell line 
from a single blastomere of an arrested four-cell stage embryo. Swiss Med 
Wkly 138:540-550. 
 
 Fletcher J, Ferrier P, Gardner J, Harkness L, Dhanjal S, Serhal P, Harper J, 
Delhanty J, Brownstein D, Prasad Y, Lebkowski J, Mandalam R, Wilmut I, 
De Sousa P (2006): Variations in humanized and defined culture conditions 
supporting derivation of new human embryonic stem cell lines. Cloning 
Stem Cells 8:319-34. 
 
 Forristal C, Wright K, Hanley N, Oreffo R, Houghton F (2009): Hypoxia inducible 
factors regulate pluripotency and proliferation in human embryonic stem 
cells cultured at reduced oxygen tensions. Reproduction Advanced online 
publication. 
 
 Forsyth N, Kay A, Hampson K, Downing A, Talbot R, McWhir J (2008): 
Transcriptome alterations due to physiological normoxic (2% O2) culture of 
human embryonic stem cells. Regen Med 6:817-833. 
 
 Gang EJ, Jeong JA, Hong SH, Hwang SH, Kim SW, Yang IH, Ahn C, Han H, Kim 
H (2004): Skeletal myogenic differentiation of mesenchymal stem cells 
isolated from human umbilical cord blood Stem Cells 22:617-24. 
 
 Garcia-Gonzalo F, Izpisua Belmonte J (2008): Albumin-associated lipids regulate 
human embryonic stem cell self-renewal. Plos One 1:1384. 
 
 Gatti RA, Meuwissen HJ, Allen HD, Hong R,Good RA (1968): Immunological 
reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 
2:1366-1369. 
 
 Genbacev O, Krtolica A, Zdravkovic T, Brunette E, Powell S, Nath A, Caceres E, 
McMaster M, McDonagh S, Li Y, Mandalam R, Lebkowski J, Fisher S 
(2005): Serum-free derivation of human embryonic stem cell lines on human 
placental fibroblast feeders. Fertil Steril 83:1517-29. 
 
 Geron (2009a): Geron receives FDA clearance to begin world's first human clinical 
trial of embryonic stem cell-based therapy. News release January 23, 2009. 
Accessed February 2, 2010, at http://www.geron.com/media/releases.aspx  
 
Geron (2009b): FDA places Geron's GRNOPC1 IND on clinical hold. News release 
May 14, 2009. Accessed February 2, 2010, at 
http://www.geron.com/media/releases.aspx.  
 
 Giles J, Foote RH (1997): Effects of gas atmosphere, platelet-derived growth factor 
and leukemia inhibitory factor on cell numbers of rabbit embryos cultured in 
a protein-free medium. Reprod Nutr Dev 37:97-104. 
 
 Gimble J, Guilak F (2003): Adipose-derived adult stem cells: isolation, 
characterization, and differentiation potential. Cytotherapy 5:362-9. 
 101
 
 Giorgetti A, Montserrat N, Aasen T, Gonzalez F, Rodríguez-Pizà I, Vassena R, 
Raya A, Boué S, Barrero MJ, Corbella BA, Torrabadella M, Veiga A, 
Izpisua Belmonte JC (2009): Generation of induced pluripotent stem cells 
from human cord blood using OCT4 and SOX2. Cell Stem Cell 5: 
 
 Goodman D (1984): Overview of current knowledge of metabolism of vitamin A 
and carotenoids. J Natl Cancer Inst 73:1375-1379. 
 
Greber B, Lehrach H, Adjaye J (2007): Fibroblast growth factor 2 modulates 
transforming growth factor beta signaling in mouse embryonic fibroblasts 
and human ESCs (hESCs) to support hESC self-renewal. Stem Cells 25:455-
464. 
 
 Greijer A, van der Groep P, Kemming D, Shvarts A, Semenza GL, Meijer GA, van 
de Wiel MA, Belien JA, van Diest PJ, van der Wall E (2005): Up-regulation 
of gene expression by hypoxia is mediated predominantly by hypoxia-
inducible factor 1 (HIF-1). J Pathol 206:291-304. 
 
Grinnemo K, Sylvén C, Hovatta O, Dellgren G, Corbascio M (2008): 
Immunogenicity of human embryonic stem cells. Cell Tissue Res 331:67-78. 
 
 Gronthos S, Franklin DM, Leddy HA, Robey PG, Storms RW, Gimble JM (2001): 
Surface protein characterization of human adipose tissue-derived stromal 
cells. J Cell Physiol 189:54-63. 
 
 Guillot PV, Gotherstrom C, Chan J, Kurata H, Fisk NM (2007): Human first-
trimester fetal MSC express pluripotency markers and grow faster and have 
longer telomeres than adult MSC. Stem Cells 25:646-654. 
 
 Haase A, Olmer R, Schwanke K, Wunderlich S, Merkert S, Hess C, Zweigerdt R, 
Gruh I, Meyer J, Wagner S, Maier LS, Han DW, Glage S, Miller K, Fischer 
P, Schöler HR, Martin U (2009): Generation of induced pluripotent stem 
cells from human cord blood. Cell Stem Cell 5:434-441. 
 
 Haimi S, Moimas L, Pirhonen E, Lindroos B, Huhtala H, Räty S, Kuokkanen H, 
Sandor G, Miettinen S, Suuronen R (2008): Calcium phosphate surface 
treatment of bioactive glass causes a delay in early osteogenic differentiation 
of adipose stem cells. J Biomed Mater Res A 91A:540-547. 
 
 Haimi S, Suuriniemi N, Haaparanta A, Ellä V, Lindroos B, Huhtala H, Räty S, 
Kuokkanen H, Sandor G, Kellomäki M, Miettinen S, Suuronen R (2009): 
Growth and osteogenic differentiation of adipose stem cells on 
PLA/bioactive glass and PLA/beta-TCP scaffolds. Tissue Eng Part A 
15:1473-1480. 
 
 Harrison N, Baker D, Andrews PW (2007): Culture adaptation of embryonic stem 
cells echoes germ cell malignancy. Int J Androl 30:275-281. 
 
 102 
Haruta M (2005): Embryonic stem cells: potential source for ocular repair. Semin 
Ophthalmol 20:17-23. 
 
 Harvey A, Kind KL, Pantaleon M, Armstrong DT, Thompson JG (2004): Oxygen-
regulated gene expression in bovine blastocysts. Biol Reprod 71:1108-1119. 
 
 Hay D, Zhao D, Ross A, Mandalam R, Lebkowski J, Cui W (2007): Direct 
differentiation of human embryonic stem cells to hepatocyte-like cells 
exhibiting functional activities. Cloning Stem Cells 9:51-62. 
 
 Heiskanen A, Satomaa T, Tiitinen S, Laitinen A, Mannelin S, Impola U, Mikkola 
M, Olsson C, Miller-Podraza H, Blomqvist M, Olonen A, Salo H, Lehenkari 
P, Tuuri T, Otonkoski T, Natunen J, Saarinen J, Laine J (2007): N-
glycolylneuraminic acid xenoantigen contamination of human embryonic 
and mesenchymal stem cells is substantially reversible. Stem Cells 25:197-
202. 
 
 Hemberger M, Yang W, Natale D, Brown TL, Dunk C, Gargett CE, Tanaka S 
(2008): Stem cells from fetal membranes - a workshop report. Placenta 
Suppl A:17-19. 
 
 Heng J, Feng B, Han J, Jiang J, Kraus P, Ng JH, Orlov YL, Huss M, Yang L, 
Lufkin T, Lim B, Ng HH (2010): The Nuclear Receptor Nr5a2 Can Replace 
Oct4 in the Reprogramming of Murine Somatic Cells to Pluripotent Cells. 
Cell Stem Cell 6:167-174. 
 
 Hentze H, Graichen R, Colman A (2007): Cell therapy and the safety of embryonic 
stem cell-derived grafts. Trends Biotechnol 25:24-32. 
 
 Herrera B, Inman GJ (2009): A rapid and sensitive bioassay for the simultaneous 
measurement of multiple bone morphogenetic proteins: Identification and 
quantification of BMP4, BMP6 and BMP9 in bovine and human serum. 
BMC Cell Biol 10:20. 
 
 Hicks AU, Lappalainen RS, Narkilahti S, Suuronen R, Corbett D, Sivenius J, 
Hovatta O, Jolkkonen J (2009): Transplantation of human embryonic stem 
cell-derived neural precursor cells and enriched environment after cortical 
stroke in rats: cell survival and functional recovery. Eur J Neurosci 29:562-
74. 
 
 Hipp J, Atala A (2008): Sources of stem cells for regenerative medicine. Stem Cell 
Rev 4:3-11. 
 
 Hisamatsu-Sakamoto M, Sakamoto N, Rosenberg AS (2008): Embryonic stem cells 
cultured in serum-free medium acquire bovine apolipoprotein B-100 from 
feeder cell layers and serum replacement medium. Stem Cells 26:72-8. 
 
 Hoffman LM, Carpenter MK (2005): Characterization and culture of human 
embryonic stem cells. Nat Biotechnol 23:699-708. 
 
 103
 Hovatta O, Mikkola M, Gertow K, Stromberg A, Inzunza J, Hreinsson J, Rozell B, 
Blennow E, Andang M, Ahrlund-Richter L (2003): A culture system using 
human foreskin fibroblasts as feeder cells allows production of human 
embryonic stem cells. Hum Reprod 18:1404-9. 
 
 Hu C, Wang LY, Chodosh LA, Keith B, Simon MC (2003): Differential roles of 
hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic 
gene regulation. Mol Cell Biol 23:9361-9374. 
 
 Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, Melton DA 
(2008a): Induction of pluripotent stem cells by defined factors is greatly 
improved by small-molecule compounds. Nat Biotechnol 26:795-797. 
 
 Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S, Muhlestein W, 
Melton DA (2008b): Induction of pluripotent stem cells from primary human 
fibroblasts with only Oct4 and Sox2. Nat Biotechnol 26:1269-1275. 
 
 Humphrey R, Beattie GM, Lopez AD, Bucay N, King CC, Firpo MT, Rose-John S, 
Hayek A (2004): Maintenance of pluripotency in human embryonic stem 
cells is STAT3 independent. Stem Cells 22:522-530. 
 
Hyslop L, Armstrong, L, Stojkovic, M, Lako, M. (2005): Human embryonic stem 
cells: biology and clinical implications. Expert Rev Mol Med 7:1-21. 
 
Imreh MP, Gertow K, Cedervall J, Unger C, Holmberg K, Szoke K, Csoregh L, 
Fried G, Dilber S, Blennow E, Ahrlund-Richter L (2006): In vitro culture 
conditions favoring selection of chromosomal abnormalities in human ES 
cells. J Cell Biochem 99:508-16. 
 
 In 't Anker PS SS, Kleijburg-van der Keur C, Noort WA, Claas FH, Willemze R, 
Fibbe WE, Kanhai HH (2003): Amniotic fluid as a novel source of 
mesenchymal stem cells for therapeutic transplantation. Blood 102:1548-
1549. 
 
In 't Anker PS SS, Kleijburg-van der Keur C, de Groot-Swings GM, Claas FH, 
Fibbe WE, Kanhai HH (2004): Isolation of mesenchymal stem cells of fetal 
or maternal origin from human placenta. Stem Cells 22:1338-1345. 
 
 Inanç B, Elçin A, Elçin Y (2008): Human embryonic stem cell differentiation on 
tissue engineering scaffolds: effects of NGF and retinoic acid induction. 
Tissue Eng Part A 14:955-964. 
 
 Inniss K, Moore H (2006): Mediation of apoptosis and proliferation of human 
embryonic stem cells by sphingosine-1-phosphate. Stem Cells Dev 6:789-
796. 
 
 
 
 
 104 
 Inzunza J, Sahlen S, Holmberg K, Stromberg A, Teerijoki H, Blennow E, Hovatta 
O, Malmgren H (2004): Comparative genomic hybridization and 
karyotyping of human embryonic stem cells reveals the occurrence of an 
isodicentric X chromosome after long-term cultivation. Mol Hum Reprod 
10:461-6. 
 
Inzunza J, Gertow K, Stromberg M, Matilainen E, Blennow E, Skottman H, 
Wolbank S, Ahrlund-Richter L, Hovatta O (2005): Derivation of human 
embryonic stem cell lines in serum replacement medium using postnatal 
human fibroblasts as feeder cells. Stem Cells 23:544-9. 
 
 ISSCR (2008): ISSCR Guidelines for the Clinical Translation of Stem Cells. Curr 
Protoc Stem Cell Biol Appendix 1:Appendix 1B. 
 
 James D, Levine A, Besser D, Hemmati-Brivanlou A (2005): 
TGFbeta/activin/nodal signaling is necessary for the meaintenance of 
pluripotency in human embryonic stem cells. Development 6:1273-1282. 
 
 Jeong C, Lee H, Cha J, Kim J, Kim K, Kim J, Yoon D, Kim K (2007): Hypoxia-
inducible factor-1 alpha inhibits self-renewal of mouse embryonic stem cells 
in Vitro via negative regulation of the leukemia inhibitory factor-STAT3 
pathway. J Biol Chem 18:13672-13679. 
 
Ji L, Allen-Hoffmann BL, de Pablo JJ, Palecek SP (2006): Generation and 
differentiation of human embryonic stem cell-derived keratinocyte 
precursors. Tissue Eng 12:665-679. 
 
 Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez 
XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, 
Low WC, Largaespada DA, Verfaillie CM (2002): Pluripotency of 
mesenchymal stem cells derived from adult marrow. Nature 418:41-9. 
 
 Joannides AJ, Fiore-Heriche C, Battersby AA, Athauda-Arachchi P, Bouhon IA, 
Williams L, Westmore K, Kemp PJ, Compston A, Allen ND, Chandran S 
(2006): A scaleable and defined system for generating neural stem cells from 
human embryonic stem cells. Stem Cells 25:731-737. 
 
 Kanatsu-Shinohara M, Inoue K, Lee J, Yoshimoto M, Ogonuki N, Miki H, Baba S, 
Kato T, Kazuki Y, Toyokuni S, Toyoshima M, Niwa O, Oshimura M, Heike 
T, Nakahata T, Ishino F, Ogura A, Shinohara T (2004): Generation of 
pluripotent stem cells from neonatal mouse testis. Cell 119:1001-1012. 
 
 Katz AJ, Parker AM (2006): Methods and Compositions for Growing Adipose 
Stem Cells. WO 2007/030652 A2:69. 
 
 Kehat I, Kenyagin-Karsenti D, Snir M, Segev H, Amit M, Gepstein A, Livne E, 
Binah O, Itskovitz-Eldor J, Gepstein L (2001): Human embryonic stem cells 
can differentiate into myocytes with structural and functional properties of 
cardiomyocytes. J Clin Invest 108:407-14. 
 
 105
 Keller G (2005): Embryonic stem cell differentiation: emergence of a new era in 
biology and medicine. Genes Dev 19:1129-1155. 
 
 Kim K, Lerou P, Yabuuchi A, Lengerke C, Ng K, West J, Kirby A, Daly MJ, Daley 
GQ (2007): Histocompatible embryonic stem cells by parthenogenesis. 
Science 315:482-486. 
 
 Kim Y, Han H (2008): High-glucose-induced prostaglandin E(2) and peroxisome 
proliferator-activated receptor delta promote mouse embryonic stem cell 
proliferation. Stem cells 3:745-755. 
 
 Klimanskaya I, Chung Y, Meisner L, Johnson J, West M, Lanza R (2005): Human 
embryonic stem cells derived without feeder cells. Lancet 365:1636-1641. 
 
Klimanskaya I, Chung Y, Becker S, Lu SJ, Lanza R (2006): Human embryonic stem 
cell lines derived from single blastomeres. Nature Aug 23 [Epub ahead of 
print]. 
 
 Kocaoemer A, Kern S, Kluter H, Bieback K (2007): Human AB serum and 
thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf 
serum for the expansion of mesenchymal stem cells from adipose tissue. 
Stem Cells 25:1270-8. 
 
 Koivisto H, Hyvärinen M, Strömberg A, Inzunza J, Matilainen E, Mikkola M, 
Hovatta O, Teerijoki H (2004): Cultures of human embryonic stem cells - 
serum replacement medium or serum-containing media and the effect of 
basic fibrolast growth factor. Reproductive BioMedicine Online 9:330-337. 
 
 Koller MR, Maher RJ, Manchel I, Oxender M, Smith AK (1998): Alternatives to 
animal sera for human bone marrow cell expansion: human serum and 
serum-free media. J Hematother 7:413-23. 
 
 Kristal B, Stavrovskaya IG, Narayanan MV, Krasnikov BF, Brown AM, Beal MF, 
Friedlander RM (2004): The mitochondrial permeability transition as a target 
for neuroprotection. J Bioenerg Biomembr 36:309-312. 
 
 Kärner E, Unger C, Sloan AJ, Ahrlund-Richter L, Sugars RV, Wendel M (2007): 
Bone matrix formation in osteogenic cultures derived from human 
embryonic stem cells in vitro. Stem Cells Dev 16:39-52. 
 
 Laflamme M, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK, 
Reinecke H, Xu C, Hassanipour M, Police S, O'Sullivan C, Collins L, Chen 
Y, Minami E, Gill EA, Ueno S, Yuan C, Gold J, Murry CE (2007): 
Cardiomyocytes derived from human embryonic stem cells in pro-survival 
factors enhance function of infarcted rat hearts. Nat Biotechnol 25:1015-
1024. 
 
 
 
 106 
 Laurent L, Chen J, Ulitsky I, Mueller F, Lu C, Shamir R, Fan J, Loring J (2008): 
Comprehensive microRNA profiling reveals a unique human embryonic 
stem cell signature dominated by a single seed sequence. Stem Cells 
26:1506-1516. 
 
 Lee J, Lee J, Park J, Kim S, Kim M, Roh S, Yoon H (2005): Establishment and 
maintenance of human embryonic stem cell lines on human feeder cells 
derived from uterine endometrium under serum-free condition. Biol Reprod 
72:42-9. 
 
 Lee S, Heo J, Han H (2007): Effect of hypoxia on 2-deoxyglucose uptake and cell 
cycle regulatory protein expression of mouse embryonic stem cells: 
involvement of Ca2+/PKC, MAPKs and HIF-1alpha. Cell Physiol Biochem 
5-6:269-282. 
 
 Lefort N, Feyeux M, Bas C, Féraud O, Bennaceur-Griscelli A, Tachdjian G, 
Peschanski M, Perrier AL (2008): Human embryonic stem cells reveal 
recurrent genomic instability at 20q11.21. Nat Biotechnol 26:1364-1366. 
 
 Lei T, Jacob S, Ajil-Zaraa I, Dubuisson JB, Irion O, Jaconi M, Feki A (2007): 
Xeno-free derivation and culture of human embryonic stem cells: current 
status, problems and challenges. Cell Res 17:682-688. 
 
 Levenberg S, Golub JS, Amit M, Itskovitz-Eldor J, Langer R (2002): Endothelial 
cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A 
99:4391-6. 
 
 Li Y, Powell S, Brunette E, Lebkowski J, Mandalam R (2005): Expansion of 
human embryonic stem cells in defined serum-free medium devoid of 
animal-derived products. Biotechnol Bioeng 91:688-98. 
 
 Lim JW, Bodnar A (2002): Proteome analysis of conditioned medium from mouse 
embryonic fibroblast feeder layers which support the growth of human 
embryonic stem cells. Proteomics 2:1187-203. 
 
 Lin T, Ambasudhan R, Yuan X, Li W, Hilcove S, Abujarour R, Lin X, Hahm HS, 
Hao E, Hayek A, Ding S (2009): A chemical platform for improved 
induction of human iPSCs. Nat Methods 6:805-808. 
 
 Lindroos B, Boucher S, Chase L, Kuokkanen H, Huhtala H, Haataja R, Vemuri M, 
Suuronen R, Miettinen S (2009): Serum-free, xeno-free culture media 
maintain the proliferation rate and multipotentiality of adipose stem cells in 
vitro. Cytotherapy 11:958-972. 
 
 Liu TM, Martina M, Hutmacher DW, Hui JH, Lee EH, Lim B (2007): Identification 
of common pathways mediating differentiation of bone marrow- and adipose 
tissue-derived human mesenchymal stem cells into three mesenchymal 
lineages. Stem Cells 25:750-60. 
 
 
 107
 Liu Y, Song Z, Zhao Y, Qin H, Cai J, Zhang H, Yu T, Jiang S, Wang G, Ding M, 
Deng H (2006): A novel chemical-defined medium with bFGF and N2B27 
supplements supports undifferentiated growth in human embryonic stem 
cells. Biochem Biophys Res Commun 346:131-9. 
 
 Livak KJ, Schmittgen TD (2001): Analysis of relative gene expression data using 
real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 
4:402-408. 
 
 Lowell S, Benchoua A, Heavey B, Smith AG (2006): Notch promotes neural 
lineage entry by pluripotent embryonic stem cells. PLoS Biol 4:121. 
 
 Lowry WE, Richter L, Yachechko R, Pyle AD, Tchieu J, Sridharan R,Clark AT 
(2008): Generation of human induced pluripotent stem cells from dermal 
fibroblasts. PNAS 105:2883-2888. 
 
 Lu J, Hou R, Booth CJ, Yang SH, Snyder M (2006): Defined culture conditions of 
human embryonic stem cells. Proc Natl Acad Sci U S A 103:5688-93. 
 
 Ludwig T, Levenstein M, Jones J, Berggren W, Mitchen E, Frane J, Crandall L, 
Daigh C, Conard K, Piekarczyk M, Llanas R, Thomson J (2006): Derivation 
of human embryonic stem cells in defined conditions. Nat Biotechnol 
24:185-187. 
 
 Mackensen A, Drager R, Schlesier M, Mertelsmann R, Lindemann A (2000): 
Presence of IgE antibodies to bovine serum albumin in a patient developing 
anaphylaxis after vaccination with human peptide-pulsed dendritic cells. 
Cancer Immunol Immunother 49:152-6.  
 
 Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, Arnold K, Stadtfeld M, 
Yachechko R, Tchieu J, Jaenisch R, Plath K, Hochedlinger K (2007): 
Directly reprogrammed fibroblasts show global epigenetic remodeling and 
widespread tissue contribution. Cell Stem Cell 1:55-70. 
 
 Mallon BS, Park KY, Chen KG, Hamilton RS, McKay RD (2006): Toward xeno-
free culture of human embryonic stem cells. Int J Biochem Cell Biol 
38:1063-75. 
 
 Martin M, Muotri A, Gage F, Varki A (2005): Human embryonic stem cells express 
an immunogenic nonhuman sialic acid. Nat med 11:228-232. 
 
 McDonald D (2004): A SNAP decision in neural cell fate. Nat Cell Biol 6:187. 
 
Menendez P, Bueno, C, Wang, L, Bhatia, M. (2005): Human embryonic stem cells: 
potential tool for achieving immunotolerance? Stem Cell Rev 1:151-158. 
 
 Meng G, Liu S, Krawetz R, Chan M, Chernos J, Rancourt DE (2008): A novel 
method for generating xeno-free human feeder cells for human embryonic 
stem cell culture. Stem Cells Dev 17:413-422. 
 
 108 
 Mesimäki K, Lindroos B, Törnwall J, Mauno J, Lindqvist C, Kontio R, Miettinen S, 
Suuronen R (2009): Novel maxillary reconstruction with ectopic bone 
formation by GMP adipose stem cells. Int J Oral Maxillofac Surg 38:201-9. 
 
 Meuleman N, Tondreau T, Delforge A, Dejeneffe M, Massy M, Libertalis M, Bron 
D, Lagneaux L (2006): Human marrow mesenchymal stem cell culture: 
serum-free medium allows better expansion than classical alpha-MEM 
medium. Eur J Haematol 76:309-16. 
 
 Mikkola M, Olsson C, Palgi J, Ustinov J, Palomaki T, Horelli-Kuitunen N, 
Knuutila S, Lundin K, Otonkoski T, Tuuri T (2006): Distinct differentiation 
characteristics of individual human embryonic stem cell lines. BMC Dev 
Biol 6:40. 
 
 Mimeault M, Batra SK (2006): Concise review: recent advances on the significance 
of stem cells in tissue regeneration and cancer therapies. Stem Cells 
24:2319-2345. 
 
 Mimeault M, Hauke R, Batra SK (2007): Stem cells: a revolution in therapeutics-
recent advances in stem cell biology and their therapeutic applications in 
regenerative medicine and cancer therapies. Clin Pharmacol Ther 82:252-
264. 
 
 Mirabet V, Solves P, Minana MD, Encabo A, Carbonell-Uberos F, Blanquer A, 
Roig R (2008): Human platelet lysate enhances the proliferative activity of 
cultured human fibroblast-like cells from different tissues. Cell Tissue Bank 
9:1-10. 
 
 Mitalipova M, Rao R, Hoyer D, Johnson J, Meisner L, Jones K, Dalton S, Stice S 
(2005): Preserving the genetic integrity of human embryonic stem cells. Nat 
Biotechnol 23:19-20. 
 
 Moore KA, Lemischka IR (2006): Stem cells and their niches. Science 311:1880-
1885. 
 
 Mountford J (2008): Human embryonic stem cells: origins, characteristics and 
potential for regenerative therapy. Transfus Med 18:1-12. 
 
 Murry C, Keller G (2008): Differentiation of embryonic stem cells to clinically 
relevant populations: lessons from embryonic development. Cell 132:661-
680. 
 
 Muruve N, Shoskes DA (2005): Genitourinary malignancies in solid organ 
transplant recipients. Transplantation 80:709-716. 
 
Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, 
Mochiduki Y, Takizawa N, Yamanaka S (2008): Generation of induced 
pluripotent stem cells without Myc from mouse and human fibroblasts. Nat 
Biotechnol. 26:101-106. 
 
 109
 Nistor GI, Totoiu MO, Haque N, Carpenter MK, Keirstead HS (2005): Human 
embryonic stem cells differentiate into oligodendrocytes in high purity and 
myelinate after spinal cord transplantation. Glia 49:385-96. 
 
 Noaksson K, Zoric N, Zeng X, Rao MS, Hyllner J, Semb H, Kubista M, Sartipy P 
(2005): Monitoring differentiation of human embryonic stem cells using 
real-time PCR. Stem Cells 23:1460-7. 
 
 Osafune K, Caron L, Borowiak M, Martinez RJ, Fitz-Gerald CS, Sato Y, Cowan 
CA, Chien KR, Melton DA (2008): Marked differences in differentiation 
propensity among human embryonic stem cell lines. Nat Biotechnol 26:313-
315. 
 
 Oshina H, Sotome S, Yoshii T, Torigoe I, Sugata Y, Maehara H, Marukawa E, 
Omura K, Shinomiya K (2007): Effects of continuous dexamethasone 
treatment on differentiation capabilities of bone marrow-derived 
mesenchymal cells. Bone 41:575-83. 
 
Pappa K, Anagnou N (2009): Novel sources of fetal stem cells: where do they fit on 
the developmental continuum? Regen Med 4:423-433. 
 
 Park I, Zhao R, West J, Yabuuchi A, Huo H, Ince T, Lerou P (2008): 
Reprogrammingof human somatic cells to pluripotency with defined factors. 
Nature 451:141-147. 
 
 Parker AM, Shang H, Khurgel M, Katz AJ (2007): Low serum and serum-free 
culture of multipotential human adipose stem cells. Cytotherapy 9:637-46. 
 
 Parson A (2006): The long journey from stem cells to medical product. Cell 125:9-
11. 
 
 Pebay A, Wong RC, Pitson SM, Wolvetang EJ, Peh GS, Filipczyk A, Koh KL, 
Tellis I, Nguyen LT, Pera MF (2005): Essential roles of sphingosine-1-
phosphate and platelet-derived growth factor in the maintenance of human 
embryonic stem cells. Stem Cells 23:1541-8. 
 
 Peerani R, Rao BM, Bauwens C, Yin T, Wood GA, Nagy A, Kumacheva E, 
Zandstra PW (2007): Niche-mediated control of human embryonic stem cell 
self-renewal and differentiation. EMBO J 26:4744-4755. 
 
 Pekkanen-Mattila M, Kerkelä E, Tanskanen J, Pietilä M, Pelto-Huikko M, Hyttinen 
J, Skottman H, Suuronen R, Aalto-Setälä K (2009): Substantial variation in 
the cardiac differentiation of human embryonic stem cell lines derived and 
propagated under the same conditions--a comparison of multiple cell lines. 
Ann Med 41:360-370. 
 
 Petersen A, Mikkelsen AL, Lindenberg S (2005): The impact of oxygen tension on 
developmental competence of post-thaw human embryos. Acta Obstet 
Gynecol Scand 84: 
 
 110 
 Peura T, Bosman A, Stojanov T (2007): Derivation of human embryonic stem cell 
lines. Theriogenology 1:32-42. 
 
 Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, 
Moorman MA, Simonetti DW, Craig S, Marshak DR (1999): Multilineage 
potential of adult human mesenchymal stem cells Science 284:143-7. 
 
 Prasad S, Czepiel M, Cetinkaya C, Smigielska K, Weli S, Lysdahl H, Gabrielsen A, 
Petersen K, Ehlers N, Fink T, Minger S, Zachar V (2009): Continuous 
hypoxic culturing maintains activation of Notch and allows long-term 
propagation of human embryonic stem cells without spontaneous 
differentiation. Cell Prolif 1:63-74. 
 
 Presnell S, Petersen B, Heidaran M (2002): Stem cells in adult tissues. Semin Cell 
Dev Biol 13:369-376. 
 
Price P, Goldsborough M, Tilkins M (1998) in International Patent Application, 
Vol. WO98/30679. 
 
Priddle H, Jones DR, Burridge PW, Patient R (2006): Hematopoiesis from human 
embryonic stem cells: overcoming the immune barrier in stem cell therapies. 
Stem Cells 24:815-824 
 
Prowse A, McQuade LR, Bryant KJ, Van Dyk DD, Tuch BE, Gray PP (2005): A 
proteome analysis of conditioned media from human neonatal fibroblasts 
used in the maintenance of human embryonic stem cells. Proteomics 5:978-
989. 
 
 Prowse A, McQuade LR, Bryant KJ, Marcal H, Gray PP (2007): Identification of 
potential pluripotency determinants for human embryonic stem cells 
following proteomic analysis of human and mouse fibroblast conditioned 
media. J Proteome Res 6:3796-3807. 
 
 Pucéat M, Ballis A (2007): Embryonic stem cells: from bench to bedside. Clin 
Pharmacol Ther 82:337-339. 
 
 Pyle AD, Lock LF, Donovan PJ (2006): Neurotrophins mediate human embryonic 
stem cell survival. Nat Biotechnol 24:344-350. 
 
 Qizhou L, Elias L, Keng Suan Y, Eileen Khia Way T, Manuel S-T, Tong Ming L, 
Nallasivam P, Reida Menshawe El O, Eng Hin L, Bing L, Sai-Kiang L 
(2007): Derivation of Clinically Compliant MSCs from CD105+, CD24- 
Differentiated Human ESCs. Stem Cells 25:425-436. 
 
 Raikwar S, Mueller T, Zavazava N (2006): Strategies for developing therapeutic 
application of human embryonic stem cells. Physiology (Bethesda) 21:19-
28. 
 
 111
 Rankin E, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS, Simon MC, Keith B, 
Haase VH (2007): Hypoxia-inducible factor-2 (HIF-2) regulates hepatic 
erythropoietin in vivo. J Clin Invest 117:1068-1077. 
 
 Rao M, Auerbach JM (2006): Estimating human embryonic stem-cell numbers. 
Lancet 367:650. 
 
Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A (2000): Embryonic stem 
cell lines from human blastocysts: somatic differentiation in vitro. Nat 
Biotechnol 18:399-404. 
 
Reubinoff BE, Itsykson P, Turetsky T, Pera MF, Reinhartz E, Itzik A, Ben-Hur T 
(2001): Neural progenitors from human embryonic stem cells. Nat 
Biotechnol 19:1134-40. 
 
 Richards M, Fong C, Chan W, Wong P, Bongso A (2002): Human feeders support 
prolonged undifferentiated growth of human inner cell masses and 
embryonic stem cells. Nat Biotechnol 20:933-6. 
 
 Richards M, Tan S, Fong C, Biswas A, Chan W, Bongso A (2003): Comparative 
evaluation of various human feeders for prolonged undifferentiated growth 
of human embryonic stem cells. Stem Cells 21:546-56. 
 
 Richards M, Tan SP, Tan JH, Chan WK, Bongso A (2004): The transcriptome 
profile of human embryonic stem cells as defined by SAGE. Stem Cells 
22:51-64. 
 
 Rinaudo P, Giritharan G, Talbi S, Dobson AT, Schultz RM (2006): Effects of 
oxygen tension on gene expression in preimplantation mouse embryos. Fertil 
Steril 86:1252-1265. 
 
 Rodríguez-Pizà I, Richaud-Patin Y, Vassena R, González F, Barrero MJ, Veiga A, 
Raya A, Belmonte JC (2010): Reprogramming of human fibroblasts to 
induced pluripotent stem cells under xeno-free conditions. Stem Cells 28:36-
44. 
 
 Roy NS, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA (2006): Functional 
engraftment of human ES cell-derived dopaminergic neurons enriched by 
coculture with telomerase-immortalized midbrain astrocytes. Nat Med 
12:1259-68. 
 
 Sakamoto N, Tsuji K, Muul LM, Lawler AM, Petricoin EF, Candotti F, Metcalf JA, 
Tavel JA, Lane HC, Urba WJ, Fox BA, Varki A, Lunney JK, Rosenberg AS 
(2007): Bovine apolipoprotein B-100 is a dominant immunogen in 
therapeutic cell populations cultured in fetal calf serum in mice and humans. 
Blood 110:501-508. 
 
 
 
 112 
 Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH (2004): Maintenance 
of pluripotency in human and mouse embryonic stem cells through 
activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. 
Nat Med 10:55-63. 
 
 Saxena S, Hanwate M, Deb K, Sharma V, Totey S (2008): FGF2 secreting human 
fibroblast feeder cells: a novel culture system for human embryonic stem 
cells. Mol Reprod Dev 75:1523-1532. 
 
 Schaffler A, Buchler C (2007): Concise Review: Adipose Tissue-Derived Stromal 
Cells-Basic and Clinical Implications for Novel Cell-Based Therapies Stem 
Cells. 25:818-827. 
 
 Schilling T, Noth U, Klein-Hitpass L, Jakob F, Schutze N (2007): Plasticity in 
adipogenesis and osteogenesis of human mesenchymal stem cells. Mol Cell 
Endocrinol 271:1-17. 
 
 Schuldiner M, Eiges R, Eden A, Yanuka O, Itskovitz-Eldor J, Goldstein RS, 
Benvenisty N (2001): Induced neuronal differentiation of human embryonic 
stem cells. Brain Res 913:201-5. 
 
 Selvaggi TA, Walker RE, Fleisher TA (1997): Development of antibodies to fetal 
calf serum with arthus-like reactions in human immunodeficiency virus-
infected patients given syngeneic lymphocyte infusions. Blood 89:776-9. 
 
Semenza G, Wang GL (1992): A nuclear factor induced by hypoxia via de novo 
protein synthesis binds to the human erythropoietin gene enhancer at a site 
required for transcriptional activation. Mol Cell Biol 12:5447-5454. 
 
 Semenza G (2000): Oxygen-regulated transcription factors and their role in 
pulmonary disease. Respir Res 1:159-162. 
 
 Shao L, Wu WS (2010): Gene-delivery systems for iPS cell generation. Expert 
Opin Biol Ther 10:231-242. 
 
 Skottman H, Stromberg AM, Matilainen E, Inzunza J, Hovatta O, Lahesmaa R 
(2006): Unique gene expression signature by human embryonic stem cells 
cultured under serum-free conditions correlates with their enhanced and 
prolonged growth in an undifferentiated stage. Stem Cells 24:151-67. 
 
 Skottman H, Narkilahti S, Hovatta O (2007): Challenges and approaches to the 
culture of pluripotent human embryonic stem cells Regen Med 2:265-73. 
 
 Soh B, Song C, Vallier L, Li P, Choong C, Yeo B, Lim E, Pedersen R, Yang H, 
Rao M, Lim B (2007): Pleiotrophin enhances clonal growth and long-term 
expansion of human mebryonic stem cells. Stem Cells 12:3029-3037. 
 
 
 
 113
 Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak 
A, Cooper O, Mitalipova M, Isacson O, Jaenisch R (2009): Parkinson's 
disease patient-derived induced pluripotent stem cells free of viral 
reprogramming factors. Cell 136:964-977. 
 
 Spits C, Mateizel I, Geens M, Mertzanidou A, Staessen C, Vandeskelde Y, Van der 
Elst J, Liebaers I, Sermon K (2008): Recurrent chromosomal abnormalities 
in human embryonic stem cells. Nat Biotechnol 26:1361-1363. 
 
 Spivakov M, Fisher, AG (2007): Epigenetic signatures of stem-cell identity. Nat 
Rev Genet 8:263-271. 
 
 Stacey G (2004): Validation of cell culture media components. Hum Fertil (Camb) 
7:113-8. 
 
 Stead E, White J, Faast R, Conn S, Goldstone S, Rathjen J, Dhingra U, Rathjen P, 
Walker D, Dalton S (2002): Pluripotent cell division cycles are driven by 
ectopic Cdk2, cyclin A/E and E2F activities. Oncogene 21:8320-33. 
 
 Stojkovic P, Lako M, Stewart R, Przyborski S, Armstrong L, Evans J, Murdoch A, 
Strachan T, Stojkovic M (2005): An autogeneic feeder cell system that 
efficiently supports growth of undifferentiated human embryonic stem cells. 
Stem Cells 23:306-14. 
 
 Strelchenko N, Verlinsky O, Kukharenko V, Verlinsky Y (2004): Morula-derived 
human embryonic stem cells. Reprod Biomed Online 9:623-9. 
 
 Strem BM, Hicok KC, Zhu M, Wulur I, Alfonso Z, Schreiber RE, Fraser JK, 
Hedrick MH (2005): Multipotential differentiation of adipose tissue-derived 
stem cells. Keio J Med 54:132-41. 
 
 Strulovici Y, Leopold PL, O'Connor TP, Pergolizzi RG, Crystal RG. (2007): 
Human embryonic stem cells and gene therapy. Mol Ther 15:850-866. 
 
 Ström S, Inzunza J, Grinnemo K, Holmberg K, Matilainen E, Strömberg A, 
Blennow E, Hovatta O (2007): Mechanical isolation of the inner cell mass is 
effective in derivation of new human embryonic stem cell lines. Human 
Reproduction 22:3051-8. 
 
 Sulzbacher S, Schroeder IS, Truong TT, Wobus AM (2009): Activin A-induced 
differentiation of embryonic stem cells into endoderm and pancreatic 
progenitors-the influence of differentiation factors and culture conditions. 
Stem Cell Rev 5:159-173. 
 
 Takahashi K, Yamanaka S (2006): Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell 126:663-
676. 
 
 114 
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S 
(2007): Induction of pluripotent stem cells from adult human fibroblasts by 
defined factors. Cell 131:861-72. 
 
 Tallheden T, van der Lee, J, Brantsing, C, Månsson, JE, Sjögren-Jansson, E, 
Lindahl, A (2005): Human serum for culture of articular chondrocytes. Cell 
Transplant 14:469-479. 
 
 Tarvainen J, Saarinen M, Laitinen J, Korpinen J, Viitanen J (2002): Creating 
images with high data contents for microworld applications. Industrial 
Systems Review 17-23. 
 
 Taylor CJ, Bolton EM, Pocock S, Sharples LD, Pedersen RA, Bradley JA (2005): 
Banking on human embryonic stem cells: estimating the number of donor 
cell lines needed for HLA matching. Lancet 366:2019-25. 
 
 Terstegge S, Laufenberg I, Pochert J, Schenk S, Itskovitz-Eldor J, Endl E, Brustle 
O (2007): Automated maintenance of embryonic stem cell cultures. 
Biotechnol Bioeng 96:195-201. 
 
 Thompson J, Simpson AC, Pugh PA, Donnelly PE, Tervit HR (1990): Effect of 
oxygen concentration on in-vitro development of preimplantation sheep and 
cattle embryos. J Reprod Fertil 89:573-578. 
 
 Thomson J, Itskovitz-Eldor J, Shapiro S, Waknitz M, Swiergiel J, Marshall V, 
Jones J (1998): Embryonic stem cell lines derived from human blastocysts 
Science 282:1145-7. 
 
 Toh W, Yang Z, Heng BC, Cao T (2007): Differentiation of human embryonic stem 
cells toward the chondrogenic lineage. Methods Mol Biol 407:333-349. 
 
 Totonchi M, Taei A, Seifinejad A, Tabebordbar M, Rassouli H, Farrokhi A, 
Gourabi H, Aghdami N, Hosseini-Salekdeh G, Baharvand H (2009): Feeder- 
and serum-free establishment and expansion of human induced pluripotent 
stem cells. Int J Dev Biol [Epub ahead of print] 
 
 Unger C, Skottman H, Blomberg P, Dilber M, Hovatta O (2008): Good 
manufacturing practice and clinical-grade human embryonic stem cell lines. 
Hum Mol Genet 17:R48-53. 
 
Unger C, Gao S, Cohen M, Jaconi M, Bergstrom R, Holm F, Galan A, Sanchez E, 
Irion O, Dubuisson JB, Giry-Laterriere M, Salmon P, Simon C, Hovatta O, 
Feki A (2009): Immortalized human skin fibroblast feeder cells support 
growth and maintenance of both human embryonic and induced pluripotent 
stem cells. Hum Reprod 24:2567-2581. 
 
 United States. Food and Drugs, Regulation, 21 C.F.R., Part 312, § 312.34.  
 
 United States. Human Cells, Tissues, and Cellular and Tissue-Based Products 
Regulations, 21 C.F.R., Part 1271.  
 115
 
 United (1998): States Food and Drug Administration. Guidance for human somatic 
cell therapy and gene therapy. FDA Center for Biologics Evaluation and 
Research.  
 
 Vallier L, Alexander M, Pedersen RA (2005): Activin/Nodal and FGF pathways 
cooperate to maintain pluripotency of human embryonic stem cells. J Cell 
Sci 118:4495-509. 
 
Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Südhof TC, Wernig M (2010): 
Direct conversion of fibroblasts to functional neurons by defined factors. 
Nature [Epub ahead of print] 
 
Vogel G (2005): Cell biology. Ready or not? Human ES cells head toward the 
clinic. Science 308:1534-1538. 
 
von Tigerstrom B (2009): Product regulation and the clinical translation of stem cell 
research. Stem Cell Rev 5:135-139. 
 
Wakayama T, Tabar V, Rodriguez I, Perry AC, Studer L, Mombaerts P (2001): 
Differentiation of embryonic stem cell lines generated from adult somatic 
cells by nuclear transfer. Science 292:740-3. 
 
 Walsh J, Andrews PW (2003): Expression of Wnt and Notch pathway genes in a 
pluripotent human embryonal carcinoma cell line and embryonic stem cell 
Apmis 111:197-210; discussion 210-1. 
 
 Wang L, Schulz T, Sherrer E, Dauphin D, Shin S, Nelson A, Ware C, Zhan M, 
Song C, Chen X, Brimble S, McLean A, Galeano M, Uhl E, D'Amour K, 
Chesnut J, Rao M, Blau C, Robins A (2007): Self-renewal of human 
embryonic stem cells requires insulin-like growth factor-1 receptor and 
ERBB2 receptor signaling. Blood 12:4111-4119. 
 
 Wang Q, Fang ZF, Jin F, Lu Y, Gai H, Sheng HZ (2005): Derivation and growing 
human embryonic stem cells on feeders derived from themselves. Stem Cells 
23:1221-7. 
 
 Warnecke C, Zaborowska Z, Kurreck J, Erdmann VA, Frei U, Wiesener M, Eckardt 
KU (2004): Differentiating the functional role of hypoxia-inducible factor 
(HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: 
erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB 
J 18:1462-1464. 
 
 Watanabe K, Ueno M, Kamiya D, Nishiyama A, Matsumura M, Wataya T, 
Takahashi JB, Nishikawa S, Nishikawa S, Muguruma K, Sasai Y (2007): A 
ROCK inhibitor permits survival of dissociated human embryonic stem 
cells. Nat Biotechnol 25:681-6. 
 
 Wenger R, Gassmann, M (1997): Oxygen(es) and the hypoxia-inducible factor-1. 
Biol Chem 378:609-616. 
 116 
 
 Wernig M, Meissner, A, Foreman, R, Brambrink, T, Ku, M, Hochedlinger, K, 
Bernstein, BE, Jaenisch, R. (2007): In vitro reprogramming of fibroblasts 
into a pluripotent ES-cell-like state. Nature 448:318-324. 
 
 Westfall S, Sachdev S, Das P, Hearne L, Hannink M, Roberts R, Ezashi T (2008): 
Identification of oxygen-sensitive transcriptional programs in human 
embryonic stem cells. Stem cells dev 5:869-881. 
 
 Wilmut I, Schnieke, AE, McWhir, J, Kind, AJ, Campbell, KH (1997): Viable 
offspring derived from fetal and adult mammalian cells. Nature 385:810-
813. 
 
 Wobus AM, Boheler KR (2005): Embryonic stem cells: prospects for 
developmental biology and cell therapy. Physiol Rev 85:635-678. 
 
 Wong R, Tellis I, Jamshidi P, Pera M, Pabay A (2007): Anti-apoptotic effect of 
sphingosine-1-phosphate and platelet-derived growth factor in human 
embryonic stem cells. Stem Cells Dev 6:989-1001. 
 
 Wrenzycki C, Niemann, H (2003): Epigenetic reprogramming in early embryonic 
development: effects of in-vitro production and somatic nuclear transfer. 
Reprod Biomed Online 7:649-656. 
 
 Xiao L, Yuan X, Sharkis SJ (2006): Activin A maintains self-renewal and regulates 
FGF, Wnt and BMP pathways in human embryonic stem cells. Stem Cells 
4:1476-1486. 
 
 Xu C, Inokuma MS, Denham J, Golds K, Kundu P, Gold JD,Carpenter MK (2001): 
Feeder-free growth of undifferentiated human embryonic stem cells. Nat 
Biotechnol 19:971-4. 
 
 Xu C, Jiang J, Sottile V, McWhir J, Lebkowski J, Carpenter MK (2004): 
Immortalized fibroblast-like cells derived from human embryonic stem cells 
support undifferentiated cell growth. Stem Cells 22:972-80. 
 
 Xu R, Peck R, Li D, Feng X, Ludwig T, Thomson J (2005): Basic FGF and 
suppression of BMP signaling sustain undifferentiated proliferation of 
human ES cells. Nat Methods 2:185-90. 
 
 Xu Y, Shi Y, Ding S (2008): Review Article A chemical approach to stem-cell 
biology and regenerative medicine. Nature 453:338-344. 
 
 Yamanaka S (2008): Pluripotency and nuclear reprogramming. Philos Trans R Soc 
Lond B Biol Sci 363:2079-87. 
 
 Yao S, Chen S, Clark J, Hao E, Beattie GM, Hayek A, Ding S (2006): Long-term 
self-renewal and directed differentiation of human embryonic stem cells in 
chemically defined conditions. Proc Natl Acad Sci U S A 103:6907-12. 
 
 117
 Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S (2009): Hypoxia 
enhances the generation of induced pluripotent stem cells. Cell Stem cell 
3:237-241. 
 
 Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie 
J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin I, Thomson JA (2007): 
Induced pluripotent stem cell lines derived from human somatic cells. 
Science 318:1917-20. 
 
 Zannettino AC, Paton S, Arthur A, Khor F, Itescu S, Gimble JM, Gronthos S 
(2008): Multipotential human adipose-derived stromal stem cells exhibit a 
perivascular phenotype in vitro and in vivo. J Cell Physiol 214:413-21. 
 
 Zhang SC, Wernig M, Duncan ID, Brustle O, Thomson JA (2001): In vitro 
differentiation of transplantable neural precursors from human embryonic 
stem cells. Nat Biotechnol 19:1129-33. 
 
 Zhang X, Stojkovic P, Przyborski S, Cooke M, Armstrong L, Lako M, Stojkovic M 
(2006): Derivation of human embryonic stem cells from developing and 
arrested embryos. Stem Cells  
 
 Zhang X, Zeng Y, Zhang W, Wang J, Wu J, Li J (2007): Co-transplantation of 
neural stem cells and NT-3-overexpressing Schwann cells in transected 
spinal cord. J Neurotrauma 24:1863-1877. 
 
 Zheng J, Wang Y, Karandikar A, Wang Q, Gai H, Liu AL, Peng C, Sheng, HZ 
(2006): Skeletal myogenesis by human embryonic stem cells. Cell Res 
16:713-722. 
 
 Zuk P (2008): Tissue engineering craniofacial defects with adults stem cells? Are 
we ready yet? Pediatr Res 63:478-486. 
 
 Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, 
Hedrick MH (2001): Multilineage cells from human adipose tissue: 
implications for cell-based therapies Tissue Eng 7:211-28. 
 
 
 
 
 
 
 
 
 
 118 
BioMed CentralBioMedical Engineering OnLine
ssOpen AcceResearch
Monitoring and analysis of dynamic growth of human embryonic 
stem cells: comparison of automated instrumentation and 
conventional culturing methods
Susanna Narkilahti†1, Kristiina Rajala†1, Harri Pihlajamäki2, 
Riitta Suuronen1, Outi Hovatta1,3 and Heli Skottman*1
Address: 1REGEA, Institute for Regenerative Medicine, University of Tampere and Tampere University Hospital, 33520 Tampere, Finland, 2The 
Finnish Defence Forces, 00131 Helsinki, Finland and 3Karolinska Institute, CLINTEC, Karolinska University Hospital Huddinge, 14186 
Stockholm, Sweden
Email: Susanna Narkilahti - Susanna.Narkilahti@regea.fi; Kristiina Rajala - Kristiina.M.Rajala@regea.fi; 
Harri Pihlajamäki - Harri.Pihlajamaki@helsinki.fi; Riitta Suuronen - Riitta.Suuronen@regea.fi; Outi Hovatta - Outi.Hovatta@ki.se; 
Heli Skottman* - Heli.Skottman@regea.fi
* Corresponding author    †Equal contributors
Abstract
Background: Human embryonic stem cells (hESCs) are a potential source of cells for use in
regenerative medicine. Automation of culturing, monitoring and analysis is crucial for fast and
reliable optimization of hESC culturing methods. Continuous monitoring of living cell cultures can
reveal more information and is faster than using laborious traditional methods such as microscopic
evaluation, immunohistochemistry and flow cytometry.
Methods: We analyzed the growth dynamics of two hESC lines HS237 and HS293 in a
conventional culture medium containing serum replacement and a xeno-free X-vivo 10 medium.
We used a new automated culture platform utilizing machine vision technology, which enables
automatic observation, recording and analysis of intact living cells. We validated the results using
flow cytometry for cell counting and characterization.
Results: In our analyses, hESC colony growth could be continuously monitored and the
proportion of undifferentiated cells automatically analyzed. No labeling was needed and we could,
for the first time, perform detailed follow up of live, undisturbed cell colonies, and record all the
events in the culture. The growth rate of the hESCs cultured in X-vivo 10 medium was significantly
lower and a larger proportion of the cells were differentiated.
Conclusion: The new automated system enables rapid and reliable analysis of undifferentiated
growth dynamics of hESCs. We demonstrate the effectiveness of the system by comparing hESC
growth in different culture conditions.
Background
Traditionally, cell cultures are monitored by time con-
suming microscopy, manual imaging and image process-
ing. Conventional time-lapse recordings have provided
new data of living cell behavior and growth. Despite the
advantages, the technique has drawbacks in particular the
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interest are limited, and analysis of data is not automated.
We tested a new technology platform for continuous
monitoring and analysis of living cell cultures. The system
applies machine vision technology to analyze and quan-
tify morphologic traits. Events such as apoptosis, cell divi-
sion, cellular movement, attachment, and the number of
single cells can be continuously observed and recorded for
up to several weeks, if needed. The optical design utilizes
a dynamic z-stack to produce all-in-focus [1-3] informa-
tion rich images enabling detailed analysis by generating
in-depth images not previously seen with other tech-
niques. Machine vision technology has traditionally been
employed in the fields of medical imaging, precision
robotics, and on factory assembly lines for consistently
differentiating shape, size, position, patterns and move-
ments [4,5].
Human embryonic stem cells (hESCs) are pluripotent
cells capable of self-renewal and differentiation into all
cell types in the body [6,7]. They hold great potential for
regenerative medicine. Significant quantities of hESCs are
needed for differentiation to a final phenotype for cell
transplantation. Current culture methods are not capable
of producing adequate quantities of hESCs at an accepta-
ble quality and price for cell transplantation. Improved
automated culture analyses for undifferentiated hESCs are
desired. In this report we describe, for the first time, the
growth dynamics of hESCs using a new automated culture
and monitoring system. Using this system, we compare
conventional culture medium (containing animal protein
serum replacement) to a xeno-free culture medium.
Methods
Human ESC cultures
Human ESC lines HS237 (passages 63, 70, and 80) and
HS293 (passages 58, 64, and 78), derived at Karolinska
University Hospital Huddinge, Karolinska Institutet, Swe-
den, were cultured as previously described [8,9]. The
hESC colonies were mechanically divided and seeded as
small aggregates onto 12-well plates (CellBIND Surface,
Corning, Inc., Corning, NY), containing gamma-irradi-
ated human foreskin fibroblasts (CRL-2429, ATCC, Man-
assas, VA) as feeder cells.
The hESCs were cultured either in a conventional medium
or in an X-vivo 10 medium. The conventional hESC
medium contained 80% (vol/vol) KnockOut Dulbecco's
Modified Eagle's Medium (DMEM) and 20% (vol/vol)
KnockOut serum replacement supplemented with 2 mM
Glutamax, 0.1 mM β-mercaptoethanol, 0.1 mM MEM
non-essential amino acids (Cambrex Bio Science, Walk-
ersville, Inc., Walkersville, MD), 50 U/ml penicillin-50
μg/ml streptomycin (Cambrex Bio Science) and 8 ng/ml
recombinant human fibroblast growth factor (bFGF, R&D
Systems, Minneapolis, MN). The X-vivo 10 medium con-
tained X-VIVO 10 (Cambrex Bio Science) medium, 0.12
ng/ml transforming growth factor β1 (Sigma, St. Louis,
MO) and the same supplements included in the conven-
tional hESC medium. All reagents were from Invitrogen
(Invitrogen, Carlsbad, CA) unless stated otherwise. Before
analysis, the hESCs were slowly adapted to the X-vivo 10
medium by gradually increasing the proportion of X-vivo
10 medium and decreasing the proportion of conven-
tional hESC medium.
Instrumentation
The Cell-IQ® system (Chip-Man Technologies Ltd., Tam-
pere, Finland) is a self – contained cell culturing instru-
ment combining phase-contrast microscopy,
environmental control, and automation (Table 1). The
instrument contains an automated optics module (Figure
1), an integrated incubator (+/- 0.2°C), 2 incubation gas
flow controllers, precision movement stages (x, y axes: ± 1
μm; z axis: ± 0.4 μm) fully controlled through machine
vision – based firmware and analysis software. The imag-
ing system enables continuous monitoring of adherent
cells in two plates in an integrated plate holder. Through
pattern recognition, individual cells can be automatically
located and monitored after culture media changes.
Machine vision enables analysis of a continuous time-
lapse image series of living cells for observing morpho-
logic changes without the use of labels and dyes.
Perfusion lid
The incubation gases are piped directly onto the culture
plate through a perfusion lid. The lid is designed with
inlet and outlet connectors. The connectors are positioned
so that gas can be piped under a purified stop-flow regime
to enable optimal well concentrations of the incubation
gas across the plate. The gas mixture is user-defined and is
under automatic control of the instrument. Two different
gases can be piped onto a single plate to allow, for exam-
ple, hypoxia studies.
Dynamic Z-stack
To enable the generation of all-in-focus images (675 ×
506 μm) of irregularly spaced objects, the detector unit
has an automatic z-focus control utilizing a dynamic z-
stack (user-defined) that translates all objects within the z-
stack into a single planar focused image. The best focus
position can change during the test. The system compen-
sates the z-position changes by adjusting the focus auto-
matically each time the system uses the z-stack
information.
Grid View
To monitor larger areas or objects like cell colonies, a
larger field-of-view (FOV) can be generated. In these
FOVs, 1 × 1 to 12 × 12 positions can be combined into aPage 2 of 8
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in these grids are stitched together as one image to enable
easy review and analysis.
Autofocus
The system has an autofocus based on the detection of
high frequencies from digital images. Autofocus is useful
when monitoring adherent monolayer cell populations,
as the well plate surfaces are uneven and the same focus
cannot be used for all positions. When the target is tens of
micrometers thick, such as in hESC colonies, there is a
large z-range of equally good focus, and hence the autofo-
cus is not recommended. In these situations the user sets
the focus manually for each position – or copies the same
focus for several positions.
Machine vision
Machine vision technology uses an imaging system and
computer for analysis and makes decisions based on that
analysis [10]. The Cell-IQ system utilizes machine vision
approaches that allow monitoring and analysis of objects
such as cell cultures without indicator labels. In the sys-
tem an Information-Rich-Image (IRI) is generated. This
IRI contains all the necessary information for an auto-
matic analysis without human intervention. The system
finds all objects in these images. It then extracts several
features from these objects and uses them for classifica-
tion. The classification module is based on statistical clas-
sifiers, which can be 'taught' to determine morphologic
changes occurring within the culture even at the single cell
level.
The hESC area measurement analysis method
We developed a new hESC area analysis method. The sys-
tem recognizes every pixel in each image and assigns the
pixel to one of the user defined classes. The colony area
measurement classes were 1) background feeder layer, 2)
undifferentiated area, and 3) differentiated area [see Addi-
tional file 1]. The total analyzed area in one image is nor-
mally 360448 pixels = (768-(2*32)) × (576-(2*32).
Where 768 is the image width and 576 is the image
height. The 32 pixel-wide strip from the image edges is not
analyzed due to method requirements. The area analysis
method results in total square pixel number for each of
the classes in every time-lapse image and that number can
be converted into the μm data. The area protocol designed
here does not count single cells or the growth of the single
cells in compact hESC colonies grown on top of the feeder
layer. Briefly, for the analysis method development [see
Additional file 2], colonies were first visually evaluated by
experienced observer using conventional microscope.
Colonies were photographed and undifferentiated and
Table 1: The Cell-IQ® instrument compositions
CELL-IQ MACHINE VISION SYSTEM
Phase contrast microscope Environment control Automation
• Light source • Temperature control and logging • Automated cell imaging for selected positions
• Optics • Incubation gas control • Label free cell analysis based on morphology
• Digital camera • Motorized XYZ translation stages
A schematic drawing of the automated optics module and sampl  monitoring systemFigur  1
A schematic drawing of the automated optics module and 
sample monitoring system. The automated optics module 
consists of a digital 768 × 576 pixel CCD Camera (Jai cv-
A10CL) coupled to a phase-contrast microscope with a 10× 
phase-contrast objective (Nikon CFI Achromat) and 200 mm 
optics (Infinity Infinitube), producing a 675 × 506 μm field – 
of – view with a spatial resolution of 0.879 μm/pixel, built 
onto a motorized z-direction movement stage. The illumina-
tion source is a green (530 nm) LED light that enables high 
quality phase-contrast images. More information [15].Page 3 of 8
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onies were imaged with Cell-IQ system. Captured images
were viewed in Cell-IQ Analyser program and Pick Sam-
ples Mode was used to collect representative area samples
(64 × 64 pixel) for each three classes described above [see
Additional file 1]. Area samples were collected from the
colonies according to the microscopic evaluation. For
each class, ~100 samples were collected. Thereafter, sam-
ple file was send to the company with Cell-IQ images of
the colonies where the analysis protocol was built and
tested for correct area recognition. Next, we tested the
designed area protocol for image series, and made few cor-
rections to the sample file in order to improve the correct
recognition.
Human ESC monitoring
On days 1 through 3 after passaging of hESCs, the plates
were transferred to the monitoring equipment. Using the
instrument's imaging software, the images from selected
plate positions were recorded as grid images and stored in
separate folders in JPEG format [11]. Every region of inter-
est was monitored every 40 to 60 minutes. Colonies were
monitored until day seven after passaging.
Validation of automated analyses
Growth of hESC colony area
To cross-validate the growth data of the colonies, all colo-
nies were photographed using a Nikon Eclipse TE2000-S
phase-contrast microscope, a Nikon DS-5M camera and
Eclipse Net software (version 1.20), enabling manual
hESC colony area measurements.
Immunohistochemistry
The colonies were fixed in culture dishes with 4% parafor-
maldehyde in phosphate-buffered saline (0.01 M PBS, pH
7.4) for 20 min at room temperature (RT) followed by
washing with PBS (2 × 5 min). The cells were permeabi-
lized and blocked with 0.1% Triton X-100, 1% bovine
serum albumin (BSA, Sigma), and 10% normal donkey
serum (Sigma) in PBS for 45 min at RT and washed once
with 0.1% Triton X-100, 1% BSA, and 1% normal donkey
serum in PBS. The cells were incubated with the primary
antibodies, polyclonal goat anti-human Nanog at a dilu-
tion of 1:200 and monoclonal mouse anti-human SSEA-1
at 1:200 (both from Santa Cruz Biotechnology, Inc., Santa
Cruz, CA), overnight at 4°C. Cells were washed (3 × 5
min) with 1% BSA in PBS and probed with the secondary
antibodies, rhodamine red-conjugated donkey anti-
mouse IgM at 1:400 (Jackson ImmunoResearch Laborato-
ries, West Grove, PA) and Alexa Fluor 488 donkey anti-
goat IgG at 1:800 (Molecular Probes, Carlsbad, CA), for 1
h in the dark at RT. After incubation, the cells were washed
with PBS (3 × 5 min) and mounted using Vectashield
mounting medium containing DAPI (Vector Laboratories,
Inc., Burlingame, CA). Labeled cells were viewed and pho-
tographed with a Nikon Eclipse TE2000-S phase-contrast
microscope with fluorescence optics and a Nikon
COOLPIX 5400 camera.
FACS analysis
A total of 143 colonies of the HS237 line cultured in the
Cell-IQ equipment was used in fluorescence-activated cell
sorting (FACS) analysis. The cells were enzymatically
removed from the culture dish with Tryple™ Select (Invit-
rogen) for 15 min at 37°C, resuspended in 1 ml FACS
buffer I (2% FBS, 0.01 % sodium azide in PBS), and
counted with Neubauer cell counter chambers. Total of 3
million cells were collected and divided into samples con-
taining 100 000 cells. The cells were probed for 15 min at
4°C with a 1:500 dilution of monoclonal mouse anti-
human SSEA-4 (Santa Cruz Biotechnology, Inc.) in FACS
buffer I. They were then washed in FACS buffer I and
probed in FACS buffer I containing a 1:500 dilution of r-
phycoerythrin-conjugated goat anti-mouse IgG (Caltag
Laboratories, Carlsbad, CA) or an appropriate isotype
control for 15 min in the dark at 4°C. The cells were then
washed once with FACS buffer I, once with FACS buffer II
(0.01% sodium azide in PBS), and fixed with 1% formal-
dehyde in PBS. The samples were analyzed using FAC-
SAria™ equipment (BD Biosciences, Franklin Lakes, NJ).
The cell population of interest was determined and dead
cells excluded using forward and side scatter parameters.
Acquisition was set for 10 000 events per sample. The data
was analyzed with FACSDiva Software (version 4.1.2).
Triplicate samples were analyzed in each experiment.
Statistics
All statistical analyses were performed with SPSS for Win-
dows software (V9.0) using a nonparametric test (the
Kruskall-Wallis test) followed by post hoc analysis (the
Mann-Whitney U-test). A P-value of < 0.05 was consid-
ered significant. Differences between the hESC lines and
culture conditions were tested using Wilcoxon's signed
rank test.
Results and discussion
We applied and further developed the new automated
monitoring and analysis platform with the goal of com-
paring hESC cultures in two different culture media. The
platform enabled us to monitor growing hESC colonies. A
grid-format picture capture system allowed the monitor-
ing of living hESC cultures ranging in size from a few hun-
dred micrometers to cell colonies of several millimetres at
a defined picture capture cycle rate. The captured images
were visualized with analysis software as movies, which
were further used for the analysis of the colony growth.
The hESCs were cultured in a defined atmosphere (5%
CO2 and 36.5°C) from days 1 to 7 after passaging (Figure
2a). The hESC colonies attached to the feeders on days 1Page 4 of 8
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hESC colonies started at day 3 (Figure 2c). At day 7, the
hESC colonies had reached a size where they needed to be
passaged (Figure 2e). Using the automated system, con-
tinuous monitoring of hESC colony growth was feasible
[see Additional file 4]. We analyzed the total area and the
areas of differentiated and undifferentiated cells in the
hESC colonies at day 6 after passaging [see Additional file
3]. Totally differentiated and non-growing hESC colonies
were excluded from the analysis. The average size of the
HS237 and HS293 colonies at day 6 was 0.99 mm2 (±
0.61, n = 24), with 91% undifferentiated cells and 9% dif-
ferentiated cells, according to the automated analysis pro-
tocol.
To confirm the results of the automated analysis, some of
the hESC colonies were also analyzed by FACS, and the
rest were stained immunohistochemically. Analysis by
FACS of the pooled HS237 colonies (n = 143), with a total
of 3.0 million cells at day 7, revealed that an average size
colony of 1.04 mm2 contained ~21000 cells (n = 29). The
analysis (in triplicate) revealed that 81% of the HS237
cells were positive for SSEA4 (Figure 2d). This result was
consistent with the automated area protocol result, which
indicated that 86.9% of the HS237 colony area (n = 29)
was undifferentiated. Immunohistochemical staining of
the automatically monitored colonies showed that these
colonies were positive for Nanog and that SSEA1 was
expressed in only a small proportion (3%) of the cells
(Figure 2f). Both Nanog and SSEA-4 are widely considered
as markers for undifferentiated hESCs although they may
not always monitor the same cell population. SSEA-1 was
used as common marker for differentiated cells since the
aim was not to address towards which lineages the cells
were differentiating.
Parallel cell culture plates were cultured in conventional
incubators in otherwise similar conditions. The colonies
grown in parallel plates were observed by an experienced
observer similarly with routine every day evaluation prac-
tise. There were no differences in the growth rates or in the
areas of undifferentiated and differentiated cells between
the hESC colonies cultured in a standard incubator or in
the automated system based on the colony size. Typically,
spontaneous differentiation of undifferentiated colonies
started six to eight days after passaging in the center of the
colonies (data not shown). This phenomenon occurred
similarly in the colonies grown in the Cell-IQ system and
in a common incubator. Also, there were similar portion
of totally differentiated and non-growing hESC colonies
in the plates that were grown in Cell-IQ system and in a
common incubator. As FACS and immunohistochemical
analyses confirmed that the automated analysis protocol
recognized undifferentiated and differentiated areas relia-
bly, we further examined the growth parameters of HS237
and HS293 lines. There was no difference in the average
colony area between lines HS237 (0.79 ± 0.32 mm2) and
HS293 (1.20 ± 0.80 mm2) at day 6 after passaging. The
growth rates of the undifferentiated areas (from days 5 to
6) of HS237 (215 ± 94 μm2/min) and HS293 (328 ± 187
μm2/min) were also similar. There were more undifferen-
tiated areas in HS293 colonies than in HS237 colonies (P
< 0.01, Figure 3).
The development of animal component-free culture con-
ditions for hESCs is a major challenge [12]. In this study,
we tested whether the automated culturing and monitor-
ing system could be used for the testing of culture media.
Two different media were used: conventional hESC cul-
ture medium and an X-vivo 10-based, xeno-free culture
medium. Both HS237 and HS293 colonies grew better in
conventional medium than in X-vivo 10 medium [see
Additional file 5]. The average colony size (both HS237
and HS293) in the X-vivo 10 medium was smaller than in
conventional hESC medium (0.44 ± 0.31 vs. 0.99 mm2 ±
0.61, P < 0.01, Figure 3), and the undifferentiated cell area
was smaller in colonies cultured in the X-vivo 10 medium
(64%) than in conventional hESC medium (91%, P <
0.01).
The continuous monitoring of living cells revealed more
information than conventional microscopic observation
of cultures. With the aid of the automated system we were
able to observe cell behavior that would be impossible to
discover by conventional microscopic observation. Tradi-
tionally, the growth rates of hESC colonies have been
manually counted from single cell suspensions as dou-
bling time during the exponential growth phase [13] or as
an expansion of the area of a single colony from micro-
scopic images [14]. The automated monitoring system
allowed a reliable area measurement of live, unlabeled,
intact cell colonies. Hence, we obtained continuous quan-
titative data from the cultures with constant real-time
feedback. In culture medium testing, the automated
machine vision culture platform, revealed that both hESC
lines grew better in conventional hESC medium than in X-
vivo 10 medium.
Conclusion
The automated cell culturing and analysis system provides
an optimal tool for the evaluation of hESC cultures, allow-
ing continuous well-to-well comparison of the effects of
different culture media or different growth factor concen-
trations on cell growth and behaviour – such as differen-
tiation. In addition, it can also be used as a tool in the
optimization of differentiation protocols for hESCs.
Whether this system can be applied to monitoring and
analysis of 3D cell differentiation remains to be studied.
Our data clearly demonstrate that continuous monitoring
of living cell cultures without disturbing the cells canPage 5 of 8
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Characterization of hESC colonies cultured in conventional hESC mediumFigure 2
Characterization of hESC colonies cultured in conventional hESC medium: (a) A representative growth graph of an 
HS293 colony cultured using the automated culture platform for 7 d after passaging. The growth rate of the colony was most 
rapid from day 5 onwards. An HS293 colony at day 1 (b), day 3 (c), and day 7 (e) after passaging, monitored using the auto-
mated system. (d) FACS analysis of HS237 colonies at day 7 after passaging. The red column represents the negative control 
sample and the white column represents SSEA4-positive cells (81%). An HS293 colony monitored with the automated system 
was immunohistochemically characterized (f) using an antibody against an undifferentiated hESC marker, Nanog (green), and a 
differentiated hESC marker, SSEA1 (red). Scale bar 200 μm (b,c,e), 100 μm (f).
BioMedical Engineering OnLine 2007, 6:11 http://www.biomedical-engineering-online.com/content/6/1/11reveal more information than conventional microscopic
observation of cultures. The automated system enables
rapid and reliable analysis of undifferentiated growth
dynamics of hESCs.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
S.N. performed the Cell-IQ experiments and data analyses
and contributed to writing the manuscript. K.R. per-
formed the cell culture and characterization experiments
and contributed to writing the manuscript. H.P. and R.S.
contributed to the conception and design of the experi-
ments. O.H. contributed to the conception, and design of
the experiments, interpretation of data, and critically
revising the manuscript for important intellectual con-
tent. H.S. contributed to the conception, and design of the
experiments, interpretation of data, and to writing the
manuscript.
Additional material
Additional File 1
Representative sample images of user-defined classes for morphologic 
analysis of hESC colonies. For the analysis (a) background feeder cells, 
(b) undifferentiated, and (c) differentiated hESC areas were defined as 
separate classes. One sample image presents an area of 56.3 × 56.3 μm 
as shown in (a) by the dotted square. Adequate numbers of sample images 
captured by the system were compared with visual evaluation of the colo-
nies using a conventional microscope to ensure that correct demonstrative 
areas were chosen for the area analysis protocol of the automated system.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-
925X-6-11-S1.tiff]
Additional File 2
The diagram representing two phases required for the analysis. The clas-
sifier must be created once (the topmost diagram) using the set of cell 
images, and then it can be used (the lower diagram) for the analysis of 
the captured images.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-
925X-6-11-S2.tiff]
Results of an automated area analysis of HS237 and HS293 hESC linesFig re 3
Results of an automated area analysis of HS237 and HS293 hESC lines. A bar chart representing the proportions of undifferen-
tiated and differentiated areas of hESC colonies cultured in conventional hESC medium and in X-vivo 10 medium.Page 7 of 8
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The resulting image of an hESC colony cultured in a conventional hESC 
medium. (a) The hESC colony was analyzed using the defined area anal-
ysis protocol. The resulting image of the analyzed colony is shown in (b). 
Green color represents undifferentiated areas and blue represents differen-
tiated areas according to the analysis result. (c) The hESC colony was 
immunohistochemically characterized using an antibody against an 
undifferentiated hESC marker, Nanog (green), and a differentiated 
hESC marker, SSEA1 (red). Scale bar = 200 μm.
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Additional File 4
The growth of an hESC colony in conventional hESC medium. The growth 
of an hESC colony from day 3 until day 7 in conventional hESC medium.
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The growth of an hESC colony in X-vivo 10 medium. The growth of an 
hESC colony from day 3 until day 7 in X-vivo 10 medium.
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Testing of nine different xeno-free culture media
for human embryonic stem cell cultures
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Riitta Suuronen1, Outi Hovatta1,3 and Heli Skottman1
1REGEA, Institute for Regenerative Medicine, University of Tampere, Tampere University Hospital, Tampere, Finland, 2The Finnish
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BACKGROUND: Human embryonic stem cells (hESC) are excellent candidates for cell replacement therapies.
However, currently used culture conditions contain animal-derived components that bear a risk of transmitting
animal pathogens and incorporation of non-human immunogenic molecules to hESC. METHODS: Nine xeno-free
culture media were compared with the conventional serum replacement (ko-SR) containing media in the culture of
hESC on human feeder cells. Cultured hESC were characterized immunocytochemically and by fluorescence-
activated cell sorter analysis. The differentiation potential of hESC cultured with xeno-free media was determined
with the RT–PCR analysis. RESULTS: The hESC cultured in xeno-free media differentiated or the proliferation
decreased substantially. Under some test conditions, the morphology of the feeder cells was altered considerably.
The hESC cultured with human serum underwent excessive differentiation in the beginning of culture, but a fraction
of hESC was able to adapt to culture conditions containing 20% of human serum. CONCLUSIONS: None of the
studied xeno-free media was able to maintain the undifferentiated growth of hESC. The medium containing 20%
human serum was found to sustain undifferentiated hESC proliferation to some extent, yet was inferior to the conven-
tional ko-SR-containing medium.
Key words: human embryonic stem cell/human serum/xeno-free culture conditions
Introduction
The first human embryonic stem cell (hESC) lines were derived
and cultured on mitotically inactivated mouse embryonic
fibroblast (MEF) cell layer using a medium containing fetal
bovine serum (FBS) (Thomson et al., 1998). Under the
FBS-containing conditions, many cells died and the hESC
colonies underwent excessive differentiation (Amit et al.,
2000; Reubinoff et al., 2000; Amit and Itskovitz-Eldor,
2002). Amit et al. (2000) described serum-free culture con-
ditions for hESC, using a commercial serum replacement
(KnockOut-Serum Replacement, ko-SR, Invitrogen) instead
of FBS in the hESC culture medium. It was shown that
ko-SR supplemented with basic fibroblast growth factor
(bFGF) was able to support a prolonged growth of hESC in
an undifferentiated state, and a higher cloning efficiency was
obtained than in the FBS-containing medium (Amit et al.,
2000). We have systematically compared different ko-SR con-
centrations for culturing hESC and found 20% to be the optimal
concentration for the undifferentiated propagation of hESC
derived and propagated on human feeder cells (Koivisto
et al., 2004). The use of ko-SR in the hESC culture medium
provides more standardized culture conditions compared with
FBS, which is highly variable from lot to lot. Currently,
ko-SR has mostly replaced the use of FBS in hESC cultures
in most laboratories. Unfortunately, ko-SR still contains
animal proteins such as bovine serum albumin (BSA) and
hence is not completely free of xeno-derived components
(Price et al., 1998). Human serum has also been used to
replace FBS in hESC culture with some success. Richards
et al. (2002) and Ellerstro¨m et al. (2006) derived hESC lines
using culture medium containing human serum. Ellersto¨m
et al. managed to propagate hESC line in the human-serum-
containing culture medium in an undifferentiated state for
over 20 passages.
The exposure of hESC to xeno-products such as animal sera
or proteins risks the contamination of hESC with undefined
retroviruses and other animal pathogens (Amit et al., 2003).
In addition, certain animal molecules such as the sialic acid
Neu5Gc are incorporated and expressed on hESC cultured in
the presence of animal-derived products. Such non-human anti-
gens result in an immune response in humans (Martin et al.,
2005). The use of MEF feeder cells in hESC culture is
# The Author 2007. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
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another major concern when aiming at developing xeno-free
culture conditions for hESC. Various types of human feeder
cells have been successfully used in maintaining hESC cultures
(Richards et al., 2002). Richards et al. (2003) showed human
adult skin fibroblasts to be the best feeder cell type in a com-
parative evaluation of 11 different human adult, fetal and
neonatal fibroblast feeder types. Our group has derived and cul-
tured hESC lines using commercial human foreskin fibroblasts
as feeder cells since 2002 (Hovatta et al., 2003; Inzunza et al.,
2005).
Various feeder-free culture conditions have also been
reported for the culture of hESC (Xu et al., 2001; Amit
et al., 2004; Beattie et al., 2005; Klimanskaya et al., 2005;
Stojkovic et al., 2005). Some of these methods have been xeno-
free by containing recombinant or human-derived extracellular
matrixes and xeno-free media. A few hESC culture studies
have been reported with X-Vivo 10 medium that contains
only human-sourced recombinant proteins supplemented with
recombinant human bFGF, stem cell factor, recombinant
human flt3 ligand and leukaemia inhibitory factor (LIF) (Li
et al., 2005) or a high concentration of bFGF (Genbacev
et al., 2005). Recently, Ludwig et al. (2006) described a feeder-
free derivation and culture of hESC using defined medium
(TeSR1) including protein components solely from recombi-
nant sources or purified from human material. However,
feeder-free culture methods may induce chromosomal abnorm-
alities in hESC due to the adaptation to more demanding
growth conditions and enzymatic passaging methods often uti-
lized in the feeder-free cultivation of hESC (Draper et al.,
2004; Mitalipova et al., 2005). In feeder-free conditions, the
importance of high concentrations of exogenously added
growth factors and other factors increases. The heterogeneity
of culture conditions and the variety and high concentrations
of growth factors tested in sustaining undifferentiated growth
of hESC reflect the fact that knowledge about the maintenance
of self-renewal and pluripotency of hESC is still inadequate.
The use of xeno-derived components in the culture of hESC
essentially limits the future clinical use of hESC-based thera-
pies, and finding alternatives to replace these xeno-derived
components has been one of the major focuses of hESC
research during the past few years. Some commercial xeno-free
serum replacements and media have recently become avail-
able. In order to find optimal culture conditions with low con-
centrations of bFGF using post-natal foreskin fibroblasts as
feeder cells, we systematically tested eight commercially avail-
able or published xeno-free media and human serum in the
culture of more than one hESC line.
Materials and methods
Culture media
Two commercial culture media, X-Vivo 10 and X-Vivo 20 (both from
Cambrex Bio Science, Walkersville, MD, USA), published TeSR1
medium (Ludwig et al., 2006; Thomson and Ludwig, 2006) with
modifications, five commercially available serum replacements—
LipuminTM 10, SerEx 10 (both from PAA Laboratories GmbH,
Pasching, Austria), SR3 (Sigma, St Louis, MO, USA), serum substi-
tute supplement (SSS) (Irvine Scientific, Santa Ana, CA, USA) and
Plasmanate (Bayer Healthcare, West Haven, CT, USA)—and human
serum (Sigma) were tested in the culture of hESC, as shown in Table I.
The control hESC medium contained 80% (vol/vol) KnockOut
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco Invitrogen,
Carlsbad, CA, USA) and 20% (vol/vol) ko-SR (Invitrogen) sup-
plemented with 2 mM Glutamax (Invitrogen), 0.1 mM
b-mercaptoethanol (Invitrogen), 0.1 mM MEM non-essential amino
acids (Cambrex Bio Science), 50 U penicillin/ml–50 mg streptomy-
cin/ml (Cambrex Bio Science) and recombinant human bFGF
(R&D Systems, Minneapolis, MN, USA) at 8 ng/ml. For feeder-free
culture experiments, the hESC medium was supplemented with
80 ng/ml of human bFGF.
Xeno-free serum replacements LipuminTM 10, SerEx 10, SR3
and SSS were tested at 10 and 20% concentrations and Plasmanate at
20 and 40% concentrations in KnockOut DMEM supplemented as
the control hESC medium without ko-SR. X-Vivo 10 medium con-
tained X-Vivo 10 basal medium and 0.12 ng/ml transforming growth
factor b1 (TGFb1, Sigma) and was supplemented as the control
hESC medium without ko-SR. X-Vivo 20 medium contained X-Vivo
20 basal medium and was supplemented as the control hESC medium
without ko-SR. The human-serum-containing culture medium con-
tained KnockOut DMEM, 10 or 20% (vol/vol) of heat-inactivated,
sterile filtered human serum (H1388, Sigma) and 50 mg/l L-ascorbic
acid 2-phosphate and was supplemented as the control hESC
medium without ko-SR. For feeder-free culture experiments, 20%
human-serum-containing culture medium was supplemented with
80 ng/ml of human bFGF.
The modified TeSR1 medium contained DMEM/F12 basal medium
(Invitrogen) supplemented with 16.5 mg/ml human serum albumin
(Sigma), 196 mg/ml insulin (Invitrogen), 108 mg/ml human holo-
transferrin (Sigma), 1:500 chemically defined lipid concentrate (Invi-
trogen), 2 mg/l reduced glutathione (Sigma), 1:1000 trace elements
B and C solution (Cellgro, Herndon, VA, USA), 6 mg/l thiamine
hydrochloride (Sigma), 0.02 mg/l sodium selenite (Sigma), 41.5 mg/
l lithium chloride (Sigma), 0.1 mg/ml g-aminobutyric acid (Sigma),
0.127 mg/ml pipecolic acid (Sigma), 0.6 ng/ml TGFb1 (Sigma) and
50 mg/l L-ascorbic acid 2-phosphate (Sigma) supplemented as the
control hESC medium without ko-SR. The modification made to the
published TeSR1 medium (Ludwig et al., 2006; Thomson and
Ludwig, 2006) was the use of 8 ng/ml of bFGF in the experiments
with human foreskin fibroblast feeder cells. Our previous testing has
showed that there is no improved effect of higher concentration of
bFGF for the growth of undifferentiated hESC in the presence of
human foreskin fibroblasts (unpublished results); hence low concen-
tration of bFGF was used for the experiments performed with human
foreskin fibroblast feeder cells. For feeder-free culture experiments,
theTeSR1mediumwas supplementedwith 100 ng/mlof humanbFGF.
hESC cultures using human foreskin fibroblast feeder layer
Human ESC lines HS181 (passages 60 and 62), HS237 (passages 59, 61
and 74), HS293 (passages 42 and 49) and HS306 (passage 50) derived at
the Karolinska Institute, Stockholm, Sweden, were used for the culture
experiments. The Karolinska Institute has an approval of the Ethics
Committee of the Karolinska Institute for derivation, characterization
and differentiation of hESC lines. REGEA, Institute for Regenerative
Medicine, University of Tampere, Finland, has the approval of the
Ethical Committee of Pirkanmaa Hospital District to culture hESC
lines derived at the Karolinska Institute. These cell lines have been
derived and cultured on human foreskin fibroblasts as feeder cells,
and the lines have been characterized earlier (Hovatta et al., 2003;
Inzunza et al., 2005). Commercially available human foreskin fibroblast
cells (CRL-2429,ATCC,Manassas, VA,USA)were used as feeder cells
for the culture of hESC. Before plating the hESC, the feeder cells were
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mitotically inactivated by irradiating with 40 Gy. The hESC were
adapted to the test culture conditions by gradually increasing the concen-
tration of the test medium and decreasing the concentration of the
control hESC culture medium every second day during the adaptation
phase. The hESC were cultured in a humidified þ378C, 5% CO2 incu-
bator. The growth of hESC was monitored microscopically and culture
media were changed daily. The hESC cultures were passaged mechani-
cally every 7–10 days to new feeder cells. Every test media experiment
was performed with at least two different hESC lines. The experiments
failing to maintain hESC undifferentiated were repeated for second time
in order to verify the results of the first experiments.
Feeder-free culture of hESC
Human ESC line HS237 (passage 78) was used for the feeder-free
culture experiments. The hESC were adapted to the TeSR1 and 20%
human-serum-containing media on human feeder cells by gradually
increasing the concentration of the test medium and decreasing the
concentration of the control hESC culture medium every second day
during the adaptation phase. After adaptation phase, hESC were
plated onto 12-well plates (CellBIND Surface, Corning, Inc.,
Corning, NY, USA) containing 10 mg/cm2 human collagen IV
(Sigma), 0.2 mg/cm2humanvitronectin (Sigma), 5 mg/cm2humanfibro-
nectin (Sigma) and 5 mg/cm2 human laminin (Sigma) coating mixture.
The hESC were cultured in a humidified þ378C, 5% CO2 incubator.
The growth of hESC was monitored microscopically and culture media
were changed daily. The feeder-free hESC cultures were passaged
mechanically every 7–10 days and plated onto a new 12-well plate con-
taining the coating mixture. The experiments which failed to maintain
hESC undifferentiated were repeated for a second time in order to
verify the results of the first experiments.
Immunofluoresence for Nanog and stage-specific
embryonic antigen-1
The hESC colonies were fixed in culture dishes with 4% paraformal-
dehyde in phosphate-buffered saline (PBS) (0.01 M, pH 7.4) for
20 min at room temperature (RT), followed by washing with PBS
(2  5 min). The cells were permeabilized and blocked with 0.1%
Triton X-100, 1% BSA (Sigma) and 10% normal donkey serum
(Sigma) in PBS for 45 min at RT and then washed once with 0.1%
Triton X-100, 1% BSA and 1% normal donkey serum in PBS.
Primary antibodies, polyclonal goat anti-human Nanog at a dilution
of 1:200 and monoclonal mouse anti-human stage-specific embryonic
antigen-1 (SSEA-1) at 1:200 (both from Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA) were used. Primary antibodies were incu-
bated overnight at 48C. The cells were washed (3  5 min) with 1%
BSA in PBS and probed with secondary antibodies:
rhodamine-red-conjugated donkey anti-mouse immunoglobulin (Ig)
M at 1:400 (Jackson ImmunoResearch Europe Ltd, Cambridgeshire,
UK) and Alexa Fluor 488 donkey anti-goat IgG at 1:800 (Invitrogen)
for 1 h in the dark at RT. Human ESC labelled only with secondary
antibodies were used as negative controls. After incubation, the cells
were washed with PBS (3  5 min) and mounted in Vectashield
mounting medium containing 40,6-diamidino-2-phenylindole (Vector
Laboratories, Inc., Burlingame, CA, USA). Human ESC line HS237
cultured with the hESC medium was used as a control in immuno-
fluoresence analysis. The labelled cells were viewed and
Table I. The tested culture media for human embryonic stem cells (hESC)
Test reagent Cell line and passage Medium compositiona
Control hESC medium HS181 p62 80% ko-DMEM; 20% ko-SR
HS237 p59, p74
HS293 p49
HS306 p50
Human serum HS237 p74 80/90% ko-DMEM; 10/20% human serum;
HS306 p50 50 mg/l L-ascorbic acid 2-phosphate
LipuminTM 10 HS181 p62 80/90% ko-DMEM; 10/20% Lipumin
HS237 p59, p74
HS293 p49
Plasmanate HS181 p62 80/60% ko-DMEM; 20/40% Plasmanate
HS237 p74
SerEx 10 HS181 p62 80/90% ko-DMEM; 10/20% SerEx
HS237 p59
HS293 p49
Serum substitute HS181 p62 80/90% ko-DMEM; 10/20% SSS
supplement (SSS) HS237 p59, p74
HS293 p49
SR3 HS181 p60 80/90% ko-DMEM; 10/20% SR3
HS237 p61
HS293 p42
HS237 p74
TeSR1 HS181 p62 DMEM/F12; 16.5 mg/ml HSA; 108 mg/ml holo-transferrin; 196 mg/ml insulin; 6 mg/l
thiamine HCl; 41.5 mg/l LiCl; 2 mg/l reduced glutathione; 50 mg/l L-ascorbic acid;
1:1000 trace elements B and C solution; 0.1 mg/ml GABA; 0.02 mg/l sodium selenite;
0.127 mg/ml pipecolic acid; 0.6 ng/ml TGFb1; 1:500 chemically defined lipid concentrate
X-Vivo 10 HS237 p59 100% X-vivo 10; 0.12 ng/ml TGFb1
HS293 p49
X-Vivo 20 HS181 p60 100% X-vivo20
HS237 p61
Ko-DMEM, KnockOut Dulbecco’s modified Eagle’s medium; ko-SR, KnockOut serum replacement; DMEM/F12, Dulbecco’s modified Eagle’s medium: F12
nutrient mixture; HSA, human serum albumin; LiCl, lithium chloride; GABA, g-aminobutyric acid; TGFb1, transforming growth factor b1.
aIn all cases, test medium is supplemented with 2 mM Glutamax, 0.1 mM b-mercaptoethanol, 0.1 mM MEM non-essential amino acids, 50 U penicillin/ml–
50 mg streptomycin/ml, and 8 ng/ml basic fibroblast growth factor.
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photographed with a Nikon Eclipse TE2000-S phase contrast micro-
scope with fluorescence optics and a Nikon COOLPIX 5400 camera.
Fluorescence-activated cell sorter analysis
The hESC (HS237) cultured in medium containing 20% human serum
were analysed using a fluorescence-activated cell sorter (FACS). The
cells were dissociated from the culture dish with TrypleTM Select
(Invitrogen) for 15 min at 378C and resuspended in 1 ml FACS
buffer I (2% FBS, 0.01% sodium azide in PBS) and counted with a
haemacytometer. A total of 0.2  106 cells were recovered, half of
which were probed for 15 min at 48C with a 1:500 dilution of mono-
clonal mouse anti-human SSEA-4 (Santa Cruz Biotechnology, Inc.)
and the other half with monoclonal mouse anti-human SSEA-1 in
FACS buffer I. The cells were then washed with FACS buffer I and
probed with FACS buffer I containing a 1:500 dilution of r-
phycoerythrin-conjugated goat anti-mouse IgG or r-phycoerythrin-
conjugated goat anti-mouse IgM (both from Invitrogen) for 15 min
in the dark at 48C. The cells were then washed once with FACS
buffer I, once with FACS buffer II (0.01% sodium azide in PBS)
and fixed with 1% formaldehyde in PBS. HS237 cells cultured in a
hESC medium were used as a control and treated similarly.
The samples were analysed using BD FACSAriaTM equipment (BD
Biosciences, Franklin Lakes, NJ, USA). Acquisition was set for
10 000 events per sample. The data were analysed using FACSDiva
Software version 4.1.2.
In vitro differentiation and RT–PCR analysis
The pluripotency of the hESC line HS237 cultured with the modified
TeSR1 medium was analysed with the RT–PCR analysis. The embry-
oid bodies (EB) were formed by mechanically dissecting upward-
growing hESC colonies at passage 7 and transferring the resulting
pieces onto a culture dish without feeder cells. The EBs were cultured
in a modified TeSR1 mediumwithout bFGF for 23 days before the iso-
lation of RNA. The medium was changed every 2–3 days. The hESC
line HS181 cultured in a hESC medium was used as a control, and
samples were prepared similarly. Total RNA was isolated from EBs
(TeSR1, n ¼ 25; control hESC medium, n ¼ 5) using RNeasy mini
kit (Qiagen, Valencia, CA, USA). The RNA extraction was performed
according to the manufacturer’s instructions. The concentration and
quality of isolated RNA were determined using a ND-1000 Spectro-
photometer (NanoDrop Technologies, USA). Complementary DNA
(cDNA) was synthesized from 50 ng of total RNA using Sensiscript
Reverse Transcription Kit (Qiagen) according to the manufacturer’s
instructions. The expression of markers characteristic of ectoderm
(neurofilament 68 kDa, sense 50-GAG TGA AAT GGC ACG ATA
CCT A-30; antisense 50-TTT CCT CTC CTT CTT CAC CTT C-30),
endoderm (a-fetoprotein, sense 50-GCT GGA TTG TCT GCA GGA
TGG GGA A-30; antisense 50-TCC CCT GAA GAA AAT TGG
TTA AAA T-30) and mesoderm (a-cardiac actin, sense 50-GGA
GTT ATG GTG GGT ATG GGT C-30; antisense 50-AGT GGT
GAC AAA GGA GTA GCC A-30) development in EBs were deter-
mined using RT–PCR primers (Proligo, Sigma). Glyceraldehyde 3-
phosphate dehydrogenase (sense 50-AGC CAC ATC GCT CAG
ACA CC-30; antisense 30-GTA CTC AGC GGC CAG CAT CG-50)
was used as a housekeeping control. One microlitre of cDNA was
used as template in the PCR reactions. The negative control contained
sterilized water instead of cDNA template. The PCR reactions were
carried out in the Eppendorf Mastercycler as follows: denaturation
at 958C for 3 min and 40 cycles of denaturation at 958C for 30 s,
annealing at 578C for 30 s and extension at 728C for 1 min, followed
by final extension at 728C for 5 min. The PCR products were analysed
with electrophoresis on 1.5% agarose gel containing 0.4 mg/ml
ethidium bromide (Sigma) and DNA standard (MassRulerTM DNA
Ladder Mix, Fermentas).
Results
Human ESC were gradually adapted to different test media,
using an increasing proportion of test media (with ratios of
test media to control hESC media at 20:80, 50:50 and 80:20)
up to 100% during the first week of culture. Different concen-
trations of commercially available serum replacements and
media were used to evaluate the growth and maintenance of
undifferentiated hESC. None of the eight xeno-free culture
media or serum replacements tested were able to maintain
the undifferentiated growth of hESC on human feeder cells.
The differentiation of hESC already began during the adap-
tation process with all test media, as indicated by the change
in colony morphology. The colonies became thinner and lost
their angular shape and sharp edges. The number of undifferen-
tiated colonies diminished significantly after the third adap-
tation phase (80:20) at all concentrations (10 and 20%),
tested with LipuminTM-, SerEx-, SSS-, SR3-, X-Vivo-10-
(100%), X-Vivo-20- (100%) and Plasmanate- (20 and 40%)
containing media.
The results were consistent in all hESC lines examined and
in repeated experiments. The differentiation was first judged by
morphology and then confirmed by immunofluoresence analy-
sis. The hESC colonies grown with the test culture media in all
tested concentrations showed an increased expression of a
marker common to the differentiated hESC (SSEA-1) and
were negative for a marker common to the undifferentiated
hESC (Nanog) (Figure 1).
The morphology of the feeder cells used was found to change
under some test conditions. Feeder cells shortened, became
spherical and started to detach in X-Vivo-10-, X-Vivo-20-,
SR3- and LipuminTM-containing media (Figure 1). In some
test conditions, the growth of the colonies was also reduced sig-
nificantly (X-Vivo 10, SSS, SerEx, modified TeSR1). Human
ESC were all differentiated (except in modified TeSR1 media)
when the adaptation process was complete, and it was imposs-
ible to passage the colonies further. The modified TeSR1
media were able to maintain the undifferentiated growth of
hESC on feeder cells for seven passages. The hESC colonies
in modified TeSR1 media began to grow upwards after seven
passages, and the experiment was aborted.
The upward-growing hESC colonies cultured in the modified
TeSR1 medium using feeder cells were differentiated in vitro
into EBs, which were analysed with RT–PCR. Ectoderm
(neurofilament 68 kDa) and mesoderm (a-cardiac actin)
specific markers were detected in the RT–PCR analysis.
However, an endoderm (a-fetoprotein) specific marker was
not detected (Figure 2). These results show a defective pluripo-
tency of hESC cultured with the modified TeSR1 medium. Our
results clearly show that the various xeno-free test media were
not able to maintain the undifferentiated growth and the pluri-
potency of hESC on human feeder cells.
Human ESC were gradually adapted to human-serum-
containing media using an increasing proportion of test
media. The human-serum-containing medium was tested with
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concentrations of 10 and 20% of heat-inactivated, sterile filtered
human serum. The hESC colonies underwent excessive differ-
entiation during the first passages, as the concentration of
human serum was gradually increased and the concentration
of ko-SR in the culture medium was decreased. The differen-
tiation was indicated by the change of hESC colony mor-
phology. The colonies got thinner and some lost their angular
shape and defined borders. The medium containing 10% of
human serum was able to maintain the undifferentiated hESC
growth for nine passages on human feeder cells. At the end of
passage 10, all colonies had differentiated completely and the
differentiation was confirmed by immunofluoresence staining
with Nanog and SSEA-1 (Figure 3). As the colonies in the
culture medium containing 20% of human serumwere passaged
further, they began to regain their thicker, undifferentiated mor-
phology at passage level 8. At passage level 11, the colonies
showed undifferentiated morphology (Figure 3), although they
were notably thinner than the hESC cultured in the presence
of a control hESC culture medium (Figure 3). At passage
level 11, the hESC cultured in the 20% human serum medium
were stained with a panel of immunocytochemical antibodies
specific to hESC markers: Nanog, OCT-3/4, SSEA-4 and
SSEA-1 (Figure 3). The expression of the markers was not
complete, and parts of the colonies were differentiated, although
there was no expression of SSEA-1 (Figure 3). As a control,
hESC cultured in a control hESC medium were stained with
Figure 1. The morphology and immunofluoresence analyses of the human embryonic stem cell (hESC) colonies cultured with eight different
xeno-free media. (A) An hESC colony after one passage (20% Lipumin); (B) the expression of Nanog (green) and stage-specific embryonic
antigen-1 (SSEA-1) (red) after one passage (20% Lipumin); (C) an hESC colony after one passage (20% Plasmanate); (D) the expression of
Nanog (green) and SSEA-1 (red) after one passage (20% Plasmanate); (E) an hESC colony after one passage (40% Plasmanate); (F) the
expression of Nanog (green) and SSEA-1 (red) after one passage (40% Plasmanate); (G) an hESC colony after one passage (20% SerEx); (H)
the expression of Nanog (green) and SSEA-1 (red) after one passage (20% SerEx); (I) an hESC colony after one passage (20% SR3); (J) the
expression of Nanog (green) and SSEA-1 (red) after one passage (20% SR3); (K) an hESC colony after one passage [20% serum substitute sup-
plement (SSS)]; (L) the expression of Nanog (green) and SSEA-1 (red) after one passage (20% SSS); (M) an hESC colony after one passage
(X-Vivo 10); (N) the expression of Nanog (green) and SSEA-1 (red) after one passage (X-Vivo10); (O) an hESC colony after one passage
(X-Vivo 20); (P) the expression of Nanog (green) and SSEA-1 (red) after one passage (X-Vivo 20); (Q) an hESC colony after seven passages
(TeSR1); (R) the expression of Nanog (green) and SSEA-1 (red) after seven passages (TeSR1); (S) an hESC colony cultured with control
hESC medium; (T) the expression of Nanog (green) and SSEA-1 (red) of hESC colony cultured with control hESC medium. Scale bar-200 mm.
Figure 2. RT–PCR analysis of embryoid bodies (EBs) differentiated
from the hESC line HS237 cultured with the modified TeSR1 medium.
EBs cultured with TeSR1 medium expressed markers for the two
embryonic germ cell layers, ectoderm [neurofilament (NF)-68] and
mesoderm (a-cardiac actin). Endoderm (a-fetoprotein) specific
marker was not detected (TeSR1). Glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) was used as a housekeeping control. EBs differ-
entiated from the hESC line HS181 cultured with control hESC
medium were used as controls (þ). Water was used as negative
control (2 ).
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Nanog and SSEA-1 and showed a strong expression of Nanog
and no expression of SSEA-1 (Figure 3).
Human ESC cultured with 20% human-serum-containing
medium on human feeder cells were further analysed with an
FACS. In total, 0.1  106 cells were labelled with SSEA-4
and 0.1  106 with SSEA-1. According to the FACS analysis,
35% of the hESC were positive for SSEA-4 (Figure 4). Of the
control hESC, 80% were positive for SSEA-4. The 20% human
serum culture medium was found to sustain an undifferentiated
hESC proliferation to some extent, however, being inferior to
the currently used culture medium containing ko-SR.
The control hESC medium, TeSR1 medium and a medium
containing 20% human serum were used to evaluate the
growth and maintenance of undifferentiated hESC on extra-
cellular matrix coating mixture without human foreskin fibro-
blast feeder cells. The attachment of hESC was poor; from
the hESC colony pieces which were plated with each
medium, only 30% attached in the TeSR1 medium, 55% in
20% human-serum-containing medium and 68% in the
control hESC medium. From the colony pieces attached, only
30% formed colonies in the TeSR1 medium, whereas 75%
formed colonies in the 20% human-serum-containing
medium and hESC medium (Figure 5). After second passaging,
only minor colony formation was observed in the hESC control
medium and in 20% human-serum-containing medium,
whereas no colony formation was observed in the TeSR1
medium and the experiment was terminated.
Discussion
In this study, nine commercially available or published xeno-
free media and serum replacements were compared with the
conventionally used serum replacement (ko-SR) containing
medium in the culture of hESC. These xeno-free reagents
were not able to maintain the undifferentiated growth of
hESC. The cell proliferation decreased during the adaptation
to the test media, and after the complete adaptation, the hESC
quickly differentiated. The use of commercially available
X-Vivo 10 medium has been previously described by two
research groups (Genbacev et al., 2005; Li et al., 2005) in
feeder-free culture conditions of hESC. Li et al. supplemented
the X-Vivo 10 medium with recombinant human bFGF, stem
cell factor, recombinant human flt3 ligand and LIF, whereas
Genbacev et al. used a high concentration of bFGF. Recently,
Ludwig et al. (2006) reported feeder-free derivation and
culture of hESC using defined medium (TeSR1) including
protein components solely from recombinant sources or purified
from human material. In addition, they used a combination of
collagen IV, fibronectin, laminin and vitronectin coating from
human sources instead of a feeder cell layer. They managed
to derive two hESC lines in these animal-product-free con-
ditions, although neither one maintained stable karyotype. The
Figure 3. The morphology and immunofluoresence analyses of the
hESC colonies cultured with human-serum-containing media. The
hESC cultured with 10% human-serum-containing medium for 10
passages; (A) a differentiated hESC colony; (B) 40,6-diamidino-
2-phenylindole (DAPI) staining; (C) an hESC colony double stained
with Nanog (green) and SSEA-1 (red). The hESC cultured with
20% human-serum-containing medium for 11 passages; (D) an
hESC colony cultured with 20% human serum; (E) DAPI staining;
(F) an hESC colony stained with SSEA-4; (G) an hESC colony
stained with Oct2 (3/4); (H) an hESC colony stained with
SSEA-1; (I) an hESC colony stained with Nanog. The hESC cultured
with control hESC medium; (J) an hESC colony cultured with control
hESC medium; (K) DAPI staining; (L) an hESC colony double
stained with Nanog (green) and SSEA-1 (red). Scale bar-200 mm.
Figure 4. Fluorescence-activated cell sorter analysis of the hESC
cultured with 20% human-serum-containing medium on human
feeder layer for 11 passages. The percentage of positive cells is
shown. (A) Surface-marker SSEA-4 expression of the hESC cultured
with 20% human serum; (B) surface-marker SSEA-4 expression of the
hESC cultured with control hESC medium.
Figure 5. The morphology of hESC colonies cultured in feeder-free
conditions at passage 1. (A) hESC cultured with control hESC
medium; (B) hESC cultured with 20% human-serum-containing
medium; (C) hESC cultured with TeSR1 medium. Scale bar-200 mm.
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TeSR1medium contains various ingredients, of whichmany are
used in high concentrations, making the medium very expens-
ive. Also, the purified human matrix components used in the
coating are expensive. Unfortunately, neither X-Vivo 10
medium nor TeSR1 with low concentration of bFGF were
able to sustain the undifferentiated growth of our hESC lines
on human foreskin feeder layer. The proliferation of hESC cul-
tured in the modified TeSR1 medium decreased significantly
after the adaptation process. Human ESC colonies began to
grow upwards, making the passaging impossible. The modified
TeSR1 media were able to maintain the undifferentiated growth
of hESC for seven passages on human feeder cells. However,
the pluripotency of hESC was incomplete, as an endoderm-
specific marker was not detected in the RT–PCR analysis of
the hESC cultured in the modified TeSR1 medium. We also
tested feeder-free cultivation of hESC in the TeSR1 medium.
However, the attachment and colony formation in the TeSR1
medium was poor compared with the control hESC medium,
and we were able to maintain hESC in the TeSR1 medium
only for two passages.
The morphology of the feeder cells used was found to
change under some test conditions. Feeder cells shortened,
became spherical and started to detach in X-Vivo-10-,
X-Vivo-20-, SR3- and LipuminTM-containing media. Because
feeder cells are an important part of our culture system, this
might have a critical effect on the differentiation of hESC. It
is reported that ascorbic acid deficiency in a fibroblast culture
causes, among other things, an easy disaggregation of the
cells from the intracellular matrix by protease action
(Schafer et al., 1967). The role of ascorbic acid in a cell
culture is to function as an antioxidant for the cells. Ascorbic
acid is not available in a standard basal culture medium and
needs to be added to the medium as a stable phosphate
(Geesin et al., 1993). The ko-SR (Gibco Invitrogen) contains
ascorbic acid (Price et al., 1998), but it is not known whether
the commercially available serum replacements and media
tested contain L-ascorbic acid. The absence or presence of
other components in the tested culture media may also have
influenced the decreased proliferation and differentiation of
hESC. It is certain that the ingredients of the control and the
test culture media differ because once the control media is
entirely replaced, the differentiation of hESC is excessive.
Our results clearly show that the eight different culture media
tested were not able to support the undifferentiated growth of
hESC. These results suggest that unknown components either
present in or absent from the tested media compared with
ko-SR induce the differentiation of hESC.
Human serum has previously been used in hESC culture with
some success. Richards et al. (2002) derived an hESC line
using 20% human-serum-containing culture medium and
were able to propagate hESC in an undifferentiated state for
10 passages. However, it was later observed that a prolonged
use of human serum beyond the 10th passage led to the
increased differentiation of hESC (Richards et al., 2003).
Recently, Ellerstro¨m et al. were able to derive and propagate
an hESC line in the human-serum-containing medium for
over 20 passages, without problems of excessive differen-
tiation. In our study, human serum medium (containing
L-ascorbic acid and 20% of human serum) was found to main-
tain undifferentiated hESC growth on human feeder cells to
some extent (11 passages), but the hESC underwent an exces-
sive differentiation in human serum culture media in the begin-
ning of the experiments. As Richards et al. (2003) stated,
human serum may contain some unknown factors that
promote the differentiation of hESC, whereas ko-SR contains
factors that enable an undifferentiated hESC culture. Since a
fraction of the cells could be passaged despite the excessive
differentiation in the beginning of the experiment and since
the colony morphology improved after several passages in
20% human serum medium, the population of cells was able
to adapt to culture conditions with human serum. The hESC
cultured in media containing 10% of human serum were not
able to adapt to these culture conditions. This is most likely
due to a lack of sufficient serum proteins in the culture
media. In particular, the amount of albumin, which is the
major blood protein, seems to be essential for hESC survival
in vitro. This notion is supported by the fact that BSA is the
major constituent of ko-SR (Price et al., 1998). Although
human serum can provide nutritive supplementation for
hESC, it is a complex mixture containing compounds both ben-
eficial and detrimental to hESC, which means that each lot
should be carefully tested prior to use.
The addition of L-ascorbic acid to the culture medium could
play a role in the ability of a subpopulation of hESC to survive
in the human-serum-containing culture medium. The hESC
cultured in 20% human serum medium maintained their undif-
ferentiated morphology with smooth, angular colony shape for
at least 11 passages, even though the colonies were thinner
when compared with those cultured in the control hESC
medium. We also tested feeder-free culture of hESC in 20%
human-serum-containing medium. The attachment and
colony formation in the human-serum-containing medium
was considerably better than that in the TeSR1 medium. We
also observed that the morphology of the cells in the colonies
was considerably different than that in the control hESC
medium and TeSR1 medium.
The use of human serum in the hESC culture medium is a
xeno-free alternative to ko-SR, but similar to FBS, human
serum is not of defined composition and is thus suboptimal.
The commercial human sera available are pooled from a het-
erogeneous group of donors. Pooling sera from selected
donors might provide more homogenous sera for hESC
culture. Yet another concern with the use of human serum is
the potential transmission of extremely serious pathogens
such as human immunodeficiency virus, which has a long
latent preclinical period and could go undetected in routine
donor screenings (Mallon et al., 2006). The optimal solution
for the xeno-problem of ko-SR would be the use of a similarly
defined serum replacement containing purified human or
human recombinant components.
The various culture conditions reported are difficult to
compare because each group has used a different base media,
matrix or feeders, cell lines and cell passage numbers.
Although hESC have been shown to grow in each of these con-
ditions, it is unclear which, if any, of these culture conditions
are optimal. The use of a single substrate for hESC growth is
Media for human embryonic stem cell culture
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desirable, but the substrates used are still undefined com-
ponents and may have a lot-to-lot variability (Hoffman and
Carpenter, 2005). It is also unclear whether the hESC main-
tained in these different substrates are equivalent. In fact, the
gene expression signature of hESC is reported to be different
when cultured with the ko-SR-containing medium and FBS
(Skottman et al., 2006).
Even though several improvements in hESC culture con-
ditions have been achieved during the past few years, a com-
pletely xeno-free, defined culture and derivation methods for
hESC, which could be reproduced in various laboratories
culturing hESC lines worldwide, have not been established.
Cells used for human transplantation are regulated by the
European Union (EU). According to new EU directives
(2003/94/EC and 2004/24/EC), hESC for transplantation
must be cultured according to good manufacturing practice
(GMP) requirements. In order to derive clinical-grade hESC
lines, the used derivation methods and all constituents of
culture must be of GMP grade. Continuous research for
identifying the mechanisms of self-renewal of hESC and
improving the current culture conditions is essential in
order to establish completely xeno-free culture systems that
meet the requirements of GMP and enable the large-scale
production of hESC.
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Abstract
Background: The growth of stem cells in in vitro conditions requires optimal balance between signals mediating cell
survival, proliferation, and self-renewal. For clinical application of stem cells, the use of completely defined conditions and
elimination of all animal-derived materials from the establishment, culture, and differentiation processes is desirable.
Methodology/Principal Findings: Here, we report the development of a fully defined xeno-free medium (RegES), capable of
supporting the expansion of human embryonic stem cells (hESC), induced pluripotent stem cells (iPSC) and adipose stem
cells (ASC). We describe the use of the xeno-free medium in the derivation and long-term (.80 passages) culture of three
pluripotent karyotypically normal hESC lines: Regea 06/015, Regea 07/046, and Regea 08/013. Cardiomyocytes and neural
cells differentiated from these cells exhibit features characteristic to these cell types. The same formulation of the xeno-free
medium is capable of supporting the undifferentiated growth of iPSCs on human feeder cells. The characteristics of the
pluripotent hESC and iPSC lines are comparable to lines derived and cultured in standard undefined culture conditions. In
the culture of ASCs, the xeno-free medium provided significantly higher proliferation rates than ASCs cultured in medium
containing allogeneic human serum (HS), while maintaining the differentiation potential and characteristic surface marker
expression profile of ASCs, although significant differences in the surface marker expression of ASCs cultured in HS and
RegES media were revealed.
Conclusion/Significance: Our results demonstrate that human ESCs, iPSCs and ASCs can be maintained in the same defined
xeno-free medium formulation for a prolonged period of time while maintaining their characteristics, demonstrating the
applicability of the simplified xeno-free medium formulation for the production of clinical-grade stem cells. The basic xeno-
free formulation described herein has the potential to be further optimized for specific applications relating to
establishment, expansion and differentiation of various stem cell types.
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Introduction
Stem cells are invaluable tools for research, drug screening, to
study diseases and can potentially serve as a resource for
regenerative therapies. Multipotent adipose stem cells (ASCs)
exhibiting immunoprivileged properties are an attractive and
abundant stem cell source for regenerative medicine that upon
induction can undergo adipogenic, osteogenic, chondrogenic,
neurogenic and myogenic differentiation in vitro [1–3]. However,
even more expectations on clinical applicability in diverse fields of
cell- and tissue-replacement therapies are focused on pluripotent
stem cells. Besides of hESCs, a promising new source of
pluripotent cells was recently discovered, as human somatic cells
were reprogrammed by introducing a set of transcription factors
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linked to pluripotency to yield induced pluripotent stem cells
(iPSC) [4,5]. Human iPSCs are a potential source of patient-
specific pluripotent stem cells that could be used to treat a number
of human degenerative diseases without evoking immune
rejection. From these stem cell types, only patient specific ASCs
have so far been used in clinical cell therapy while clinical trials
using hESCs is at the very beginning (http://www.geron.com).
Many major challenges including teratoma formation, immuno-
genicity and the use of oncogenes and retroviruses in the
reprogramming of iPSCs need to be addressed before hESCs
and iPSCs can be safely used as a source for clinical cell therapy.
One of the major challenges for the clinical use of stem cells is the
exposure to undefined animal-derived products during in vitro
establishment and expansion of the cells. Considerable progress has
been made towards the generation of defined culture conditions for
stem cells. FBS has been mostly replaced with knockout- serum
replacement (KO-SR, Invitrogen) [6–8] and human feeder cells have
been successfully used to replace mouse embryonic fibroblasts (MEFs)
in the derivation and expansion of hESCs and iPSCs [9–15]. In
addition, various feeder cell-free culture conditions have been
developed for the culture of hESCs and iPSCs [16–19]. Despite the
progress, most existing stem cell lines have been exposed to a variety of
undefined animal-derived products which makes these cell lines
undesirable for clinical applications. In addition to establishment and
culture of stem cells, many differentiation protocols utilize a variety of
undefined products that may have unknown effects to the cell
characteristics and differentiation. The potential consequences of
transplanting human cells exposed to animal-derived products into
patients include an increased risk of graft rejection, immunoreactions,
and viral or bacterial infections, prions, and yet unidentified zoonoses
[20–22]. Therefore, optimization and standardization of a fully defined
xeno-free establishment, culture and differentiation methods for stem
cells is needed for research and especially for clinical application.
Since there is a clear indication that hESCs cultured without
feeder cells in long-term cultures may be more prone to
undesirable abnormalities caused by suboptimal culture conditions
and enzymatic passaging of hESCs [23,24], we believe that the
goal for developing clinical-grade hESCs and iPSCs should be
focused on the use of qualified human feeder cells. In the present
study we have developed a completely new defined xeno-free
medium capable of supporting the expansion of hESCs, iPSCs and
ASCs while maintaining their characteristics. In addition, we
describe the derivation and long-term culture of new hESC lines
using the xeno-free medium.
Results
Initial development of a xeno-free culture medium
formulation
We developed a xeno-free medium (RegES) composed of a
knockout-Dulbecco’s modified Eagle’s medium (KO-DMEM,
Invitrogen, Carlsbad, CA) base supplemented with human serum
albumin, amino acids, vitamins, antioxidants, trace minerals, and
growth factors (Table S1). All medium components were synthetic,
recombinant, or of human origin. Removal of any of the
components resulted in reduced growth or excess differentiation
of hESCs (data not shown). Initially, the xeno-free RegES medium
was evaluated with hESC lines HS237, HS346 and HS401 [25,26]
and it was noticed that the colonies were thinner and the growth of
the hESCs was slower than in hESC lines derived and cultured in
the conventional medium containing KO-SR (hES medium, data
not shown). Despite the thinner colonies and slower growth, new
hESC line, Regea 06/015, was successfully derived using the first
version of the xeno-free RegES medium and hFF cultured in
human serum. After a couple of passages, the growth of the Regea
06/015 cell line declined and, to avoid losing the cell line, the cell
line was transferred at passage 7 to conventional culture medium
containing KO-SR. Since then, we have been culturing the Regea
06/015 cell line continuously for over 3 years in hES medium
containing KO-SR. The cell line exhibits normal hESC
characteristics including pluripotency as determined by embryoid
body analysis and teratoma formation and is karyotypically
normal (Figure S1, S2, S3).
Next, the medium was further optimized by addition of several
different components and by adjusting the osmolarity to 320–
330 mOsm/kg. (Table S1). These improvements markedly
enhanced the cell characteristics, including the colony morphology
and growth (data not shown). Comparison of xeno-free RegES
medium with the commercially available xeno-free HEScGRO
medium specifically developed for hESC cultures using feeder cells
revealed that in our study and in contrast to RegES, HEScGRO
medium was not able to maintain the undifferentiated growth of
the hESCs but instead resulted in excess differentiation as judged
by the morphology of the hESC colonies (Fig. 1). For that reason
in the following studies, the hESC line Regea 06/040 derived and
cultured in the hES medium was used as a control cell line instead
of hESC line cultured in HEScGRO.
Optimized formulation supports the derivation and
culture of new hESC lines
The optimized RegES medium was used to derive two
additional hESC lines (Regea 07/046 and Regea 08/013; Fig. 2
and 3) from 26 surplus embryos that did not undergo proper
blastocyst formation. Both hESC lines have been continuously
cultured for over 80 passages. The cell lines have been maintained
by mechanical passaging but a single-cell enzymatic dissociation
(SCED) method developed and described by Ellersto¨m and co-
workers [27] utilizing recombinant enzyme TrypLE Select
(Invitrogen), is feasible with RegES as well (Fig. 4A). With the
enzymatic propagation method, hESCs can be passaged with a
1:10 split ratio, enabling a rapid increase in the number of cells. In
addition, the RegES medium can also be used for freezing and
thawing of the hESCs (Fig. 4B).
Both of the hESC lines derived and cultured in RegES medium
have been karyotyped regularly and exhibit a normal diploid
karyotype (Figure S2). Analysis of these cell lines by immunocy-
tochemical stainings (Nanog, Oct4, Sox2, SSEA-4 and TRA-1-60)
and flow cytometry (SSEA-4, TRA-1-81) demonstrated that both
cell lines express markers that are characteristic of hESCs at levels
comparable to the control hESC line Regea 06/040 derived and
cultured using hES medium (Fig. 2B, 3A). In quantitative reverse
transcription PCR (qRT-PCR) no significant differences (over 2-
fold) in the expression levels of markers Nanog, Oct4, GABRB3,
GDF3, DNMT3B and TDGF1 were detected between hESC lines
derived in RegES and in control hESC line derived in hES
medium (Fig. 3C). An enzyme-linked immunosorbent assay
(ELISA)-based analysis of cell proliferation showed that the cell
proliferation rates of Regea 07/046 (A= 0.286) and Regea 08/013
(A= 0.272) were comparable to that of control cell line Regea 06/
040 (A= 0.287) cultured in hES medium (Fig. 3B).
Human ESCs cultured for prolonged periods in xeno-free
culture medium maintain their pluripotency and
differentiation characteristics
To confirm that the new cell lines maintain their pluripotency in
vitro, we performed an embryoid body (EB) assay. The EB-derived
cells from the cell lines Regea 07/046 and 08/013 as well as from
Xeno-Free Culture Method
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the control cell line Regea 06/040 expressed markers from the
three different embryonic lineages; endoderm, ectoderm, and
mesoderm, although the expression of T was not detected in cells
from Regea 08/013 cell line, and T, SOX17 and SOX1 were not
detected in cells from control Regea 06/040 cell line (Fig. 5A). As
demonstrated for the hESC line 06/015 (Figure S3), an in vivo
pluripotency assay was also performed for the cell lines Regea 07/
046 and Regea 08/013 and for the control cell line Regea 06/040
using teratoma formation in severe combined immunodeficient
(scid)-beige mice and structures from all three germ layers were
detected (Figure S4, S5, S6).
We also tested whether hESCs derived and cultured in xeno-
free conditions can differentiate to cardiomyocytes and neural cell
lineages. To initiate cardiomyocyte differentiation, undifferentiat-
ed hESC colonies were dissected into aggregates and plated on the
top of END-2 cells [28]. Spontaneously beating areas were
observed after 12-16 days after the initiation of the cardiac
differentiation. Dissociated, spontaneously beating cells had
striated patterning and were stained with cardiac troponin T
and ventricular myosin heavy chain markers (Fig. 5B). To generate
neuronal cells, hESC colonies cultured in RegES and hES media
were dissected into small clusters and cultured in suspension for up
to 20 weeks [29]. The differentiated cells expressed neural
precursor markers, neuronal markers and astrocytic marker in
RT-PCR (Fig. 5C). Immunocytochemical staining verified the
neuronal and glial fate of the cells (Fig. 5D). The cardiac and
neural differentiation efficiency was similar in hES and RegES
medium (data not shown). These results indicated that hESC lines
derived and cultured in xeno-free culture medium maintain their
pluripotency and furthermore cardiomyocytes and neuronal cells
can be generated from these cell lines.
Xeno-free conditions support the culture of human iPSCs
To further demonstrate the performance of the developed
medium for human pluripotent cells, we cultured two iPSC lines
on human feeder cells in these conditions. Currently, both iPSC
lines have been continuously cultured in RegES medium for over
20 passages. The morphology and molecular characteristics of the
cells are similar as compared to the cells cultured in hES medium
as demonstrated by immunocytochemical stainings (Nanog, Oct4,
Sox2, SSEA-4 and TRA-1-60), flow cytometry analysis (SSEA-4,
TRA-1-81) and qRT-PCR were no significant differences (over 2-
fold) in the expression levels of markers Nanog, Oct4, GABRB3,
GDF3, DNMT3B and TDGF1 were detected between iPSC lines
cultured in RegES and in hES medium (Fig. 6A-D). In addition,
analysis of EBs demonstrated that iPSCs cultured in xeno-free
RegES medium maintain their ability to differentiate to all three
germ layers although the expression of T was not detected in cells
from FiPS 6–14 cell line (Fig. 6E).
Xeno-free conditions enhance proliferation and cell
surface marker expression profile of human ASCs
ASCs isolated from adipose tissue samples were used to assess
the performance of xeno-free RegES medium for the culture of
mesenchymal stem cells. To determine the proliferation rate of
ASCs grown in xeno-free RegES medium and allogeneic human
serum-containing medium (HS medium) we performed the WST-
1 proliferation analysis at several time points (1, 4, 7 and 11 days).
Seven ASC lines were used for the analysis in both conditions.
Concurrently, cell morphology was observed by light microscopic
examination to confirm the proliferation assay results (Fig. 7A).
The proliferation analysis showed already at day 4 that cultures
with RegES medium exhibited a higher proliferation rates of
ASCs as compared to HS medium (Figure 7B). Subsequently,
ASCs continued to proliferate at a higher rate in RegES medium
compared to HS medium at day 7 and 11. Significant differences
in the proliferation rates were observed between the RegES
medium and HS medium at day 4 (p= 0.035), day 7 (p= 0.022)
and day 11 (p= 0.018) (Fig. 7B).
Flow cytometric characterization was performed to compare
surface marker expression characteristics of ASCs expanded in
xeno-free RegES medium and HS medium (Table 1). Four cell
lines were analyzed for every culture condition. The flow
cytometry analysis revealed .50% expression for ASCs cultured
in both culture conditions for the adhesion molecule CD105 and
extracellular matrix protein CD90. ASCs cultured in both culture
conditions showed no expression (,4%) of CD34 and CD45,
markers of hematopoietic cell lineage. Additionally, no expression
Figure 1. Comparison of RegES and HEScGRO xeno-free culture media. Human ESC line HS401 during the adaptation phases in RegES
culture medium and in HEScGRO medium. Human ESC line HS401 was transferred from hES culture medium to new culture conditions using stepwise
adaptation: 20:80, 50:50, 80:20 and 100%. A) Adaptation phases to HEScGRO medium. Note excess differentiation of hESC colonies at adaptation
phases 80:20 and after completion of the adaptation (100%). B) Adaptation phases to RegES culture medium.
doi:10.1371/journal.pone.0010246.g001
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Figure 2. Morphology and immunocytochemical characterization of hESC lines. A) Bright-field (scale bar, 500 mm) microscopic images
showing undifferentiated colony morphology of hESC lines Regea 07/046 at passage 44, Regea 08/013 at passage 12, and control cell line Regea 06/
040 at passage 45. B) Fluorescent images (scale bar, 100 mm) showing qualitative immunocytochemistry of cells positive for Nanog, Oct4, Sox2, SSEA-
4 and TRA-1-60. Insets represent DAPI staining. Regea 07/046 at passage 63, Regea 08/013 at passage 51, and control cell line Regea 06/040 at
passage 42.
doi:10.1371/journal.pone.0010246.g002
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(,1%) of MHC Class II isotype HLA-DR was observed for ASCs
cultured in HS or RegES media and modest expression (10%) of
MHC Class I isotype HLA-ABC was seen in RegES cultured
ASCs. While both culture conditions maintained the characteristic
surface marker expression profile of ASCs, statistical analysis
revealed significant differences in the expression of sialomucin-like
adhesion molecule CD34 (p= 0.043), leucocyte common antigen
CD45 (p= 0.017), adhesion molecule CD105 (p = 0.020) and
MHC Class I isotype HLA-ABC (p= 0.021) of ASCs cultured in
HS and RegES media.
The multilineage differentiation capability of ASCs expanded in
RegES was examined by culturing cells at passage 3 under
conditions that support osteogenic, adipogenic and chondrogenic
differentiation. The osteogenic induction was evident after 14 days
in culture in osteogenic RegES medium (Figure 7C). After less
than 7 days of adipogenic induction, accumulation of small lipid
droplets was visible in the cells grown in adipogenic RegES
medium by light microscopic inspection within the ASCs (data not
shown). At day 14, ASCs in RegES adipogenic induction cultures
proliferated rapidly and grew in a layered manner, with lipid
droplets forming in several layers (Figure 7D). In the chondrogenic
induction cultures, ASCs expanded in chondrogenic RegES
medium began to aggregate and form condensed pellets within
2–3 days after induction. At day 14, the chondrogenic induction
was confirmed with Alcian blue staining (Figure 7E).
Discussion
As the number of potential applications for stem cell
transplantation in the treatment of various degenerative diseases
is rapidly increasing a strong focus is needed on safety,
reproducibility and quality of stem cell transplants. To generate
therapeutically safe and usable stem cell-derived products for
clinical cell therapies, all animal-derived material must be
eliminated from the establishment, culture, and differentiation
steps. A completely xeno-free culture system was described by
Ellerstro¨m and co-workers [30] in which they used a xeno-free
derivation procedure, human serum, and xeno-free human
Figure 3. Stem cell marker expression and proliferation of hESC lines. A) Quantitative flow cytometry analyses showing comparable
expression levels of SSEA-4 and TRA-1-81 in all hESC lines at day 7. Regea 07/046 at passage 45, Regea 08/013 at passage 41, and Regea 06/040 at
passage 26. B) Cell proliferation analysis demonstrating comparable growth rates of hESC lines Regea 06/040 at passage 29, Regea 07/046 at passage
53 and Regea 08/013 at passage 41. C) Quantitative RT-PCR analysis of Nanog, Oct4, GABRB3, GDF3, DNMT3B and TDGF1 expression in hESC lines
Regea 07/046 at passage 52, Regea 08/013 at passage 45, and Regea 06/040 at passage 33. No significant differences (over 2-fold) were detected
between hESC lines.
doi:10.1371/journal.pone.0010246.g003
Figure 4. Enzymatic passaging, freezing and thawing of hESC in RegES medium. A) Bright-field (scale bar, 500 mm) microscopic images
showing undifferentiated colony morphology of hESC line 08/013 (p40) cultured in RegES medium and passaged with a single-cell dissociation
method for 6 passages. B) Bright-field (scale bar, 500 mm) microscopic image showing undifferentiated colony morphology of hESC line 07/046 (p33)
after freezing and subsequent thawing in RegES medium at passage 1.
doi:10.1371/journal.pone.0010246.g004
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foreskin feeder (hFF) cells to derive a hESC line. We have
previously demonstrated, however, that several commercial xeno-
free serum replacements and human sera are not suitable for long-
term undifferentiated culture of hESCs [31]. Recently Crook and
co-workers described the proof-of-concept for the generation of six
clinical-grade hESC lines using hFF as feeder cells [32]. These
lines were established and banked in a clinical-grade manufactur-
ing process (cGMP) facility in compliance with international
regulatory requirements. Although they used cGMP-compliant
reagents and materials in the production process of the hESC
lines, not all the reagents were xeno-free, possibly compromising
the safety of the established hESC lines for clinical application. In
this study, we have identified all the essential nutrients and growth
factors required to enable feasible growth characteristics and to
maintain the undifferentiated state of hESCs, iPSCs and ASCs.
The described RegES medium formulation is designed to meet the
special requirements of stem cell culture and the quality
requirements for clinical use of stem cells.
Our data demonstrate that hESCs can be successfully derived
and cultured long-term in the RegES formulation while
maintaining their undifferentiated state. Furthermore, EB forma-
tion, teratoma analysis and differentiation of cardiomyocytes and
neural cells demonstrated that hESCs derived and cultured in
xeno-free RegES medium maintain their pluripotency and
differentiation characteristics. The characteristics and differentia-
tion potential of hESCs cultured in the xeno-free RegES medium
were comparable to hESCs cultured in the conventional hES
culture medium. In the comparison of the RegES medium to the
xeno-free commercially available HEScGRO medium it was
noticed that HEScGRO was unable to maintain the undifferen-
tiated growth of hESCs. Human ESCs can be frozen and thawed
using the xeno-free medium RegES and both mechanical
passaging and single-cell enzymatic dissociation methods can be
used. With enzymatic single-cell propagation, the number of cells
can be multiplied rapidly, thereby enabling up-scaling and large-
scale cultivation of hESCs [27]. As demonstrated with the first
derived hESC line Regea 06/015, hFF can be cultured without
any animal-derived materials, enabling the establishment and
production of xeno-free hESC lines in the future. Furthermore,
our formulation enables feasible culture environment for iPSCs.
We believe that these results suggest that the derivation of iPSC
lines is also possible by using xeno-free RegES medium and should
be tested.
In the culture of ASCs the replacement of FBS with pooled
allogeneic human serum and human serum derivatives has been
reported to support equal or higher proliferation rates and
multipotentiality [33–35]. However, serum composition is largely
unknown, and shows significant lot-to-lot variability that may
affect the reproducibility of the results [2]. In clinical therapy, a
feasible option would be to use patient’s autologous serum but it
may not always be available in large quantities. In the culture of
ASCs our results show that the xeno-free RegES medium
exhibited significantly higher proliferation rates compared to the
reference media containing HS. Both culture conditions main-
tained the characteristic surface marker expression profile of ASCs
with expression of markers verifying the mesenchymal origin of
cells and no expression of markers of the hematopoietic origin of
cells. However, statistical analysis revealed significant differences
Figure 5. Analysis of pluripotency and differentiation characteristics of the hESC lines derived in xeno-free medium RegES. A) RT-
PCR analysis of in vitro-derived EBs showing transcripts for AFP and SOX17 (endodermal markers), a-cardiac actin and T (Brachyury; mesodermal
markers), SOX1 and PAX6 (ectodermal markers), and b-actin. Lane 1, 50-bp DNA ladder. Regea 07/046 at passage 42, Regea 08/013 at passage 35, and
Regea 06/040 at passage 101. B) Differentiated cardiomyocytes from hESC line Regea 08/013 were stained with a) cardiac troponin T (red) and b)
ventricular myosin heavy chain (green). c) Merged picture of a) and b) with DAPI staining. Scale bar is 100 mm. C) RT-PCR analysis of neurospheres
derived from hESC line Regea 08/013 cultured in RegES medium showed expression of neural precursor markers Musashi, Nestin and PAX6; neuronal
markers MAP-2, NF68 and OTX2; and astrocytic marker GFAP. No expression of pluripotent markers Oct4 and Nanog, nor endo- AFP or mesodermal
markers T/Brachyury were detected. D) Most of the cells migrating out from the plated neurospheres stained positive for neuronal marker MAP-2
(green) and few cells were positive for astrocytic marker GFAP (red). DAPI staining (blue). Scale bar is 100 mm.
doi:10.1371/journal.pone.0010246.g005
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Figure 6. Characterization of iPSC lines. A) Bright-field microscopic images (scale bar, 500 mm) showing undifferentiated colony morphology of
iPSCs cultured in hES and RegES media. Cell line FiPS 5-7 in hES medium is at passage 15, in RegES medium at passage 5 and FiPS 6-14 in hES medium
at passage 18, in RegES medium at passage 9. B) Fluorescent microscopic images (scale bar, 100 mm) of iPSCs cultured in RegES medium showing
cells positive for Nanog, Oct4, Sox2, SSEA-4 and TRA-1-60. Insets represent DAPI staining. Cell line FiPS 5-7 is at passage 23 and FiPS 6-14 at passage
26. C) Quantitative flow cytometry analyses indicating expression of SSEA-4 and TRA-1-81 of iPSC lines cultured in hES and RegES media. Cell samples
cultured in hES medium are from 6 day old colonies, cell samples from cell line FiPS 5-7 cultured in RegES from 7 day old colonies and samples from
cell line FiPS 6-14 from 8 day old colonies. Cell line FiPS 5-7 in hES medium at passage 15, in RegES medium at passage 14 and FiPS 6-14 in hES
medium at passage 16, in RegES medium at passage 7. D) Quantitative RT-PCR analysis of Nanog, Oct4, GABRB3, GDF3, DNMT3B and TDGF1
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in the surface marker expression of ASCs cultured in HS and
RegES media. In addition, RegES culture medium is able to
maintain the differentiation capacity of the ASCs and thus
maintain the multipotency of the ASC population. Our results
indicate that RegES medium possess all the inherent promise for
translational use in clinical applications and after additional pre-
clinical safety and efficacy studies, it could be used to replace
autologous or allogenous HS in the clinical cell therapy studies
with ASCs undergoing in our institute [3] and elsewhere.
Although all stem cell lines worldwide share the expression of
characteristic stem cell markers, different culture conditions are
known to influence gene expression and therefore many of the cell
properties. The use of completely defined conditions will allow for
better understanding of stem cell regulation and provide more
reproducible results. Currently, there are at least three commer-
cially available xeno-free culture media, HEScGRO (Millipore),
developed for the culture of hESC lines with feeder cells,
KnockOut SR Xeno-free (Invitrogen) which can be used with or
without feeder cells and TeSR2 (StemCell Technologies) for the
culture of hESC lines in feeder-cell free conditions. In the present
study we have successfully developed a new totally xeno-free
effective culture medium for human ESCs, iPSCs and ASCs.
These cells can be maintained in the same defined xeno-free
medium formulation supporting feasible proliferation while
maintaining their characteristics. In addition, we have described
the derivation of new hESC lines using the xeno-free RegES
medium and showed that these lines retain their differentiation
potential after long-term culture in the xeno-free RegES culture
medium. However, further studies of in vitro differentiated
derivatives are needed to evaluate the functionality of the
differentiation protocols with the xeno-free RegES medium.
Recently a large-scale multi-laboratory comparison study of
different culture conditions for hESCs was published [36]. Future
studies should focus on comparison of different xeno-free culture
conditions and on validation of these conditions to demonstrate
long-term culture, maintenance of key features of self-renewal,
pluripotency, and genetic stability, as well as derivation,
reprogramming or isolation of new stem cell lines as a full proof-
of-principle. As many of the current differentiation protocols
utilize a variety of undefined products we suggest that xeno-free
RegES medium should be tested as a base for differentiation
protocols for stem cells. The use of defined products in the
expression of day 6 colonies in iPSC lines FiPS 5-7 in hES medium at passage 10, in RegES medium at passage 7 and FiPS 6-14 in hES medium at
passage 11, in RegES medium at passage 8. No significant differences (over 2-fold) were detected between iPSC lines. E) RT-PCR analysis of in vitro-
derived EBs showing transcripts for AFP and SOX17 (endodermal markers), a-cardiac actin and T (Brachyury; mesodermal markers), SOX1 and PAX6
(ectodermal markers), and b-actin. Lane 1, 50-bp DNA ladder. Both cell lines at passage 10.
doi:10.1371/journal.pone.0010246.g006
Figure 7. Characterization of human ASCs. A) Morphology of ASCs cultured in HS medium and RegES medium at day 8 and day 11. (Scale bar
500 mm) B) WST-1 proliferation assay. Proliferation of ASCs was examined in HS medium and RegES medium analyzed at time points 1, 4, 7, and 11
days. The data in diagram is presented as mean 6 SD. *p,0.05 (n = 7 donors with 4 replicate wells). Significantly higher proliferation rates were
detected in ASCs cultured in RegES medium at time points 4, 7 and 11 days when compared to ASCs cultured in HS medium. C) Osteogenic
differentiation of ASCs at passage 3 in RegES medium demonstrated by alkaline phosphatase staining 14 days after the initiation of the
differentiation. D) Adipogenic differentiation of ASCs at passage 3 in RegES medium confirmed by Oil red O staining after 14 days of differentiation.
E) Chondrogenic differentiation of ASCs at passage 3 in RegES medium after 14 days of differentiation as verified by Alcian blue staining.
doi:10.1371/journal.pone.0010246.g007
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differentiation protocols will facilitate the discovery of molecular
mechanisms behind the differentiation to various cell types and
reproducibility of differentiation processes. Our results indicate
that the basic RegES culture medium is applicable for further
optimization of xeno-free establishment, culture and differentia-
tion of stem cells and can ultimately serve as a platform for the
production of clinical-grade pluripotent stem cells and their
derivatives for safer clinical cell therapy treatments.
Materials and Methods
Ethics Statement
The study was conducted in accordance with the Karolinska
Institutet Ethics Committee to derive and culture hESCs, with the
Ethics Committee of Pirkanmaa Hospital District to culture,
characterize and differentiate hESCs derived at Karolinska
Institutet (R05051), to derive, culture, characterize and differen-
tiate new hESC lines at Regea (R05116) and with the permission
of the National Authority for Medicolegal Affairs to do research
with human embryos (Dnro 1426/32/300/05). Donated embryos
were received from Tampere University Hospital in vitro
fertilization (IVF) clinic. An informed consent form was signed
by both partners after receiving an oral and written description of
the study. The donors did not receive financial compensation.
Animal experiments were performed at the animal facilities of
Karolinska University Hospital or at Turku Center for Disease
Modeling and Department of Physiology, Institute of Biomedicine,
University of Turku in accordance with the approval of the
institution’s Ethics Committee. Adipose stem cells (ASCs) were
isolated from adipose tissue samples collected from female donors
undergoing elective surgical procedures at the Department of
Plastic Surgery, Tampere University Hospital with the permission
of the Ethics Committee of Pirkanmaa Hospital District. Human
iPS cells were derived and characterized at the University of
Helsinki, with the permission of the Ethics Committee of the
University of Helsinki.
Cell Culture
The hESC lines HS237, HS346, and HS401 used in the
optimization of the xeno-free formulation RegES were initially
derived and characterized at the Karolinska Institutet, Stockholm,
Sweden [25,26]. These cell lines were derived and cultured using
conventional hES medium containing KO-DMEM basal medium
supplemented with 20% KO-SR, 2 mM Glutamax, 0.1 mM b-
mercaptoethanol (all from Invitrogen, Carlsbad, CA), 0.1 mM
MEM non-essential amino acids (NEAA), 1% penicillin-strepto-
mycin (both from Cambrex Bio Science, Walkersville, MD) and
8 ng ml/ml recombinant human bFGF (R&D Systems Inc.,
Minneapolis, MN). Human iPSC lines FiPS 5-7 and FiPS 6-14
were derived and characterized at the University of Helsinki.
Briefly, human cDNAs of Oct4, Sox2, Nanog, Klf4 and Lin28, were
amplified by direct PCR from hESC cDNA, and cloned into
pMXs retroviral vector (Addgene Inc., Cambridge, MA). 293-
GPG packaging cells were transfected with each pMXs-cDNA
vector separately using Fugene HD (Roche Diagnostics GmbH,
Mannheim, Germany). Next day, fresh MEF media was added.
Viral supernatant was collected 3 times at days 4, 5, and 6 post-
transfection, combined and then filtered. The human neonatal
foreskin fibroblast line CCCD-1112Sk (ATCC) was plated on
gelatin-coated petri dishes and incubated overnight. Cells were
then infected with an equally mixed combination of fresh virus-
containing supernatant twice at 24 h intervals. At day 3, infected
cells were harvested and re-seeded on a Mitomycin C-treated
MEF layer. The following day, the medium was changed to hES
medium. After 20 to 30 days post-transduction, ES-like colonies
were picked, expanded, and characterized as previously described
for hESCs [37]. Transgene expression was studied using RT-PCR
to confirm transgene silencing. FiPS 5-7 was generated using
Oct4, Sox2, Nanog, and Lin28 encoding retroviruses, while FiPS
6-14 was generated using the same factors plus to Klf4.
Human ESCs and iPSCs were gradually adapted to the RegES
medium (Table S1) (20:80, 50:50, 80:20, and 100:0) during the
first four passages. Commercially available hFFs (CRL-2429,
ATCC, Manassas, VA) cultured in IMDM with L-glutamine and
25 mM HEPES (Invitrogen) supplemented with 10% FBS
(Invitrogen) and 1% penicillin-streptomycin (Cambrex Bio Sci-
ence) were used for hESCs and iPSCs culture. Confluent
monolayers of hFFs were mitotically inactivated by irradiation
(40 Gy) and plated at a density of 3.86104 cells/cm2. The growth
of hESCs and iPSCs was monitored microscopically and culture
media were changed daily. The hESC and iPSC cultures were
mechanically passaged every 6 to 7 days to new mitotically
inactivated feeder cells. Single-cell enzymatic passaging was
performed for hESCs as described previously [27] using TrypLE
Select (Invitrogen) and an 8 to 12 day splitting interval. The
hESCs were frozen using RegES medium supplemented with 10%
DMSO (Sigma-Aldrich, St. Louis, MO). Xeno-free commercially
available HEScGRO medium (Millipore Corporation, Billerica,
MA) without any supplementation was compared to RegES
medium for the culture of hESCs.
ASCs were isolated from adipose tissue samples collected from
female donors undergoing elective surgical procedures in the
Department of Plastic Surgery, Tampere University Hospital.
Isolation of ASCs from adipose tissue samples was carried out as
Table 1. Surface marker expression characteristics of ASCs cultured in HS and RegES media.
Surface Protein Antigen HS medium (n=4) RegES medium (n=4)
CD34 * Sialomucin-like adhesion molecule 3.5%61.7 1.2%60.7
CD45 * Leukocyte common antigen 0.4%60.0 2.4%61.2
CD90 Thy-1, T-cell surface glycoprotein 93.1%611.2 99.8%60.1
CD105 * SH-2, endoglin 52.0%68.3 75.7%66.6
HLA-ABC * Major histocompatibility class I antigen 0.6%60.4 10.0%611.4
HLA-DR Major histocompatibility class II antigen 0.8%60.6 0.4%60.1
Cell lines 5/08, 19/08, 24/08 and 25/08 cultured in HS medium were at passage 2–3 and cell lines 9/08, 11/08, 25/08 and 31/08 cultured in RegES medium were at
passage 3–4. Data are presented as mean 6 standard deviation from the number of donors/samples indicated in parentheses.
*p,0.05.
doi:10.1371/journal.pone.0010246.t001
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described previously [38,39]. Briefly, the adipose tissue was
minced manually into small fragments and digested with
1.5 mg/mL collagenase type I (Life Technologies, Paisley, UK)
in a shaking water bath at 37uC. To separate the adipose stem cells
from the surrounding tissue the digested tissue was centrifuged and
filtered in sequential steps. The isolated cells were expanded in
DMEM/F-12 1:1, supplemented with 1% GlutaMAX, 1%
antibiotics/antimycotic (a/a; 100 U/mL penicillin, 0.1 mg/mL
streptomycin, and 0.25 mg/mL amphotericin B) (all from Invitro-
gen) and 10% alloHS (PAA Laboratories GmbH, Pasching,
Austria), (HS medium). For testing defined, xeno-free conditions,
ASCs were transferred to RegES culture medium in flasks with
pre-coated CELLstart (Invitrogen). For detachment of ASCs
TrypLE Select (Invitrogen) was used.
Derivation of hESC lines
Surplus poor quality embryos that could not be used for
infertility treatment were obtained as donations from couples
undergoing in vitro fertilization treatment at Tampere University
Hospital, Tampere, Finland. The mechanical derivation of the cell
lines from blastocyst-stage embryos with a hardly visible inner cell
mass was performed using a specially made flexible metal needle
(Hunter Scientific, Essex UK) and surgical knife as described
previously [26]. For successful derivation of the 06/015 cell line,
we used 10 surplus embryos (arrested around day 3–4) without
blastocyst development. Derivation of the cell line Regea 06/015
was performed by removing the zona pellucida and plating the
remaining cells on the top of hFF cells using a flexible needle.
Human ESC line Regea 06/040 was derived using hES medium
and hESC lines Regea 06/015, Regea 07/046, and Regea 08/013
were derived using RegES medium. Human ESC line Regea 06/
015 was derived on feeder cells (C-12300 PromoCell GmbH,
Heidelberg, Germany) cultured in IMDM with L-glutamine and
25 mM HEPES (Invitrogen) supplemented with 10% human
serum (Sigma-Aldrich), 0.1 mM NEAA (Cambrex Bio Science),
and 0.1 mM penicillin-streptomycin (Cambrex Bio Science).
Immunocytochemistry
Immunocytochemistry was performed as previously described
[31]. The primary antibodies used for hESCs and iPSCs were
specific for Nanog, Oct4 (both from R&D Systems), SSEA-4 and
Sox2 (both from Santa Cruz Biotechnology, Inc., Santa Cruz, CA)
and TRA-1-60 (Millipore). The cells were incubated with primary
antibody solution overnight at 4uC. The cells were probed with
Alexa Fluor 568 or Alexa Fluor 488 (both from Invitrogen)
secondary antibodies for 1 h in the dark at room temperature. The
differentiated cardiomyocytes were incubated overnight at 4uC
with anti-cardiac troponin T (Abcam, Cambridge, UK) and anti-
ventricular myosin heavy chain (Chemicon). Alexa Fluor 488 or
568 (Invitrogen) conjugated anti-goat and anti-mouse antibodies
were used as secondary antibodies. Differentiated neural cells were
immunostained after 9 weeks of differentiation. For immunocyto-
chemical staining neurospheres were plated on human laminin
(Sigma Aldrich) coated wells in the absence of bFGF and after
growing three days the cells were fixed. The fixed neuronal cells
were incubated overnight at 4uC with polyclonal rabbit anti-
MAP-2 (Chemicon) for neuronal cells and polyclonal sheep anti-
GFAP (R&D Systems) for astrocytes. Alexa Fluor 488 and 568
conjugated anti-rabbit or anti-sheep (Invitrogen) were used as
secondary antibodies. Human ESCs labeled only with secondary
antibodies, were used as negative controls and no fluorescense in
these samples were detected. After incubation, the cells were
mounted in Vectashield mounting medium containing 49,6-
diamidino-2-phenylindole (Vector Laboratories, Inc., Burlingame,
CA). The labeled cells were photographed with an Olympus IX51
phase contrast microscope with fluorescence optics and Olympus
DP30BW camera (Olympus Corporation, Tokyo, Japan).
Alkaline phosphatase staining
The in vitro osteogenic differentiation capacity was determined 14
days after the initiation of differentiation by alkaline phosphatase
staining (ALP) as described previously [33,40,41]. The cell cultures
were fixed with a 4% paraformaldehyde (PFA) solution and stained
with the leukocyte alkaline phosphatase kit according to the Sigma
Procedure No. 86 (#86R-1KT). The ALP staining was confirmed
by a purple staining visualized by microscopy.
Adipogenesis Oil red O staining
The adipogenic differentiation was confirmed with Oil red O
staining as described previously [33]. Cell cultures were main-
tained for 14 days and subsequently fixed with 4% PFA,
pretreated with 60% isopropanol and stained with a 0.5% Oil
red O solution in 60% isopropanol. After fixation and staining, the
wells were rinsed with distilled water and visualized by
microscopy. Adipocytes were identified as cells with red-stained
lipid vesicles.
Chondrogenesis Alcian blue staining
The chondrogenic differentiation cultures were maintained for 14
days and were subsequently fixed with 4% PFA, and stained with 1%
Alcian blue stain. Cells stained with Alcian blue verified the presence
of sulphated proteoglycans within the chondrogenic cell pellet.
Flow cytometry
Human ESCs and iPSCs cultured in hES and RegES media
were analyzed by flow cytometry using antibodies against SSEA-4-
PE (R&D Systems) and TRA-1-81-FITC (BD Pharmingen, San
Diego, CA). Human ESC samples cultured in hES and RegES
media were from 7 day old colonies, iPSC samples cultured in hES
medium from 6 day old colonies and samples cultured in RegES
medium from 7 day old (5–7) or 8 day old colonies (6–14). Both
undifferentiated and differentiated cells present in the culture dish
were included in the analyses. Alexa Fluor 488 (Invitrogen) and R-
phycoerythrin-conjugated (Caltag-Medsystems Ltd, Buckingham,
UK) secondary antibodies were used as isotype controls. ASCs
cultured in HS and RegES media (n = 4, passages 2–4) were
analyzed by flow cytometry using monoclonal antibodies against
CD90-APC (BD Biosciences), CD45-FITC (Miltenyi Biotech,
Bergisch Gladbach, Germany), CD34-APC, HLA-ABC-PE, HLA-
DR-PE (all from Immunotools GmbH Friesoythe, Germany), and
CD105-PE (R&D Systems). The samples were analysed by flow
cytometry (FACSAriaH, BDBiosciences). The acquisition was set
for 10 000 events per sample. The data were analyzed using
FACSDiva Software version 4.1.2 (BD Biosciences).
RNA isolation and reverse transcription
Total RNA was isolated using an RNeasy mini plus kit (Qiagen,
Valencia, CA) according to the manufacturer’s instructions. The
concentration and quality of isolated RNA was determined using a
ND-1000 Spectrophotometer (NanoDrop Technologies, Wilming-
ton, DE). Complementary DNA (cDNA) was synthesized from
50 ng of total RNA using a Sensiscript Reverse Transcription Kit
(Qiagen) according to the manufacturer’s instructions.
Quantitative RT-PCR
Both undifferentiated and differentiated hESCs and iPSCs in
the culture plate were included in the quantitative RT-PCR
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analyses. Quantitative RT-PCR was performed for hESCs and
iPSCs with Applied Biosystems Gene Expression Assays: GAPDH
(Hs99999905_m1; 122-bp product), DNMT3B (Hs01003405_m1;
80-bp product), TDGF1 (Hs02339496_g1; 102-bp product), Nanog
(Hs2387400_g1; 109-bp product), GDF3 (Hs00220998_m1; 65-bp
product), GABRB3 (Hs01115771_m1; 72-bp product), and Oct4
(Hs00999632_g1; 77-bp product). All samples and the no-template
controls were analyzed in triplicate. Quantitative RT-PCR was
performed with an Applied Biosystems 7300 Real-Time PCR
system using the following conditions: 40 cycles of 50uC, 2 min;
95uC, 10 min; and 95uC, 15 s; followed by 60uC, 1 min. The data
were analyzed with a 7300 System SDS Software (Applied
Biosystems). The cycle threshold (Ct) values were determined for
every reaction. Relative quantification was calculated using the
22DDCt method [42]. All data were normalized to the expression of
the gene GAPDH whose expression does not change under the
experimental conditions. The data are presented as mean fold-
change. Neural cells: RNA isolation and reverse transcription of
RT-PCR samples ($10 spheres/sample) was performed as
described above. The primer set for RT-PCR contained Oct4,
Nanog for undifferentiated hESC; a-fetoprotein for endodermal
lineage; brachyury/T for mesodermal lineage; Musashi, Nestin, and
PAX6 for neuroectodermal cells; MAP-2, NF68 and OTX2 for
neuronal cells; GFAP for astrocytes, and Olig1 for oligodentrocyte
precursor cells. Data were normalized to the expression of the
gene GAPDH whose expression does not change under the
experimental conditions. Primer sequences are shown in supple-
mentary Table S2. The RT-PCR reactions were performed in an
Eppendorf Mastercycler using 35 PCR cycles with an initializing
step at 95uC for 3 min, denaturation at 95uC for 30 s, annealing at
55uC for 30 s, and extension at 72uC for 1 min, followed by a final
extension at 72uC for 5 min. The PCR products were analyzed by
electrophoresis on a 1.5% agarose gel containing 0.4 mg/ml
ethidium bromide (Sigma-Aldrich).
Cell proliferation assay
Cell proliferation of the hESC lines was determined using a
colorimetric immunoassay (Roche Diagnostics) based on the
measurement of bromodeoxyuridine (BrdU) incorporation during
DNA synthesis. The assay was performed according to the
manufacturer’s instructions. The hESC colonies at day 5 were
labeled with BrdU-labeling solution overnight at 37uC. The
hESCs (105 cells/well) were added to a 96-well plate, with 8
replicates per cell line. Cells that were not labeled with BrdU were
used as a background control. The absorbance of the samples was
measured at 450 nm using a Viktor 1429 Multilabel Counter
(PerkinElmer-Wallace, Norton, OH).
The cell viability and proliferation activity of the ASCs was
assessed using PreMix WST-1 Cell Proliferation Assay System
(Takara Bio Inc., Shiga, Japan). The ASCs (n= 7 donor cell
samples, with 4 replicates per cell line) were seeded on a 48-well
plate at a density of 4500 cells/cm2, and the proliferation was
determined at 1, 4, 7 and 11 days. Briefly, the cell culture medium
was removed and DPBS and PreMix WST-1 were added 10:1.
The well plate was incubated for 4 hours in 37uC and the cell
proliferation activity was measured using a Viktor 1429 Multilabel
Counter at 450 nm.
Karyotyping
Karyotype analysis was performed by G-banding technique in
Medix Laboratories Inc, Helsinki, Finland. In brief, the hESCs
were treated with colchicine for 2 hours, and cells in metaphase
were analyzed using conventional light microscopy (Olympus, BX
50). Karyotypes were determined using IKAROS-software
designed for chromosome analysis (MetaSystems GmbH, Altlus-
sheim, Germany). A total of 20 cells in metaphase were analyzed
for each cell line.
Analysis of pluripotency in vitro
The embryoid bodies (EBs) formed by mechanically dissecting
the hESC and iPSC colonies were cultured without feeder cells in
RegES or hES medium without bFGF for 4 weeks before RNA
isolation. The media was changed every 2 to 3 days. RNA
isolation and reverse transcription from EBs was performed as
described above. The expression of markers characteristic of
ectoderm (PAX6 and SOX1, DNA Technologies Inc. Gaithersburg,
MD), endoderm (a-fetoprotein and SOX17, DNA Technologies Inc.),
and mesoderm (a-cardiac actin, Proligo, Sigma-Aldrich and T, DNA
Technologies Inc.) development in EBs was determined using RT-
PCR primers. b-actin (DNA Technologies Inc.) whose expression
does not change under the experimental conditions was used as a
control. Primer sequences are shown in supplementary Table S2.
Negative controls contained sterilized water instead of the cDNA
template. The RT-PCR reactions were performed in an
Eppendorf Mastercycler as follows: denaturation at 95uC for
3 min and 40 cycles of denaturation at 95uC for 30 s, annealing at
57uC for 30 s, and extension at 72uC for 1 min, followed by a final
extension at 72uC for 5 min. The PCR products were analyzed by
electrophoresis on a 1.5% agarose gel containing 0.4 mg/ml
ethidium bromide (Sigma-Aldrich) and 50 bp DNA standard
(MassRulerTM DNA Ladder Mix, Fermentas).
Analysis of pluripotency in vivo
Animal experiments with hESC lines Regea 06/015, Regea 06/
040 and Regea 07/046 were performed at the infection-free
animal facility of Karolinska University Hospital and experiments
with hESC line Regea 08/013 at the animal facility of Turku
Center for Disease Modeling and Department of Physiology,
Institute of Biomedicine, University of Turku. Human ESCs were
harvested from the culture plates using dispase or TrypleSelect
and mechanical treatment. Five colonies (103 to 104 hESC) were
washed twice in PBS and subsequently implanted beneath the
testicular capsule of a young (6–8 week-old) severe combined
immunodeficiency (scid)/beige male mouse (C.B.-17/GbmsTac-
scid-bgDF N7, M&B, Ry, Denmark) or in the case of Regea 08/
013 male Nude mouse (Hsd;Athymic Nude-Foxn1nu, Harlan).
Three animals were used for cell line. Teratoma growth was
determined by palpation once per week, and the mice were killed
by cervical dislocation 8 to 9 weeks after implantation. The in vivo
pluripotency of the hESC lines Regea 06/015, Regea 06/040 and
Regea 07/046 was analyzed as previously described [8,25].
Immunohistochemical studies of Regea 08013 cell line teratomas
were done in paraffin sections. The dewaxed and rehydrated
sections were treated in pressure cooker in 1 mM EDTA, pH 8,
(Desmin and HNF3b) or 10 mM sodium citrate buffer, pH 6,
(NCAM) for 5 minutes to reveal antigenic sites, cooled at room
temperature (RT) for 2 hours, and rinsed in phosphate buffer
saline (PBS). After rinsing with PBS the sections were incubated
with primary antibodies (rabbit anti-desmin, sc-14026, mouse anti-
HNF3b, sc-101060, purchased from Santa Cruz Biotechnology, or
rabbit anti-NCAM, AB5032, purchased from Chemicon Interna-
tional. Primary antibodies were diluted (1:1000, 1:3000, and 1:800
respectively) in PBS containing 0.05% TweenH and incubated
overnight at +4 degrees. The next day, after several rinses with
PBS, endogenous peroxidase was inactivated with 1% hydrogen
peroxide in PBS for 20 minutes. After rinsing several times with
PBS, the sections were incubated with secondary antibodies (HRP
conjugated Dako EnvisionTM+ Systems) for 30 minutes (RT).
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Slides were rinsed with PBS. Color was developed with
diaminobenzidine substrate (Dako EnvisionTM+ Systems). Sections
were slightly counterstained with Mayer’s hematoxylin, dehydrat-
ed, and mounted.
Differentiation of hESCs to cardiomyocytes and neural
cells
Cardiomyocyte differentiation was carried out as described
previously [28] by co-culturing Regea 08/013 hESCs, maintained
in RegES (p46) and in hES (p52) media, with mouse visceral
endodermal-like (END-2) cells, which were a kind gift from Prof.
Mummery, Humbrecht Institute, Utrecht, Netherlands. Briefly,
undifferentiated hESC colonies were dissected mechanically into
aggregates containing a few hundred cells and placed on the top of
plated END-2 cells in hES culture medium without KO-SR and
bFGF. Differentiating cell colonies were monitored by microscopy
daily and the medium was changed after 5 days of culturing. After
12 days the 10% KO-SR (Invitrogen) was added to the medium.
Differentiation was performed in 12-well plates, 15 hESC colony
pieces in a well. The beating areas were dissociated by collagenase
II treatment. The cells were plated on 0.1% gelatin coated cell
culture plates in a medium containing 7.5% FBS.
Neural differentiation was performed as previously described
[29]. Briefly, hESC (Regea 08/013) colonies maintained in RegES
(p53) and in hES (p58) media, were mechanically dissociated into
small clusters containing ,3000 cells. Clusters were transferred
into 6-well ultra low attachment plates (Nunc, Thermo Fisher
Scientific, Rochester, NY) and cultured as floating aggregates, e.g.
neurospheres, for up to 20 weeks in neural differentiation medium
consisting of 1:1 DMEM/F-12:Neurobasal media supplemented
with 2 mM Glutamax, 1xB27, 1xN2 (all from Invitrogen), 25 U/
ml penicillin-streptomycin (Lonza Group Ltd), and 20 ng/ml
bFGF (R&D Systems). Medium was changed 3 times/week and
the spheres were mechanically passaged weekly.
Differentiation of ASCs to adipogenic, osteogenic and
chondrogenic lineages
ASCs (passage 3) cultured in RegES medium were analyzed for
their capacity to differentiate toward the adipogenic, osteogenic, and
chondrogenic lineages with ASCs cultured in medium containing HS
as reference. Briefly, osteogenic differentiation analyses were
performed on ASCs seeded onto a 12-well plate at a density of
2.56103 cells/cm2 in RegES media supplemented with 150 mM L-
ascorbic acid 2-phosphate (Sigma), 10 mM b-glycerophosphate
(Sigma) and 100 nM dexamethasone (Sigma) in culture vessels were
pre-coated with CELLstart. The control cultures were maintained in
RegES media without supplements in pre-coated culture vessels. The
cultures were maintained 14 days and osteogenic differentiation was
detected by alkaline phosphatase activity staining.
Adipogenic differentiation was induced by culturing ASCs for two
weeks in adipogenic media with an initial seeding density of
26104 cells/cm2 in culture vessels were pre-coated with CELLstart.
For the adipogenic induction, RegES media supplemented with
33 mM biotin (Sigma), 1 mM dexamethasone, 100 nM insulin
(Invitrogen) and 17 mM pantothenate (Fluka, Buchs, Switzerland)
was used while the control cultures were maintained in RegES
without adipogenic supplements. The cultures were analyzed using
an Oil red O stain as an indicator of intracellular lipid accumulation.
The chondrogenic differentiation capacity analysis was assessed
by micromass culture technique [1,43]. Briefly, 16105 cells were
seeded onto a 24-well culture plate in a 10 ml volume, and were let
adhere for 3 h in a cell incubator prior to addition of the
chondrogenic RegES media containing 1% ITS+1 (Sigma),
50 mM L-ascorbic acid 2-phosphate, 55 mM sodium pyruvate
(Invitrogen), L-proline 23 mM (Sigma). The control cultures were
maintained in RegES without chondrogenic supplements. The
chondrogenic induction cultures and control cultures were
performed without CELLstart pre-coating. The cultures were
maintained for 14 days prior to analysis. Chondrogenesis was
confirmed using Alcian blue stain.
Statistical analyses
ANOVA by the methodology of mixed models was used for the
proliferation data analysis of ASCs between the different culture
media compositions within each separate experiment setup to
account for the correlation of multiple measurements within
donors. Mann-Whitney U test was applied in the surface marker
expression of ASCs to compare the different culture conditions.
The surface marker expression of ASCs was analyzed using
Wilcoxon signed-rank statistics, which was used for pairwise
comparison between the different culturing conditions. The
statistical analyses were performed at the significance level
p,0.05. The analyses were performed using SPSS software
version 13 (SPSS Inc., Chicago, IL, USA).
Supporting Information
Table S1 Complete Formulation for RegES Medium.
Found at: doi:10.1371/journal.pone.0010246.s001 (0.05 MB
DOC)
Table S2 Primer sequences.
Found at: doi:10.1371/journal.pone.0010246.s002 (0.05 MB
DOC)
Figure S1 Characterization of a hESC line Regea 06/015
derived in xeno-free medium RegES. A) Bright-field (scale bar,
500 mm) microscopic image of Regea 06/015 cell line at passage 3
after derivation. B) Bright-field (scale bar, 500 mm) microscopic
image showing undifferentiated colony morphology of Regea 06/
015 cell line at passage 35. C) RT-PCR analysis of in vitro-derived
EBs of hESC line Regea 06/015 at passage 60 showing transcripts
for AFP and SOX17 (endodermal markers), a-cardiac actin and T
(Brachyuru; mesodermal markers), SOX1 and PAX6 (ectodermal
markers), and b-actin as a housekeeping control. Lane 1, 50 bp
DNA ladder. D) Fluorescent (scale bar, 200 mm) microscopic
images showing undifferentiated colony morphology and qualita-
tive immunocytochemistry of hESCs positive for the transcription
factor Nanog, Oct4, Sox2, SSEA-4, and TRA-1-60. Insets
represent DAPI staining.
Found at: doi:10.1371/journal.pone.0010246.s003 (7.33 MB TIF)
Figure S2 Karyograms of hESC lines. A G-banding karyograms
showing normal karyotypes of hESC lines, Regea 06/015 at
passage 35, Regea 07/046 at passage 36, Regea 08/013 at passage
25 and Regea 06/040 at passage 71.
Found at: doi:10.1371/journal.pone.0010246.s004 (9.41 MB TIF)
Figure S3 Histology of teratomas from cell line Regea 06/015 at
passage 35. A) An overview of a teratoma. B) Endoderm: detail
from the right part of the overview showing a lumen outlined by
high cylindrical cells (*). The cells are compatible with endodermal
differentiation of intestinal or respiratory type. C) Ectoderm: a
cluster of neurons assembled into a ganglion like structure (arrow).
Fibers tracts emanates from the cluster. D) Ectoderm: a
squadmous epithelial island composed of fairly vacuolated cells
(arrow). E) Mesoderm: lower part an island composed of
hypertrophic chondrocytes (arrow).
Found at: doi:10.1371/journal.pone.0010246.s005 (7.14 MB TIF)
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Figure S4 Histology of teratomas from cell line Regea 07/046 at
passage 17. A) This image shows tubular structures lined by
cuboidal to cylindrical epithelium and aggregates consisting of
smooth muscle cells (sm) are seen. B) Endoderm: some PASD+
cells (arrow) can be seen in the image, which are compatible with
Goblet cells indicating the endodermal differentiation. C)
Endoderm and mesoderm: a single tubule (*) lined by cuboidal
to cylindrical epithelium. Note that it is embedded in a loosely
arranged connective tissue - primitive mesenchyme. An interpre-
tation would be that this represents endodermal (epithelial tubules)
and mesodermal components. D) Endoderm or ectoderm: this
image shows an epithelium lined tubule (*) embedded within a
very loosely arranged mesenchyme. The epithelium can be
interpreted as bilayered potentially representing a squamous
variant. It is impossible to state if it is endodermal or ectodermal
in origin.
Found at: doi:10.1371/journal.pone.0010246.s006 (8.57 MB TIF)
Figure S5 Histology of teratomas from cell line Regea 08/013 at
passage 86. A) Ectoderm: Large area of NCAM-positive, neuronal
cells (arrow). B) Mesoderm: Bundles of muscle cells are stained
positive for Desmin (arrow). C) Endoderm: Pseudostratified
ciliated columnar epithelium stained positive for HNF3b (arrow).
Found at: doi:10.1371/journal.pone.0010246.s007 (6.05 MB TIF)
Figure S6 Histology of teratomas from cell line Regea 06/040 at
passage 34. A) and B) An overview of teratomas. Endoderm and
mesoderm: note cartilage (c) and tubular structure (*) outlined by
cylindrical cells suggesting mesodermal differentiation and varying
amounts of Goblet cells suggesting endodermal differentiation. C)
Endoderm: a high power view of an area from B is shown. Note
smooth muscle like cells (sm) and cylindrical cells with scattered
mucous producing Goblet cells. D) Ectoderm: a strong nuclear
expression of MITF (arrow) specific for retinal pigment epithelial
cells is seen indicating ectodermal differentiation.
Found at: doi:10.1371/journal.pone.0010246.s008 (5.84 MB TIF)
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